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5Abstract of Thesis
Innate pattern recognition receptors (PRRs) expressed on dendritic cells (DC) 
link direct recognition of pathogens to initiation of T cell responses. Here I 
describe evidence that Dectin-1   is a novel pattern recognition receptor involved 
the activation of dendritic cells by the yeast cell wall preparation, zymosan.
Zymosan contains ligands for the known PRR Toll-like Receptor-2 (TLR2). 
Interestingly, recent work in macrophages has implicated the p-glucan receptor 
Dectin-1   in zymosan recognition. This thesis demonstrates that Dectin-1   can 
function as a PRR independently of the Toll-like Receptor system to induce DC 
cytokine production (IL-2, IL-10) and Notch-ligand upregulation (Jagged-1).
My work has helped determine that Dectin-1  can signal via a novel HemlTAM 
motif to the tyrosine kinase Syk. DC stimulated with zymosan upregulate IL-10, 
IL-2 and Jagged-1   in a Syk-dependent manner. Indeed, IL-10 and Jagged-1  
induction is independent of TLR-mediated recognition of zymosan. In addition, 
zymosan induced ERK activation is entirely dependent on signalling through 
Syk and is independent of TLR signalling. I demonstrate that this ERK 
activation is necessary for the induction of IL-2 and IL-10 in response to 
zymosan. Finally I present preliminary findings on how the unusual cytokine 
signature of zymosan-stimulated DCs may bias Thl  and Thl7 differentiation 
induced in vitro.
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91  Chapter 1: Introduction
1.1  Microbial Recognition and A daptive I  mm unity
The foundations of this thesis lie in two central paradigms in immunology:  1) 
The concept of pattern recognition, as proposed by Charlie Janeway Jr in 1989 
[ 1  ] and 2) the realisation that dendritic cells (DC) are the most efficient cells at 
translating innate immune activation into priming of adaptive immunity 
(reviewed in [2, 3]). I hope to explain why the study of pattern recognition is 
important to our understanding of immunity and to summarise the enormous 
wealth of data which has made it possible to identify a novel pattern recognition 
pathway involved in the recognition of yeasts by dendritic cells.
1.1.1  The Mammalian immune system
The innate immune system is evolutionarily ancient. Indeed, it can be argued 
that parasitism has existed for almost as long as life itself and therefore aspects 
of “innate immunity” are found in the majority of living organisms [4] [5]. 
Responses of the innate immune system are rapid and broadly specific, 
discriminating between classes of pathogens rather than between particular 
species [6]. We now recognise the striking homology between innate immunity 
in mammals, flies, and plants both at the level of detection of microbes (e.g. the 
use of LRR and TIR domains [7]), and at the levels of effectors (e.g. anti­
microbial peptides [8]). However, throughout evolution there has been an 
ongoing ‘arms race’ between pathogens and hosts such that whilst highly 
successful strategies are maintained (for example Toll-like receptors), new 
innate immune proteins are also being selected for (such as NK cell receptors) 
which give the host a competative advantage in the presence of certain 
pathogens [9].
10Around 412 million years ago something dramatic happened [10]. With the 
evolution of jawed vertebrates, came the evolution of an adaptive immune 
system. Unlike the innate immune system, which uses phylogenetically ancient 
receptors to recognise infection and raise the alarm, the mammalian adaptive 
immune system uses clonally-expressed receptors that are generated 
somatically, by the recombination of genome-encoded receptor fragments [11]. 
The ability of evolution to select for pathogen-specific clones is minimal in this 
system (beyond biasing the repertoire of possible fragments) [11]. Since the 
recombination events that generate receptors are error-prone this leads to an 
enormous range of receptor specificities which will include specificities for self.
In order for the adaptive immune system not to destroy the body it exists to 
protect it must be tightly regulated by more than cognate antigen-recognition. In 
the case of T lymphocytes, the antigen recognised is a peptide presented by host 
MHC molecules [12], [13]. Developing T cells are selected such that cells 
expressing a T-cell receptor with a high affinity of self-MHC-self-peptide are 
deleted, as are cells bearing a receptor with very low affinity of self-MHC -  a 
process described as clonal selection [14]. The remaining repertoire is biased 
towards the recognition of self-MHC presenting particular foreign peptides. 
However, this is insufficient to explain the observed pattern of T cell activation, 
for example the adaptive immune system still ignores most of the foreign 
antigen encountered in food (as discussed in [15] [1]).
1.1.2  Adaptive Immunity requires innate signals
In his seminal opinion of 1989 [1] Janeway proposed the existence of “Pattern 
Recognition Receptors” (PRRs) that have evolved to recognise components of 
microbes not present in our own bodies and which are essential for the survival 
of that microbe -  so called pathogen associated molecular patterns (PAMPs). 
According to this theory, induction of costimulatory factors by signalling 
through PRRs would lead to the activation of T cells, only where there is 
evidence of infectious challenge. An alternative hypothesis was proposed by 
Matzinger in 1994 stating that the real trigger for full-blown immune activation
11is “danger” [15]. In this model “danger” is defined as abnormal cell death and 
inflammatory mediators (see figure 1.1).
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Figure 1-1: PAMPs  vs DAMPs in the initiation of adaptive immune responses
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12Both models explain important observations, such as the requirement for 
adjuvant in vaccination and the link between tissue necrosis and transplant 
rejection. A full discussion of their relative merits is not central to this thesis, 
beyond stating that the innate immune system can clearly respond to both 
“danger” and PAMPs and in very particular circumstances one or the other may 
be sufficient for activation of the adaptive immune system. However, in the 
majority of cases when an adaptive immune response is induced and is 
beneficial to the host the challenge is infection, and will have both PAMPs and 
“danger” associated with it. The elucidation of PRR’s involved in triggering the 
responses to different classes of pathogens will reveal much about the workings 
of the immune system.
1.2  Pattern Recognition Receptors
1.2.1  Toll-like receptors: The archetypal PRRs
Janeway’s theoretical PRRs led to the discovery of Toll-like receptors. In  1996 
Jules Hoffmann, working on immune responses in Drosophila, characterised the 
Spaetzle/Toll/Cactus pathway as being responsible for the induction of anti- 
fungal immunity in flies [16]. Recognition of fungi by Glucan-binding proteins 
(GNBP) leads to the Persephone-mediated cleavage and activation of Spaetzle 
(a Nerve Growth Factor-like molecule) which then binds to Toll [16]. This 
signals to Cactus (an iKB-like protein) to induce expression of several anti- 
fungal cationic peptides [16]. In 1997 Medzhitov and Janeway demonstrated 
that a human homologue of Drosophila Toll could signal for macrophage 
activation [17]. Human Toll showed remarkable homology to Drosophila Toll 
in both intracellular and extracellular domains, as well as showing homology to 
the intracellular domain of the IL-1 receptor (see figure  1-2, [17]). Positional 
cloning identified Toll-like receptor 4 as the gene mutated in LPS- 
hyporesponsiveness in C3H/HeJ mice and BL/lOScCr mice [18], the same gene 
identified by Medzhitov and Janeway as stimulating macrophage activation 
[17]. There are now 11 known mammalian Toll-like Receptors, all implicated as
13pattern recognition receptors essential for the activation of adaptive immunity in 
response to particular microbial adjuvants.
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Figure 1-2: Homology between Drosophila Toll and mammalian TLR signalling. Proteins 
represented in the same colours are direct homologues (drawn with reference to [19])
Physiological ligands have been identified for most of the 11  known Toll-like 
receptors characterised. In keeping with Janeway’s original hypothesis [1] the 
majority of the ligands are essential components of the microorganisms from 
which they are derived, and include viral genomes, bacterial cell wall
PGRPs and GNBPs 
recognise fungi and 
gram-positive bacteria
Persephone
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14components or structures involved in bacterial motility and adhesion. There are 
two clusters within the mammalian TLRs made up of TLRs  1, 2, 6 and 10 [20] 
which recognise lipopeptides at the cell surface, and TLRs3, 7 and 9 [21] which 
recognise nucleic acids in endosomes (recently reviewed in [22]). Notably 
TLR1, TLR6 and TLR10 are very close together on mouse chromosome 5, and 
on human chromosome 4 (human genome resources; National Centre for 
Biotechnology Information, ncbi.nlm.nih.gov), and all pair with TLR2 in order 
to signal [22] [20]. Toll-like receptors and their ligands are shown in the table 
below (adapted from [23] and [20])
Toll-like receptor Ligands
TLR1/2 Triacyl lipopeptides (e.g. Pam3Cys)
TLR2 homodimers Pam2Cys
TLR3 Double-stranded RNA
TLR4 LPS
Uric acid
TLR5 Flagellin (Bacterial)
TLR2/6 Diacyl lipopeptides (e.g.MALP2)
Zymosan
Lipoteichoic acid
TLR7 Single-stranded RNA, Imidazoquinolines
TLR8 Single-stranded RNA (pseudogene in mouse)
TLR9 CpG-containing DNA
TLR10 Unknown (gene disrupted by retroviral insertion in 
mouse)
TLR11 Profilin-like protein (T. gondii) 
Uropathogenic bacterial
Toll like receptors are type I membrane proteins with an N-terminal 
(extracellular) leucine-rich repeat (LRR) domain, followed by one or more 
cysteine-rich domains. The transmembrane domain connects this to the 
intracellular TIR (Toll-Interleukin-1-Receptor) domain (reviewed in [22]. As 
with many biological systems, Toll is used multiple times during the life-time of
15drosophila, for immunity in adults and larvae and for dorsal-ventral patterning 
in the embryo [16].  Studies of Toll in Drosophila embryonic development 
identified mutations indicative of constitutively active dToll [24, 25]. Of these 
several were found to be deletions or mutations of the cysteine residues within 
the cysteine-rich domain, or complete deletion of this domain [24, 25]. The 
original Medzhitov and Janeway paper of 1997 [17] used this information to 
generate a constitutively active human TLR4 molecule in which the LRR and 
most of the cysteine-rich domain were replaced with human CD4, suggesting 
that mammalian TLRs are also activated by ligand-induced conformational 
changes in the cysteine-rich regions.
A notable difference between TLRs in mammals and Toll in flies is that Toll is 
an indirect PRR activated after PAMP-induced cleavage and activation of the 
cytokine-like protein Spaetzle [16]. There does not appear to be a Spaetzle 
homologue involved in innate immunity in mammals. It seems likely, in fact 
that TLRs in mammals are direct pattern recognition receptors [26] [27]. In 
mice, TLR4 signalling can be activated by the presence of LPS or the partial 
LPS structure tetraacyl LPS [27]. However, in humans complete LPS, but not 
tetraacyl structures lead to TLR4 signalling [27]. Complementation of murine 
TLR4-mutant (C3H/HeJ) macrophages with human TLR4 confers the ability 
only to recognise the complete LPS implying that the ability to recognise 
different LPS structures lies with TLR4 itself [27]. It is likely that this is 
achieved by direct binding of LPS by TLR4.
Ligand-activated TLRs form homotypic TIR-TIR interactions with adaptor 
proteins MyD88, TRIF, TIRAP and TRAM (recently reviewed in [22]). All 
TLRs excluding TLR3 require the TIR-containing adaptor MyD88 to signal 
Recently reviewed in [28]. TLR2 and TLR4 require TIRAP [29], a further TIR- 
containing adaptor molecule, whilst TLRs 3 and 4 require TRIF [30], and TLR4 
additionally requires TRAM [31](see figure  1.3), demonstrating that although 
all the TLRs use the same domain to signal there is some variation in the usage 
of TIR-containing adaptors.
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Figure 1-3: Mammalian TLRs associate with TIR-containing adaptors MyD88,  TIRAP, TRAM 
and TRIF (drawn with reference to [28])
Many real infections encountered by the immune system will present ligands 
for more than one TLR. It has been observed that co-ligation of TLRs linking to 
different TIR-containing adaptors (such as TLR3 using TRIF, with TLR7 using 
MyD88) results in a synergistic increase in cytokine production [32] [33]. The 
same is true when LPS, signalling via TLR4 and all four known TIR-containing 
adaptors, is combined with R848, signalling via TLR7 and only MyD88. 
Assuming uniform expression of TLR7 and TLR9 in this system, this would 
indicate that MyD88 activation via TLR7 is not functionally equivalent to 
MyD88-dependent TLR4 signalling as there is at least an additive effect of
17combining the ligands at saturating doses [32] [33]. The ability of PRRs to 
synergise may be critical to our understanding of the responses to infection 
where this is likely to be commonplace.
1.2.2  Non-TLR Pattern Recognition Receptors: NLRs and RLHs
Whilst TLR’s remain the paradigm of true pattern recognition receptors, it is 
becoming clear that other systems exist. A number of PRRs have been defined 
that recognise PAMPs in the cytosol. These are the NOD-like receptors (NLRs)
[34] [35] and RIG-Like helicases (RLHs) (Reviewed in [35]). NLRs are soluble 
cytosolic proteins with LRR domains, a central NACHT (nucleotide-binding- 
and oligomerisation) domain and either a CARD (caspase activation and 
recruitment domain) or Pyrin domain [35]. NOD proteins have CARD domains 
and are involved in sensing cytosolic peptidoglycan [34], whilst NALP proteins 
have N-terminal pyrin domains and are required for the response to a wide 
range of stimuli (recently reviewed in [35]). It is currently unclear whether an 
exclusive NLR ligand would act as an adjuvant for adaptive immunity or 
whether the NLRs modify ongoing innate immune responses [36] but use of 
synthetic ligands and knock-out mice should soon address this question.
The RLH proteins RIG-I and MDA-5 are cytosolic receptors implicated in 
cytosolic recognition of viruses. Mice defective in either of these proteins show 
a marked increased susceptibility to particular viral infections (reviewed in
[35]).
Recognition of yeasts by the immune system can occur via TLR2 and TLR4 
(Reviewed in [37, 38]). However, several studies have revealed certain aspects 
of innate immune activation in the absence of TLR signalling when animals, or 
isolated cells, are challenged with yeast extracts such as zymosan, hinting at the 
existence of non-TLR pattern recognition in anti-fungal responses (reviewed in
[38]).
181.2.3  Zymosan is a source of fungal PAMPs
Zymosan is the insoluble residue that remains after Saccharomyces cerevisiae is 
extracted in hot water, trypsanised and extensively washed.  This produces 
particles of denatured yeast cell wall with a composition of 54.7% glucan,
18.8% mannan,  14.5% protein and 12% lipids, inorganic materials and chitin
[39]. Yeast cells walls are well conserved between yeast species. They consist 
of single or triple helices of 1,3-p-glucans with l,6-(3-glucan chains that cross­
link the glucans to extensively O- and N-glycosylated mannoproteins, either via 
glycosyl phosphatidylinositol linkage or by unknown alkali-sensitive bonds [40- 
42] (Schematic diagram; Figure 1.4). The wall is built up of minimal units that 
are non-covalently associated in the basal p-glucan layer, and covalently cross- 
linked in the outer mannoprotein layer [40]. Both p-glucans and mannoproteins 
are essential for yeast growth and survival. Chitin forms a further essential 
component of yeast cell walls although it is less abundant than glucans and 
mannans [43]. It consists of N-acetlyglucosamine chains which form a crystal­
like rigid structure. Chitin is particularly critical at yeast budding where it forms 
the primary septum between the bud and the mother cell. A secondary septum 
of P-glucan and mannoprotein is then laid-down before chitinase digests the 
primary septum to release the daughter cells [41]. Chitin is therefore greatly 
enriched at bud scars, along with exposed P-glucans, possibly making both of 
these compounds good markers of actively replicating yeasts. Chitin is also 
enriched in hyphal walls where p-glucan molecules are well masked.
Studies on Candida have confirmed that this opportunistic pathogen has a cell 
wall, almost identical in composition to that described for S. cerevisiae 
(Reviewed in [44]).  Although the structure of yeast cell wall has been disrupted 
in zymosan, the majority of essential components are maintained, and it is 
reasonable to use zymosan as a source of yeast PAMPs.
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Figure 1-4: A schematic diagram of  yeast cell walls adapted  from Lipke and Ovale 1998 [40]
1.2.4  Innate recognition of zymosan
Recognition of zymosan by the innate immune system has been proposed to 
involve complement receptors [45], mannose receptors [46] [47] and p-glucan 
receptors [48, 49]. Zymosan is a very efficient surface for complement fixation 
and complement is likely to play an important role in clearing yeast infections 
in vivo [50]. However, complement does not distinguish between different types 
of infectious organism and therefore will not be considered further. The role of 
mannose receptors is controversial. The original observation by Sung et al [46] 
that phosphomannan inhibits binding and phagocytosis of zymosan by murine 
peritoneal macrophages is brought into question by the observations of Kaddish 
and Goldman [48, 49] that p-glucan is far more effective at inhibiting yeast 
phagocytosis and that treatment of mannan preparations with a P-glucanase to 
remove any traces of contaminating p-glucan abrogated the inhibitory effect of 
mannan on zymosan phagocytosis by macrophages. It now appears that the 
major yeast PAMP recognised by macrophages is p-glucan, an essential 
structural component of yeast cell walls.
20Dectin 1   is a type II membrane protein with an extracellular C-type lectin 
domain lacking the residues normally involved in calcium binding [51] [52].
The intracellular tail is just 32aa long and contains an ITAM-like motif [52]. It 
shows significant homology to LOX-1  (the oxidised LDL-receptor), CD94, 
CD69 and NKG2D [53]. The receptor was originally identified by subtractive 
cloning from a murine DC-like cell line XS52 versus the macrophage-like line 
J774  [52]. However, whilst this group identified that Dectin-1  contained a 
putative carbohydrate binding domain they found that a soluble His-tagged 
version of the protein bound to the surface of T cells in a protease-dependent 
but N-glycosidase independent manner suggesting the presence of a protein 
ligand for Dectin-1   expressed on T cells. Shortly afterwards Brown and Gordon 
identified Dectin-1 as a zymosan-binding receptor in a screen of RAW264.7 
cDNAs [54]. They, along with Gantner et al, found that the binding of zymosan 
by Dectin-1  transfectants was efficiently inhibited by p-l,3-linked and [3-1,6- 
linked P-glucans such as Laminarin and glucan phosphate [55, 56]. Using a 
carbohydrate array it was suggested that it is the presence of pi,3-linked 
glucans that lends Dectin-1  binding specificity [57]. Site-directed mutagenesis 
identified a triple a a  Trp-Ile-His motif as well as the 4  cysteine residue as 
critical for binding both to p-glucan and an antagonistic antibody [58]. The Trp- 
Ile-His motif is not shared by the NKG2 proteins, supporting the possibility that 
it is important for the specific binding of Dectin-1. Interestingly, the binding of 
T cells to Dectin-1  transfectants was unaffected by soluble P-glucans suggesting 
that an alternative ligand-binding site on Dectin-1 exists.
21Dectin-1
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Figure 1-5: Dectin-1 is a C-type lectin with extracellular CLECT domain and intracellular 
ITAM-like motif, shown compared to the consensus sequences for ITAMs and ITIMs. Drawn 
with reference to [38].
The PRR for zymosan had previously been identified as TLR2/6 heterodimers 
[59], although the TLR2/6 ligands within zymosan have not yet been identified. 
Inhibiting the interaction between Dectin-1  and zymosan with soluble p- 
glucans, or an anti-Dectin-1  antibody, decreased zymosan binding by 
macrophages [55, 56, 60]. Inhibiting Dectin-1  binding also caused a decrease in 
TLR2-dependent production of TNFa in response to zymosan [55, 56]. 
However, using inhibition alone it is impossible to distinguish between a simple 
requirement of Dectin-1  to present zymosan to TLR2 for pattern recognition,
22and a requirement for Dectin-1  signalling. Over-expression of wild-type Dectin- 
1   was demonstrated to amplify TNFa production stimulated by zymosan in the 
macrophage-like cell-line RAW264.7. Dectin-1 mutants which either lack the 
intracellular tail, or lack the ITAM-like motif are unable to induce this 
amplification despite efficiently increasing zymosan binding. This indicates that 
the Dectin-1  intracellular tail may play a role in signalling for TNFa production 
[55].  A similar system in which wild-type Dectin-1  or mutants lacking 
intracellular signalling capacity were cotransfected into 293T cells with TLR2 
and an NF-kB reporter demonstrated that only wild-type Dectin-1  could amplify 
NF-kB activation induced by zymosan [56]. Intriguingly, it was demonstrated 
that p-glucan recognition alone was sufficient to induce an oxidative burst in 
TLR2-deficient macrophages [56], implying that Dectin-1  may have a TLR2- 
independent signalling role, beyond binding and uptake of yeasts. In dendritic 
cells TLR signalling is completely dispensable for zymosan induction of IL-10 
suggesting the existence of a TLR-independent pattem-recognition pathway for 
yeasts, potentially involving p-glucan recognition by Dectin-1. Since p-glucan 
fills the criteria of a yeast PAMP very well, Dectin-1  is a good candidate PRR.
In support of Dectin-1   as a yeast PAMP receptor, Dectin-1   appears to recognise 
Candida yeasts effectively, but not Candida hyphae [61]; as well as Aspergillus 
fumigatus conidia, but not hyphae [62, 63](reviewed in [64]). Cytokine 
production by peritoneal macrophages stimulated with the primary pathogen 
Coccidioides posadasii requires signalling through TLR2, MyD88 and Dectin-1 
[65].
Innate recognition of p-glucans is phylogenetically ancient. In drosophila, and 
the silkworm Bombyx mori, yeast p-glucans are recognised by soluble, or GPI- 
anchored PRR’s with homology to the P-l,3-glucanase of Bacillus circulans 
leading to the indirect activation of Toll signalling [66] [67]. In jawed 
vertebrates this mechanism appears to have been superceded by Dectin-1, 
providing direct pattern recognition. Dectin-1  is encoded within a cluster of C- 
type lectins [53], many of which have immune functions, such as the NKG2
23proteins. This suggests it has evolved as the result of gene duplications 
relatively recently in evolutionary history.
1.3  Translating innate into adaptive immunity
1.3.1  PRRs link the type of challenge encountered to recruitment of 
appropriate effector mechanisms
It has long been recognised that the immune response to an infection must not 
simply be activated but must also be directed to include effector mechanisms 
that will best combat that infection [1]. For example successful immune 
responses to viruses require the production of high levels of type I interferons 
[68] cytotoxic T cells, NK cells and neutralising antibodies (predominantly Thl 
responses). Gut nematode infections such as trichuriasis and ascariasis are 
instead associated with eosinophilia, high levels of Ig-E and Ig-A, mastocytosis, 
increased mucous secretion, mucosal permeability and gut motility 
(predominantly Th2 responses)[69]. Induction of inappropriate (Th2) responses 
to mycobacteria results in progressive disease, highlighting the importance of 
controlling the class of immune response induced (Reviewed in [70], [71],
[72]).
There is evidence that a similar story exists in Drosophila. Anti-microbial 
peptides targeted against either fungi (including Metchnikowin,and 
Drosomycin) or gram-negative bacteria (including Defensin, Cecropin, and 
Attacin) are induced downstream of receptors which recognise these classes of 
infection; Toll and 18-wheeler respectively [73]. This suggests that 
evolutionarily ancient mechanisms not only alert the immune system to the 
presence of potential infections but also provide some general information on 
the nature of the challenge.
How does recognition of microbial stimuli lead to the observed priming of 
appropriate adaptive immune responses?  The ‘real’ answer to this is 
exceedingly complex since the immune system operates in an intricately
24interconnected manner to initiate, propagate, feedback and hone the responses 
induced. In most cases when a pathogen is encountered an acute inflammatory 
reaction is triggered [6]. Tissue fluid and inflammatory cells (neutrophils, 
macrophages, NK cells) accumulate in the region of tissue affected, cascades of 
tissue factors lead to the production of bradykinin and extracellular matrix 
remodelling, inducing pain and behavioural changes and favouring containment 
of infection and migration of leukocytes [6]. The majority of these responses 
will occur regardless of whether the challenge is viral, bacterial, eukaryotic, or 
even sterile injury such as myocardial infarction (e.g. complement fixation 
producing the potent anaphylatoxins C3a and C5a will occur in all of these 
situations [74, 75]). If the acute inflammatory response was triggered by 
microbial stimuli acting via PRRs, then immediately a specific set of events will 
be set in motion. For example we know that production of extremely high 
systemic levels of type I interferons occurs very rapidly after viral inoculation 
(reviewed in [76]) when compared to infection with gut nematodes. These 
initially minor differences become amplified as different cell-types and humoral 
effectors are recruited to the site of infection.
1.3.2  Dendritic cells translate innate into adaptive immunity
Dendritic cells are a heterogeneous group of leukocytes with superior abilities to 
capture antigen and integrate signals from the site of acute inflammation [77]. 
Integrated information on the nature of the challenge is then translated into 
signals that prime appropriate T cell responses [78]. Concentrating on how DC 
respond to particular challenges, and how T cells respond to particular DC 
provides a powerful framework on which we can start to ask how appropriate 
adaptive immune responses are initiated. It is important to recognise the 
reductionist nature of this line of enquiry, as necessarily it is only an 
approximation of the complex behaviour demonstrated during immune priming 
in vivo.
Dendritic cells were first identified by Steinman and Cohn in  1973 as a novel 
population of splenocytes [79]. Subsequently these cells were found to express
25high levels of MHC molecules and to be extremely potent stimulators of MLR 
responses [80], [81], [82]. DC were found to be the main antigen-bearing cells 
after intravenous or intraperitoneal injection of antigen in mice [83] hinting at 
their powerful antigen-capture abilities in vivo.
Langerhans cells in skin had been identified some time earlier and suggested to 
play a role in T cell activation. However, their ability to stimulate T cells was 
found to be only comparable to that of macrophages [84]. Schuler and Steinman 
[85] found that ex vivo culture of Langerhans cells caused the upregulation of 
MHCII which correlated with an increase in MLR-stimulating ability and hence 
defined Langerhans cells as efficient antigen-presenting cells. They also 
proposed that Langerhans cells are the immature counterparts of  immunogenic 
DC in secondary lymphoid tissues.
In fact Langerhans cells are not precursors of splenic DC but are an epidermal 
dendritic cell subset, the mature counterparts of which are found in skin- 
draining lymph nodes [86]. Several subsets of DC have now been described in 
spleen, lymph nodes and tissues under steady state conditions [86] with 
additional populations found during inflammatory responses [87]. To take 
splenic DC as an example, these are now classified into at least 4 subsets that do 
not interconvert. Three populations are defined as ‘conventional’ DC and are 
defined by high expression of CD1 lc and MHC II combined with expression of 
CD4, CD8 or neither. Functional differences have been described between the 
subsets, for example CD8-positive DC are extremely good at cross-presenting 
cell-associated antigen (reviewed in [88]) and produce high levels of IL-12 p70, 
whereas CD4-positive cDC are relatively poor producers of IL-12 p70 (for 
example TLR7 is expressed in CD8-negative, but not CD8-positive DC [89]). In 
addition there are differences in the expression pattern of PRR’s. The 
significance of this is not entirely clear, as at least in vitro, all subsets are 
capable of flexibly inducing different patterns of T cell differentiation 
depending on the PRR triggered [90] [78]. The fourth splenic DC subset are 
plasmacytoid DC. These have a markedly different morphology to cDC and are
26notable in their ability to produce very high levels of type I interferons in 
response to extracellular viral PAMPs [91].
The majority of work in this thesis has employed dendritic cells differentiated 
from bone marrow in the presence of GM-CSF [92]. These have recently been 
reported to bear similarity to a DC subset that differentiates from monocytes 
during inflammatory conditions in vivo [87].
A further implication of the observations of Schuler and Steinman was that DC 
are not constitutively immunogenic. Koide et al [93]demonstrated that the 
proposed role of IL-1  as a costimulator of T cell responses was actually due to 
its effect on dendritic cells, rather than direct costimulation of T cells [93] 
further supporting this notion. It is now well accepted that the majority of DC, 
regardless of subset, are in an “immature” state in a healthy animal and acquire 
the ability to instruct T cells only after triggering of maturation.
271.3.3  Dendritic cell maturation is induced by innate signals
Immature DC express low levels of surface costimulatory molecules and MHC 
and have high pinocytic and endocytic activity [77]. On stimulation, a 
maturation programme is initiated in which captured antigen is loaded onto 
MHC and delivered to the cell surface, costimulatory molecules such as B7.1, 
B7.2 and CD40 are displayed, cytokines are produced and DC migrate to the T 
cell areas of secondary lymphoid tissues [77]. There is considerable flexibility 
in phenotype of mature DC produced depending the stimulus [94], [95], [96]. 
Quantitative differences in MHC upregulation (Recently reviewed in [97, 98]); 
differential display of a wide range of costimulatory molecules with both 
positive and negative effects on T cell differentiation (B7-related molecules 
B7.1, B7.2, B7-H3, PD-L1, B7-H4 and TNF-TNFR relations OX40L, 
TRAIL/LIGHT, CD70, GITRL, HVEM, 4BBL amongst others, (recently 
reviewed in [99], [100])) and production of a variable cocktail of cytokines 
define these phenotypes. The particular combination of costimulatory 
molecules, cytokines etc produced by a dendritic cell (and possibly the timing 
of production of such factors) can profoundly influence the differentiation of a 
T cell clone encountering its cognate antigen on that particular dendritic cell
[101], [102],  [103], [104].
A good, if extreme, example of this is in mixed bone marrow chimeras in which 
half of the DC population cannot respond to the TLR9 ligand CpG [101]. 
Injection of CpG into the mixed chimeric mouse will directly stimulate only the 
TLR-9 sufficient DC. Inflammatory mediators produced by the TLR9-sufficient 
cells are sufficient to result in upregulation of surface MHC and surface 
costimulatory molecules on the TLR9-deficient DC. However, despite almost 
equivalent maturation in terms of surface markers only the TLR9-sufficient DC 
can produce IL-12 [101]. If an MHC mismatch is introduced such that TLR9- 
expressing DC cannot present to antigen-specific T cells but TLR9-deficient DC 
can, it is found that T cells primed by this route proliferate almost as well as T 
cells primed in control chimeras in which TLR9-sufficient DC can also present
28cognate antigen. However T cells primed on indirectly activated DC do not 
differentiate into IFNy-producing effector cells whilst those primed in TLR9- 
sufficient DC do [101]. This indicates that DC stimulation by inflammatory 
mediators is sufficient for costimulatory molecule upregulation and instruction 
of T cell proliferation by DC. However, inflammatory mediators alone cannot 
induce DC cytokine production and fail to instruct effector T cell differentiation 
in vivo. There are also numerous reports of cytokines such as TNFa, IFNa, and 
IL-15 [105-107] leading to upregulation of surface markers on DC without 
inducing DC cytokine production.
1.3.4  Intracellular Signalling linking PRRs and DC activation
A well characterised trigger of DC maturation is TLR ligation, therefore a good 
starting point for study of signalling in DC maturation is to assess the signalling 
requirements in this specific example. As already mentioned, ligand-induced 
dimerisation leads to the recruitment of TIR-containing adaptor proteins 
(MyD88 and TRIF) to the TIR domains of TLRs through TIR-TIR interactions. 
It has recently been demonstrated that in the case of TLR4 (and by analogy 
TLR2) a second TIR-containing adaptor, TIRAP, is crucial to deliver MyD88 to 
PIP2-enriched membrane domains where these TLRs are localised, implying 
that TIRAP is a “sorting adaptor” [108]. By analogy it seems likely that TRAM 
plays a similar role in bringing TRIF into the correct location for TLR4 
signalling [31] [108]. TRIF is required for TLR3 signalling but TRAM is not, 
fitting with the observation that TLR3 is present in a different endomembrane 
compartment (endosomes) and would hence require a different sorting adaptor. 
IL-1-Receptor, TLR5, TLR7 and TLR9 signal via MyD88 with no requirement 
for TIRAP possibly also due to alternative membrane localisation. (Reviewed in 
[23])
MyD88 interacts with the serine/threonine kinases IRAKI and IRAK4 via its 
death domain. This leads to the recruitment and activation of the E3 ubiquitin 
ligase TRAF6 and the MAP3KTAK1. K63-polyubiquitination ofTAKl  leads 
to the activation of MKK3/6 and the p38 MAPK cascade and to K63-
29polyubiquitination of NEMO/IKKy and N K -kB activation, (reviewed in [22], 
depicted in figure  1.6). IRAK4-deficient mice show massively decreased 
sensitivity to Interleukin-1, LPS (TLR4), CpG (TLR9) and slight decreases in 
response to Peptidoglycan (TLR2/NOD2), and polyI:C (TLR3) [109] reflecting 
the TRIF-dependence of TLR3 signalling and the divergent signalling 
downstream of NOD-protein recognition [109]. TRAF6-/- mice show no MAP 
kinase phosphorylation and no IkB degradation in response to CpG or Pam3Cys 
(TLR2/1) but partial responses to LPS and wild-type responses to polyI:C [110] 
indicating an essential role in MyD88 signalling, but not TRIF signalling (See 
figure  1.6).
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Figure 1-6: MyD88-dependent TLR signalling,  (drawn with reference to [22])
TRIF, like MyD88, associates with particular TLRs through a TIR domain, but 
it bears little homology to MyD88 over the rest of the molecule and signals in a 
correspondingly divergent manner (as reviewed in [111]). Signalling 
downstream of TRIF appears to require TRAF3 [110]and TBK1  leading to the 
activation of IRF3/7 and production of type I interferons [112].
It has been proposed that the use of different signalling adaptors is sufficient to 
explain the differences in cytokine production observed downstream of TLRs
31[28]. This is an attractive idea but implies the existence of further adaptors yet 
to be described that explain the subtleties of TLR5, TLR7, TLR9 and 
Interleukin-1  responses which all use the MyD88 adaptor exclusively but elicit 
dramatically different responses from a single purified subset of dendritic cells 
(for example in GM-CSF BMDC, TLR9 ligands induce high levels of IL-12 
p40, IL-6 and IL-2 [96] whereas IL-1 does not induce cytokine secretion). An 
alternative explanation is that the localisation of TLRs to different membrane 
microdomains or compartments gives access to slightly different signalling 
components, for example the delivery of CpG to different endosomal 
compartments can alter the ability to induce production of IFNa from PDC 
[113] [113]. Further to this, TIR domains show only around 20% sequence 
conservation (Recently reviewed in [111]) implying that the different TLRs 
have evolved to form divergent signalling interactions, either in terms of 
affinity/kinetics of interactions with known signalling partners or association 
with alternative signalling molecules.
NF-kB, MAP kinase and IRF3/7 pathways are known to be activated directly by 
TLR signalling (Reviewed in [22]). Considerable work has been devoted to 
determining the requirements of known signalling components for particular 
features of DC maturation. Cytokine production is induced primarily as a direct 
result of PRR signalling [101,  114], i.e. is the result of a restricted pattern of 
signalling events. It is therefore possible to define a relatively large number of 
signalling components found downstream of PRRs which are necessary for 
cytokine production.
IL-12 p40 is produced by DC in response to TLR ligation (with the possible 
exception of TLR5) and in response to zymosan ([96], Chapter 4). Induction of 
IL-12 p40 is inhibited by disruption of the p38 MAPK [115] pathway or the NF- 
kB pathway [116]. In addition, IkB^, an immediate-early gene induced 
downstream of TLR signalling is essential for IL-12 p40 production [117]. 
ICSBP (IRF8), IRF1  and NFAT have all been proposed to play a role in the 
induction of IL-12 by various stimuli in macrophages and DC [118-122]. 
However it is unclear how these transcription factors become active after TLR
32ligation. Conversely, inhibition of ERK MAPK increases IL-12 production in 
response to a number of stimuli [123] [124]. This may be partially due to the 
role of ERK in the induction of IL-10, which can negatively feedback to inhibit 
IL-12 production.
Several reports suggest similarity in the requirements for IL-6 and IL-12 
production by DC. Production of IL-6 also requires IkB^ [117]. In addition an 
elegant paper by Saccani et al suggests that robust p38 MAPK activation is 
essential to phosphorylate Histone H3 at the promoters of IL-6, IL-8, MCP-1 
and IL-12 p40 to allow recruitment of NF-kB[125]. The authors demonstrated 
their hypothesis directly for the MCP-1   and IL-8 promoters, although poor 
quality of c-Rel antibodies made direct observations of IL-12 p40 and IL-6 NF- 
kB recruitment impossible. The authors further go on to show that stimulation 
of DCs with TNFa, CD40L or IL-113 resulted in similar NF-kB activation but 
much weaker p38 MAPK activation when compared to LPS. This correlated 
with decreased H3 phosphorylation suggesting that the ability of a stimulus to 
induce cytokine transcription may dependent on its ability to induce a strong 
p38 MAPK signal.
The 3’ UTR of mRNAs for IL-6, TNFa and IL-2 contain AU-rich elements. 
Tristetraprolin binds ARE-containing mRNAs by sequestering mRNA into 
stress-granules or related protein complexes that inhibit translation and promote 
mRNA degradation [126]. MAPKAP Kinase 2 (MK2) the MAP kinase target, 
phosphorylates Tristetraprolin leading to association with  14-3-3 proteins, 
relocalisation and therefore mRNA stabilisation [126]. Macrophages deficient in 
MK2 show a dramatic decrease in IL-6 and TNFa production in response to 
LPS and TNFa production becomes MK2-independent if the AU-rich element 
is deleted from the TNFa mRNA 3’UTR [127].  MK2-deficient mice show a 
defect in the induction of IL-12, IL-10, IL-6, IL-1  p and TNF from splenocytes 
after LPS injection [128] although it is not clear whether all of these cytokines 
are regulated at the translational level or whether MK2 has additional functions. 
It has been suggested that ERK signalling regulates nuclear export of TNFa 
mRNA [129]. There are further reports that the ERK pathway can influence
33cap-dependent translation initiation through the phosphorylation of eIF4E and 
eIF2a by promoting Protein Phosphatase 1  activity, or via Mnkl and 2 
respectively [130,  131]. Clearly both transcriptional and post-transciptional 
events control cytokine production downstream of TLR ligation.
Control of IL-2 production in T cells is also mediated by Tristetraprolin-binding 
to the AU-rich element within the 3’ UTR of IL-2 mRNA [132]. Although this 
is yet to be characterised in DC, it is a reasonable hypothesis that MK2 
phosphorylation of TTP is also an important step in IL-2 production in DC. 
Other known requirements for IL-2 production by dendritic cells include a 
requirement for paracrine or autocrine signalling by IL-15[ 133].
IL-10 is associated with the suppression of inflammatory responses and 
inhibition of Thl polarisation (reviewed in [134]). IL-10 can decrease the 
production of IL-12 p70 by DC, and blocking of IL-10 will increase IL-12 p70 
production in response to ligands for TLR2, TLR4 or TLR9 [132]. The 
induction of IL-10 by TLR ligands requires ERK activation via TPL2/NF-kB1. 
TPL2 is a MEK kinase that becomes active on NF-kB p i05 degradation^35]. 
Downstream of ERK, c-fos is required for transcription of the IL-10 gene [136].
Although attempts have been made to study signalling required for surface 
marker upregulation, results are highly variable and can be contradictory. A 
case in point is the upregulation of B7 costimulatory molecules during DC 
maturation. Multiple interconnected signalling pathways, including the 
production of autocrine and paracrine intercellular signals such as IFNa[106] 
and IL-15[ 107], play a role in the upregulation of costimulatory molecules by 
DC. Inhibition of NF-kB by overexpression of IkB or use of inhibitory peptides 
limits B7 upregulation in response to LPS (signalling through TLR4) and 
CD40L [116,  137,  138]. However, TREM2 signalling through DAP 12 appears 
not to activate the NF-kB pathway in DC but is still capable of producing robust 
B7 upregulation [139]. ERK and p38 MAPK inhibitors appear to have either 
neutral [139,  140], positive [140]or negative effects on B7 levels [141], possibly
34depending on whether the stimulus applied elicits a MAPK-dependent inhibitor 
or promoter of DC maturation.
DC must respond specifically to an enormous number of external cues using a 
comparatively limited number of signalling pathways. There is unlikely to be a 
specific pathway for each PRR. A plausible alternative is that each PRR 
initiates a specific sequence of intricately networked events, the identity, but 
also the timing and localisation of which encode the signal received.
The ERK MAP Kinase pathway provides a good example of how localisation of 
signalling is controlled. ERK MAP kinase signalling could propagate as a series 
of phospho-protein waves from the cell surface to the nucleus, but this process 
would be rapidly attenuated by phosphatases that limit the half-life of active 
kinases and therefore the distance over which the signal can be propagated by 
diffusion (as discussed in [142]). It now appears that scaffolds promote the 
physical association of kinases in a cascade (for example KSR can bind to Rafl, 
MEK and ERK -  reviewed in [143]). This induced proximity increases 
processivity of the cascade. In addition KSR can control the localisation of ERK 
activity. In response to growth factor signalling KSR translocates to the plasma 
membrane from lipid rafts or the cytosol (reviewed in [143]). Evidence suggests 
that scaffolding proteins can associate with molecular motors or trafficking 
endosomes to propagate signals between two or more compartments. Sef, an 
alternative ERK scaffold appears to retain active ERK on the Golgi apparatus 
preventing phosphorylation of nuclear targets and promoting the 
phosphorylation of cytoplasmic proetins  (reviewed in [142], [143]).  These 
observations, combined with the classic PC 12 cell experiment in which 
prolonged ERK activation promotes differentiation whilst transient ERK 
activation promotes proliferation (reviewed in [144]) suggest that even single 
components in signalling networks can instruct very different outcomes. Whilst 
it is possible to identify important players in the signalling networks that are 
absolutely required for signal propagation the actual outcome of signalling may 
often depend on much more subtle interactions that are not revealed by deletion 
of specific components. It is relatively simple therefore to show that in response
35to a defined signal a signalling component links the network to a particular facet 
of the response. To demonstrate that signalling via a particular pathway or 
component is sufficient for a given response is almost impossible due to the 
high levels of interconnectivity.
The production of cytokines by murine DC, as discussed earlier, appears to 
reflect bona fide direct pattern recognition [101], suggesting an absolute 
requirement for particular patterns of signalling occurring exclusively 
downstream of PRRs. This correlates well with the greater number of genetic 
and chemical disruptions found to inhibit the production of particular dendritic 
cell cytokines. For these reasons cytokine production is used in this thesis as a 
mark of direct pattern recognition by DC, and as a useful phenomenon to 
elucidate the signalling downstream of zymosan recognition.
1.3.5  Intracellular Signalling linking Zymosan recognition and DC 
maturation
Innate recognition of zymosan by dendritic cells induces upregulation of MHC 
class II, B7.1, B7.2 and CD40 and production of large amounts of IL-12 p40,
IL-10 [96] and IL-2 [145]. In chapter 4 of this thesis I demonstrate that BMDC 
also produce large amounts of TNFa, IL-6 and IL-12p 19 (IL-23) and upregulate 
the Notch-ligands DLL1, DLL4, Jagged-1   and Jagged-2. Both TLR2/6 
heterodimers and p-glucan recognition, putatively via Dectin-1   are implicated in 
these responses. Whilst the production of IL-2, IL-6, IL-12 and DLL4 has a 
strong TLR2/MyD88-dependent component, IL-10 and Jagged-1   are 
upregulated in a TLR-independent fashion. It has previously been demonstrated 
that upregulation of surface markers is also completely TLR-independent [96].
TLR2/6 signalling via MyD88 stimulates the ERK pathway strongly [136]in a 
TPL2-dependent fashion (Dr MJ Robinson, Cancer Research UK, London, 
personal communication). This leads to the induction of IL-10 in response to 
well-defined TLR2 ligands such as synthetic lipopeptides. However, I have 
found that the amount of IL-10 produced in response to lipopeptides is orders of
36magnitude lower than that induced in response to zymosan (see chapter 4). 
MyD88-deficient DC show no defect in IL-10 induction suggesting that the 
Dectin-1  pathway alone provides a potent IL-10 -inducing stimulus.
Dectin-1  signalling is implied by the presence of an ITAM-like motif in the 
cytoplasmic tail [52]. We demonstrate that this ITAM-like motif couples to Syk 
to mediate downstream signalling. Syk-deficient DC produce almost no IL-10 
or IL-2 in response to zymosan although production of IL-12 p40 is unaltered 
(see chapter 4, [146]). Also, ERK activation is completely dependent on Syk in 
response to zymosan and appears to require different downstream targets to 
induce IL-10 transcription from those implicated downstream of TLRs (see 
chapter 5).
Dectin-1  signalling through Syk may deviate slightly from classical IT AM 
signalling such as that occurring downstream of the B cell receptor. A very 
recent example of this is the report that Dectin-1  mediated NF-kB activation is 
induced through Bel 10 and MALT1  [147], both of which are used in antigen- 
receptor signalling. However the upstream activator of Bel 10 in Dectin-1 
signalling is CARD9 and not CARMA1, which is normally used in IT AM 
signalling [147].
Dectin-1  is the first example of a bona-fide cell surface PRR which is 
evolutionarily distinct from the TLRs and uses distinct signalling pathways to 
mediate DC activation and cytokine production.
1.4  Instruction of T cell differentiation into appropriate effectors
The process of DC maturation leads to the instruction of optimal T cell 
responses. As discussed previously dendritic cells are extremely efficient at 
inducing effector T cells in vitro and in vivo and may be the only cell types 
capable of priming naive T cells. Upregulation of antigen-presentation and 
costimulatory molecules on DC by inflammatory stimuli is sufficient to induce 
T cells proliferation in vivo [101]. However most evidence suggests that these
37signals alone are not sufficient for T cells to acquire effector functions. DC that 
have been stimulated via bona fide PRRs induce the differentiation of effector T 
cells [78], [90].
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Figure 1-7: T cell differentiation into Thl,  Th2 or Thl7 effector T cells can be controlled by 
cytokines from innate immune cells.
Thl  effector T cells produce IFNy, TNFa, IL-2 and occasionally IL-10 [148]. 
IL-12 produced by TLR-stimulated DC correlates well with Thl  induction [103] 
and mice deficient in any of the components of IL-12 production or signalling 
show severely impaired Thl responses [149,  150].
Expression of the T-bet transcription factor is both necessary and sufficient for 
Thl  polarisation. It has been suggested that IFNy can directly turn on T-bet
38expression and although production of IFNy by murine DC has not been 
convincingly demonstrated, this agrees well with data suggesting that activated 
DC can recruit IFNy-producing NK cells into lymph nodes to promote Thl 
priming [151].
It is clear in vivo that DC stimulated by PAMPs and delivering IL-12 in cis can 
instruct the development of robust Thl responses [101] whilst indirectly 
activated DC are much less potent. It is currently unclear whether IL-12 is the 
decisive cis-restricting factor or whether IL-12 correlates with a novel Thl- 
polarising stimulus that can only be induced by direct PRR signalling. Notch 
ligation by Delta-like ligands has been proposed as a potential alternative 
(reviewed in [152]). It remains possible that IL-12 and IFNy are the critical 
requirements for Thl differentiation and that the initial stage of T cell priming 
is identical for both Thl  and Th2 producing clones which stochastically adopt 
one or other fate.  In support of this notion an elegant set of experiments 
demonstrate transcription of both IL-4 and IFNy within  lhr of T cell stimulation 
regardless of Thl  orTh2 polarising conditions [153].
Thl7 cells are a recently discovered type of effector T cell [154,  155]. These 
produce high levels of IL-17, as well as TNFa and have been predominantly 
associated with aggressive autoimmune diseases such as Inflammatory Bowel 
Disease [156]. Thl 7 cells were recently identified as a distinct lineage of helper 
T cells and IL-23 production (a cytokine made up of IL-12 p40 with the IL-23 
p 19 homologue of IL-12 p35) was implicated in promoting Thl7 responses 
[154,  155]. It now appears that TGFp plays an instructive role in Thl7 
differentiation [102] in combination with IL-6, whilst IL-23 is critical for the 
survival and expansion of Thl 7 clones.
Th2 cells produce IL-4, IL-5 and IL-13. Th2 responses are critical for the 
clearance of large eukaryotic parasites such as the gut nematodes ascaris and 
trichuris [69]. The link between DC maturation and Th2 induction has been 
relatively elusive. Th2 inducing stimuli such as Schistosome Egg Antigen 
(SEAg) are poor inducers of DC maturation both at the level of costimulatory
39molecules and in cytokine production [157]. The presence of IL-4 is suggested 
to play a critical role as IL-4 deficient, and STAT6 deficient mice have a severe 
defect in Th2 development (reviewed in [158]) and in clearance of gut 
nematode infections [159]. C-Maf and Mel 18 interact with GAT  A3 and mice 
deficient in any of these proteins have defective Th2 responses [158]. Recently 
there has been significant interest in the role of Notch signalling in Th2 
specification (reviewed in [152]).
1.4.1  Notch-ligands and Signalling
Interest in the role of Notch-ligands in T cell differentiation has been ignited by 
a recent claim that Jagged-like ligands may be the elusive dendritic cell factors 
that drive Th2 differentiation [160]. However, this is still some way from being 
conclusively proven.
There are 4 mammalian Notch receptors (Notch 1-4) and 5 ligands (Jagged-1, 
Jagged-2, DLL-1, DLL-2 and DLL-4) (reviewed in [161]). Variable levels of 
ligands and receptors are expressed by both T cells and antigen-presenting cells 
(reviewed in [161] [152]). Notch activation occurs when the receptor binds to a 
ligand presented on an adjacent cell. Proteases of the ADAM/TACE family then 
mediate cleavage of Notch at the extracellular S2 site. S2-cleaved Notch is 
endocytosed by the T cell and then further cleaved by the y-secretase complex 
(S3 cleavage) releasing the intracellular domain of Notch (NICD) into the 
cytosol (reviewed in [162] [161]). NICD translocates into the nucleus where it 
associates with RPBJk/CSL and forms protein complexes that activate 
transcription from particular promoters (reviewed in [161]).
There is now strong evidence for the modulation of mRNA levels of Notch- 
ligands in APC on microbial recognition [32] [160] as well as some evidence 
for modulation at the protein level (chapter 4). The different Notch-ligands 
differ significantly in their extracellular and intracellular domains but all contain 
the conserved DSL motif, required for Notch-binding, and a number of EGF 
repeats (reviewed in [161]). These differences in structure are at least partially 
responsible for observed differences in binding of Notch-ligand-Fc-fusion-
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DLLl-Fc gives intermediate staining and Jagged-1-Fc mediates only very weak 
staining as compared to isotype controls [163]. The ability of the immobilised 
recombinant ligands to bind T cells correlates well with the induction of 
classical notch signalling (reviewed in [152]).
The Notch receptors and ligands are heavily glycosylated and regulation of this 
glycosylation can affect the affinity of Notch/Notch-ligand interactions [164]. 
Fringe (0-fucose-|31,3-N-acetylglucosaminyltransferases) proteins add pi,3-N- 
acetylglucosamine residues onto extensively O-fucosylated EGF repeats of 
Notch receptors, altering interactions with Delta-like ligands and Jagged-ligands 
[164]. Effects of Fringe expression are however difficult to predict as even 
when considering Notch-1   in isolation the three mammalian Fringes can either 
increase or decrease Notch-1   signalling in response to Jagged-1, although all 
three Fringes increase the sensitivity of Notch-1   to Delta [164]. The effect of 
Fringe on Notch-signalling appears to act at the level of induction of S2 
cleavage rather than inhibition of binding suggesting that Fringe expression is 
not responsible for the variable binding of purified Notch-ligands to naive T 
cells [163].  At the time of writing, published data on the regulation of Fringe 
expression in T cells was not available.
Simply ligating Notch is insufficient for activation. Studies on Drosophila 
mutants suggest that dynamin-dependent endocytosis of the ligand is required to 
activate signalling through the Notch receptor [162]. Mice have been generated 
which carry a deletion of the E3 ubiquitin-ligase Mind bomb  1   which is 
implicated in ligand endocytosis [165]. Homozygous embryos die at El 1.5 due 
to multiple defects attributable to deficient Notch signalling. Cells from mutant 
embryos show an accumulation of DLL 1  at the cell surface, compared to 
predominant perinuclear distribution in wild-type cells, demonstrating a defect 
in ligand endocytosis that phenocopies the defect in drosophila lacking Mind 
bomb [165]. It is unclear whether the requirement for ligand endocytosis is a 
physical requirement for S2 cleavage of Notch or whether recycling through 
endosomes is necessary for the generation of active Notch-ligands [162]. Free,
41soluble ligands can antagonise Notch activity induced by both membrane-bound 
Notch-ligands and plastic-bound Notch-ligands, apparently by allowing S2, but 
not S3 cleavage to take place [162] [166]. Intriguingly, S3 cleavage requires 
endocytosis of S2-cleaved Notch, possibly due to the localisation of y-sectretase 
complexes within endosomes (Reviewed in [166] [162]).
1.4.2  Notch-ligands and T cell differentiation
A high profile paper recently implicated Jagged-1  and Jagged-2 as Th2- 
inducing ligands induced on DC by typical Th2 stimuli whilst DLL 1   and DLL4 
acted as Thl-inducing ligands [160]. This was concluded as a results of 
overexpressing either human Jagged-1   or DLL 1  on a mouse fibroblast cell line 
previously engineered to express murine MHC-class II and B7 molecules 
(DCEK cells). Ectopic expression of human Jagged-1   induced Th2 
differentiation of naive T cells, DLL-1  expression induced Th 1   differentiation 
[160]. In addition, Jagged-2 upregulation correlates with DC recognition of 
classic Th2 stimuli such as Cholera toxin and Prostaglandin E2, whilst DLL4 is 
upregulated by strong Thl-inducing stimuli [160]. The authors’ statement that 
Jagged-1   and Jagged-2 are functionally equivalent is slightly dangerous 
generalisation in this context as the primary structure of these ligands is 
relatively divergent (reviewed in [161]). More compelling is the observation 
that Th2 differentiation in the presence of IL-4, a strong Th2 polarising 
stimulus, is impaired in RBPJk-/- T cells and that expression of the Notch 1   ICD 
in T cells can upregulate IL-4 and GAT  A3 expression and down-regulate T-bet 
[160].
A role of DLL-1  in Thl polarisation has been suggested previously using 
DLLl-Fc fusion proteins to promote Thl responses in vitro [167]. In addition, 
treatment of BALB/c mice with DLLl-Fc at the site of infection with 
Leishmania major resulted in increased Thl responses and improved pathogen 
clearance. The authors demonstrate that Fc-receptor binding by the DLLl-Fc is 
critical for the enhancement of Thl differentiation, presumably allowing DLLl- 
Fc endocytosis and therefore full Notch-cleavage [167].
42Notch-1   is recruited into the immunological synapse where it can participate in 
signalling for T cell activation [167]. Further support for a role of Notch in Th2 
priming was obtained using T-cell specific expression of dominant-negative 
MAML to block classical Notch-signalling [168]. This was found to impair Th2 
differentiation in vitro and in vivo. In addition, mice expressing DN-MAML 
showed significantly delayed clearance of a gut nematode infection due to 
impaired Th2 responses [168] suggesting that this is physiologically relevant to 
Th2 differentiation.
This picture of the literature is slightly selective. Several papers propose that 
Jagged-1   expression by APC leads to the induction of antigen-specific 
regulatory T cells [169] [170]. It has also been suggested that Notch-ligands 
modulate CD25 expression and therefore IL-2 sensitivity of T cells [171], and 
that Notch-1   signalling increases the production of IFNy, IL-4, IL-5, IL-10, 
TNFa and IL-2 [167]. Contrary to many of these observations, T cell-specific 
deletion of Notch-1  has no effect on T cell differentiation [172], although this is 
easily explained by invoking redundancy between the 4 Notch-receptors.
Confusion in the literature arises from the widely different models employed by 
different groups, for example the use of dendritic cells or B cells as antigen 
presenting cells, and use of total splenocytes versus purified T cells as the 
responders. In addition, use of y-secretase inhibitors to block Notch signalling 
yields variable results depending on the particular inhibitor used [167] which 
suggests variable selectivity of these inhibitors. Careful genetic dissection of the 
Notch receptors and ligands required in T cell differentiation induced by 
different microbial stimuli will be important in establishing the actual effects of 
Notch signalling in these processes.
1.4.3  Is a “third cell” required for T cell differentiation?
The combination of regulatory T cells with dendritic cells making inflammatory 
cytokines biases the development of Thl 7 cells in a TGF (3-dependent manner
43[102]. It is interesting to note a slightly earlier observation that TLR-mediated 
activation of DC induced resistance to Treg-mediated suppression in a process 
partially dependent on IL-6 [173]. In both Thl  differentiation where NK cells 
are proposed to be an initial source of IFNy for T cell priming [151]and in Thl 7 
where regulatory T cells induce TGF|3 production for Thl7 priming [102], there 
is evidence that at least 3 cell-types contribute to the instruction of T cell fate. 
As of yet the 3rd cell has not been positively identified in Th2 differentiation but 
several innate immune cells are reported to produce IL-4 directly in response to 
SEAg, most notably basophils (reviewed in [174]). This hints that the robust 
induction of appropriate effectors in vivo, when compared to highly variable 
results in vitro, may reflect the absence of reinforcing cells that respond to 
mature DC by helping to polarise differentiating T cells.
1.4.4  T cell differentiation induced by Zymosan
Dendritic cell recognition of zymosan leads to the upregulation of MHC class II 
and costimulatory molecules B7.1  and B7.2 thus making DC competent to 
induce the proliferation of antigen-specific T cells [96]. In addition a broad 
spectrum of factors that could contribute to T cell differentiation are produced 
such as IL-10, IL-23, IL-2 and IL-6 (data presented in chapter 4). The effector 
function of these T cells has typically been reported as mixed Thl and Th2 [90], 
with further reports that use of zymosan as an adjuvant in vivo actually induces 
dominant tolerance to co-injected antigen [175]. In vivo experiments with 
zymosan are complicated by the particulate nature of zymosan. Particles 
injected intravenously are almost exclusively taken up by granulocytes (Dr MN 
Nolte, unpublished observations 2004) suggesting that DC activated in this 
situation may be indirectly activated, correlating with the increased tolerance to 
secondary challenge observed [175]. In vitro the situation is clearer as purified 
cell populations are used and heat-inactivated serum minimises any effects of 
complement fixation that will occur on the surface of zymosan in vivo. In 
experiments by Manickasingham et al [90], zymosan stimulation of any of the 
splenic DC subsets did not particularly bias the development of Thl or Th2 
cells.
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Notch-ligand Jagged-1. As will be described in chapter 4 of this thesis, the 
levels of IL-10, IL-2 and Jagged-1   are much higher in zymosan-stimulated DCs 
that in DCs sitmulated with conventional TLR ligands.
IL-2 has controversial roles in T cell differentiation. It can be produced by Thl 
cells but can also promote Th2 polarisation. IL-2 is essential for the 
maintenance of regulatory T cells in the periphery suggesting DC-derived IL-2 
may play a role in the crosstalk between naive T cells, DC and Tregs [176],[177]. 
IL-2 can also promote NK cell recruitment and activation, potentially 
modulating the “3rd cells” to promote Thl differentiation [178]. IL-2 is also 
necessary for the induction of Th2 responses to Nippostrongylus brasiliensis as 
determined by antibody production [179]. Administration of IL-2 with anti- 
CD40 to mice infected with the pathogenic fungus Cryptococcus neoformans 
increased survival times in an IFNy-dependent but CD4-T cell independent 
manner, further hinting at a role for NK cell activation by IL-2 in anti-fungal 
responses. Despite all of these reported functions, it has also been found that 
DC-derived IL-2 is apparently completely dispensable for T cell polarisation 
when LPS is used as the adjuvant in vivo [180].
IL-10 is typically associated with suppression of inflammatory responses and 
inhibition of Thl  induction (reviewed in [134]). IL-10 deficient animals develop 
enterocolitis [181], suggesting that IL-10 may play a role in control of 
microflora and/or regulation of inappropriate responses to microflora in these 
locations. IL-10/ IL-23 p i9 doubly deficient mice, but not IL-10/ IL-12 p35 
doubly deficient mice, have a milder disease phenotype than IL-10-deficient 
mice, attributable to defective Thl7 differentiation [182]. IL-17-producing T 
cells are over-represented in ulcerative colitis or Irritable Bowel Disease patient 
samples [156]. This suggests that excessive Thl7 differentiation contributes to 
pathology in IL-10-/- animals. As with many models of gut inflammation, it is 
yet to be determined whether the pathology is due to failure to control the 
expansion and gut lumen restriction of commensals or to inappropriate 
inflammatory responses to normally abundant and normally localised
45commensals. IL-10 may act to limit the aggressive immunopathology that can 
arise from excessive Thl7 induction. IL-10 induction via TLR2 in response to 
Candida appears to delay clearance of the infection, in keeping with its ability 
to limit inflammatory immune responses [183]. It is paradoxical that pattern 
recognition leads to worse clearance of a pathogen. A possible reconciliation of 
these data is suggested by Montagnoli et al [184] who propose that IL-10 
producing DC turn on CD4+,CD25+ Tregs which are necessary for acquired 
resistance to reinfection.
The role of Jagged-1  in T cell differentiation has been suggested in a number of 
T cell differentiation assays in vitro. When overexpressed on DC-EK cells, 
Jagged-1   led to Th2 differentiation of AND T cells specific for pigeon 
cytochrome C [185]. When used as a soluble ligand, ligand immobilised on 
plastic, or when over-expressed on B cells Jagged-1   can induce the 
differentiation of regulatory T cells [152,  170,  186].
The majority of the clues suggest that zymosan has the ability to induce patterns 
of T cell differentiation that differ from those induced by pure TLR-ligands due 
to the induction of particular factors by TLR-independent pattern recognition 
receptors. The exact nature of this response is being worked on currently, and 
the initial results are presented in chapter 6.
1.4.5  Immunology of Yeast Infections
Yeasts infections can be divided into those that infect healthy individuals, i.e. 
are primary pathogens; and those which only infect immunocompromised 
individuals, i.e. are opportunistic pathogens. Primary pathogens include 
Coccidoides immitis, Histoplasma capsulation, Blastomyces and Paracoccoides 
and are extremely rare [187]. The opportunistic pathogens, Candida albicans, 
Aspergillus fumigatus, Trichosporon, and Fusarium, are increasingly common 
infections at least partly due to the increased numbers of immunocompromised 
individuals [187]. Susceptibiltiy to systemic opportunistic infection is 
associated with prolonged corticosteroid use or generalised leukopaenia,
46particularly neutropaenia, (mycoses are commonly lethal in these patient 
groups) with lymphopaenia alone providing only a small increased risk above 
that of the general population. This suggests that the innate immune system 
normally prevents the invasion of yeasts through mucosal barriers. However, 
superficial yeast infections show a high incidence in lymphopaenic patients, to 
the extent that oral Candidiasis is now almost diagnostic for HIV. It seems 
likely that a functional T cell response is essential to control superficial yeast 
infections (reviewed in [188] [187]). In addition to systemic and opportunistic 
mycoses, fungi are associated with a number of severe allergic disorders in 
humans including allergic broncho-pulmonary aspergillosis and A. fumigatus- 
related allergic asthma [187]. Additionally, mti-Saccharomyces cerevisiae 
antibodies are considered diagnostic for Crohn’s disease but do not fluctuate 
with disease severity leading to the hypothesis that a propensity to develop 
inappropriate responses to yeasts is linked to the genetic susceptibility for 
Crohn’s disease [189].
Predominant Thl responses are associated with clearance of fungal infections. It 
has been observed that IL-12 treatment of BALB/c mice during Coccidoidies 
infection aids recovery [ 190] putatively by favouring Th 1  responses. More 
recently it has been reported that IL-17-deficient mice are very susceptible to 
Candida infection implying a role for Thl7 cells [191]. Before work on Thl7, it 
was observed that TGF|3 production by splenocytes after Candida albicans 
infection correlated with clearance of the infection [192]. Blockade of TGF(3 
signalling during infection with a live-vaccinating strain severely impaired 
acquired resistance of infection with virulent Candida [192]. We now know that 
TGFp can play an instructive role in Thl7 differentiation [102]so it seems 
possible that the observed effect of TGF|3 in this system was on induction of 
Thl 7 differentiation. It is therefore of considerable interest whether zymosan- 
stimulated DC are particularly good at inducing Thl7 differentiation.
Fungal p-glucans can induce anaphylactic responses if released into the blood 
stream and cardiac arteritis is common in patients with disseminated mycoses 
[42], [187]. Whether this is a due to direct recognition of (3-glucan or to cross-
47linking of previously induced anti-p-glucan antibody has not been investigated. 
However, combined with the observation of allergic responses (pathological 
Th2 responses) to yeasts it appears that yeast-recognition is capable of inducing 
strong antibody and/or Th2 responses in certain circumstances.
Anti-P-glucan antibodies induced by immunising mice with laminarin (a soluble 
p-glucan) are protective against systemic and vaginal candidiasis [193] 
implying that p-glucan binding antibody allows successful clearance of yeast 
cells. The same antibody provides powerful protection from reinfection. Most 
protective function was associated with the IgG fraction, rather than IgM 
fraction of anti-P-glucan antibody, although detailed isotyping was not carried 
out.
In summary, successful control of yeast infections that cannot be contained by 
innate immune mechanisms apparently requires either a Thl  or T hl7 response, 
and whilst Th2 responses are found these are generally detrimental to the host.
1.4.6  Questions Addressed in this Thesis
My work was started in order to define the precise mechanisms by which 
recognition of yeast PAMPs leads to a particular mature dendritic cell 
phenotype. Experiments are described that aim to link the activation of DC by 
zymosan to the induction of T cell differentiation. The questions addressed can 
be summarised as:
1.  What T cell polarising factors (cytokines and Notch-ligands) do 
zymosan-stimulated dendritic cells produce?
2.  What are the respective contributions of TLR-dependent and TLR- 
independent pattern recognition in this response?
3.  What signalling components are necessary for the TLR-independent 
induction of IL-10 and IL-2 in response to zymosan?
484.  How might this relate to T cell priming?
492  Chapter 2: Materials and Methods
2.1  : Reagents
2.1.1  : Common Buffers, Solutions and Media
PBS-Dulbeccos: (GIBCO-BRL, Gaithersburg, MD)
PBS-EDTA: PBS-Dulbeccos containing 2mM EDTA (Sigma, Poole, UK)
MACS-Buffer: PBS-Dulbeccos containing 2mM EDTA (Sigma) and 1% FCS 
(Batch 154-161457: Autogen Bioclear, Mile Elm Caine, UK)
RPMI  1640 medium: (GIBCO-BRL)
RIO: RPMI  1640 medium supplemented with  10% FCS (Batch  154-161457: 
Autogen Bioclear), Penacillin  lOOU/ml, Streptomycin  lOOU/ml, L-Glutamine 
0.3pg/ml (GIBCO-BRL), 50pM p-mercaptoethanol (GIBCO-BRL)
Dulbeccos Modified Eagle Medium -  DMEM: (GIBCO-BRL)
DIO: DMEM (GIBCO-BRL) supplemented with 10% FCS (Batch  154-161457: 
Autogen Bioclear), Penacillin lOOU/ml, Streptomycin lOOU/ml, L-Glutamine 
0.3pg/ml (GIBCO-BRL), 50pM P-mercaptoethanol (GIBCO-BRL)
RBC lysis buffer:  155mM NH4C1 (Sigma),  lOmM KHC03  (Sigma), O.lmM 
EDTA (Sigma), MilliQ H2O, pH 7.0-7.2, sterile filtered.
PBS (Tor analytical assays only): 8g NaCl, 0.25g KCL,  1.43g Na2HP0 4 , 0.25g 
KH2PO4, (all from Sigma) dissolved in 11 dH20, pH 7.2. Solution is autoclaved 
before use.
50FACS buffer: PBS, 5mM EDTA (Sigma),  1% FCS (Autogen Bioclear), 0.02% 
NaN3 (w/v) (Sigma)
ELISA block: PBS, 2.5% FCS (Autogen Bioclear), 0.02% NaN3 (w/v) (Sigma) 
ELISA coating buffer: 0.1M NaHC03 (Sigma) in dH20, pH 8.2 
ELISA wash: 0.05% Tween-20 (Sigma) in PBS
TAE buffer: 0.04M Tris-acetate (Sigma), 0.002M EDTA (Sigma)
2.1.2  : Microbial Stimuli
MALP2, Pam3Cys, and Zymosan were purchased from InvivoGen (San Diego, 
CA) and resuspended as per the manufacturer’s instructions. Curdlan, purified 
from Alcaligenes faecal  is was purchased from Wako Pure Chemicals Industries 
Ltd (Osaka, Japan). Highly purified Salmonella LPS was a kind gift from Dr S. 
Vogel (University of Maryland, Baltimore, MD). Flagellin was purchased from 
Alexis Biochemicals (San Diego,CA). CpG 1668 was synthesised by the Cancer 
Research UK in-house oligonucleotide synthesis service as:
TCCATGACGTTCCTGATGCT -  all phosphorothioate linked and HPLC- 
purified.
2.2  : Cells and Mice
2.2.1  : Mice
Wild type C57BL/6 (H-2b) and congenic B6.SJL CD45.1  mice were from the 
Cancer Research UK animal facility (Clare Hall, South Mimms, UK). OT-II 
mice bearing a transgenic TCR specific for OVA323-339 presented on I-Ab 
were a gift from Dr. A. Pirel (Transgenic Alliance, L’Arbresle, France) and are 
bred at the Cancer Research UK animal facility (Clare Hall, South Mimms, UK)
[194]. Mice genetically deficient in MyD88 were a king gift from Dr S Akira
[195] and are are bred at the Cancer Research UK animal facility (Clare Hall, 
South Mimms, UK).
51ROSA-YFP mice [196] were a kind gift from Dr R Adams (Cancer Research 
UK London Research Institute, London, UK).
Sapl-/- [197] and Elkl-/- [198] mice were analysed in collaboration with Dr R 
Treisman and Dr P Costello (Cancer Research UK London Research Institute, 
London, UK). Mice heterozygous for deletion of Net [199] were a gift from Dr 
B Wasylyk and used in breeding double and trible knock-out animals. Net-/- 
mice die in utero. c-Fos-/- ([200] a kind gift of Dr A. E. Grigoriadis); Sapl,Elkl 
double knock-out; and Sapl, Elkl, Net triple knock-out foetal livers were used 
to reconstitute lethally irradiated B6.SJL hosts as described in 2.2 to generate 
chimeras as part of the same collaboration.
Syk-/- [201 ] and litter-mate control foetal liver was a kind gift from Dr V. L. 
Tybulewicz (National Institute for Medical Research, Mill Hill, UK).
2.2.2  : Bone marrow chimeras
Host mice were kept on acidified drinking water (0.1ml conc.HCL in 840ml 
water, sterile filtered) for at least one week before irradiation and then for at
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least 4 weeks after reconstituition. Mice were y-irradiated using a  Cs source 
(IBL 637; CISbio International, Gif-sur-Yvette, France) with two doses of 5.5 
Gy (1.24 Gy/min) separated by 3hrs. Mice were reconstituted within 24 hrs with 
>  106 bone marrow or foetal liver cells in PBS. The health status of the mice 
was closely monitored after irradiation and reconstituition. Six weeks after 
reconstituition blood samples were taken for FACS analysis of congenic marker 
expression on granulocytes and T cells. Typically close to  100% of the 
granulocytes were of donor origin at this time-point.
2.2.3  : Isolation of conventional DC from spleen
Freshly isolated spleens were injected with serum-free medium containing
Liberase Cl  (1.7 Wunsch-U/ml, Roche Diagnostics, Lewes, UK) and DNase I 
(0.2 mg/ml, Roche Diagnotics) and incubated at 37°C for 30mins to digest 
extracellular matrix. Digested spleens were mashed through a 50 pm cell sieve
52and washed twice with cold MACS buffer (PBS-Dulbeccos (GIBCO ), 2mM 
EDTA (Sigma),  1% FCS (Autogen Bioclear)). Splenocytes were labelled with 
CD1 lc-MACS beads (clone N418, Miltenyi Biotec, Bisley, UK) for lOmins at 
4°C. After washing in cold MACS buffer CD1 lc cells were positively selected 
using either the autoMACS or varioMACS. (Miltenyi Biotec). LS columns were 
used for varioMACS selection according to the manufacturer’s instructions. A 
“possel” program was used on the autoMACS as per the manufacturer’s 
instructions.
2.2.4  : Isolation of CD4 T cells
T cells were isolated from pooled lymph node and spleen of either OT-II or 
C57BL/6 mice. Spleen and lymph nodes were digested with Liberase Cl (1.7 
Wunsch-U/ml, Roche Diagnostics, Lewes, UK) /DNasel (0.2 mg/ml, Roche 
Diagnotics) in serum-free medium for 15mins at 37°C. A cell suspension was 
produced by mashing lymph nodes and spleen through a 50|iM cell strainer. 
Recovered cells were washed twice in ice-cold MACS buffer. A lineage-
depletion cocktail was used to stain the cells. All antibodies were used at  1:100 
and were purchased from PharMingen, (Becton-Dickinson, Oxford, UK)
Antibody Clone
FITC-anti-CD8a 53-6.7
FITC-anti-TCRyb GL3
FITC-anti-B220 RA3-6B2
FITC-anti-CD 16/CD32 2.4G2
FITC-anti-I-Ab 25-9-17
FITC-anti-CD 1  lc HL3
FITC-anti-CD lib Ml/70
FITC-anti-Gr-1 RB6-8C5
Aftger 1  Omins staining at 4°C cells were washed in ice-cold MACS buffer and 
resuspended in anti-FITC multisort MACS beads (Miltenyi Biotec) for 1  Omins 
at 4°C. Cells were then washed and a “depletes” autoMACS program was used 
to remove FITC-positive cells. The depleted fraction was incubated with
53“release reagent” (part of the FITC-multisort kit, Miltenyi Biotec) for at least 
30mins at 4°C. After washing, the remaining cells were incubated with Bt-anti- 
CD4 (PharMingen) for 1  Omins at 4°C, followed by washing and incubation with 
Streptavatin-MACS beads (Miltenyi Biotec). CD4+ cells were enriched using 
the “possel” autoMACS program. Typically the final enriched fraction 
comprised >95% CD4+ T cells.
Where used, CFSE labelling was carried out directly after isolation. Enriched 
cells were washed and resuspended in PBS containing 2pM CFSE (Molecular 
Probes, Invitrogen, Paisley, UK). After 15mins incubation at 37°C, FCS was 
added to 20% to quench extracellular CFSE. Cells were then washed twice in 
10% FCS and resuspended in complete medium.
2.2.5  : Production of GM-CSF BMDC
Mice femurs and tibias were removed under sterile conditions and bone marrow 
was flushed out with RIO and a 23G needle syringe. The resulting cell 
suspension was strained through a 70pm cell sieve and resuspended in  10ml 
RIO per mouse and plated at 10ml per 10cm TC dish (Falcon, Becton- 
Dickinson, Oxford, UK). After 30mins at 37°C non-adherent cells were 
recovered into 24ml R10 supplemented with GM-CSF (GM-CSF was made by 
the Cancer Research UK protein purification service, and batches were titrated 
to give optimal growth conditions for BM-DCs) and plated in a 6 well plate 
(Falcon). After 48hrs incubation at 37°C, 5% CO2 2.5ml of medium is removed 
from each well and replaced with 3ml R10 supplemented with GM-CSF and 
cells are incubated overnight at 37°C, 5% C02. The next day nonadherent and 
loosely-adherent cells are removed by gentle washing with culture medium. The 
remaining cells consist of an adherent macrophage-like population and small 
round DC progenitors. 4ml of complete R10 supplemented with GM-CSF is 
added to each well. DC can be used up to 2 days later. DC harvested at  120hrs 
will give a yield of approximately 107  cells per mouse.
54BMDC are routinely MACS enriched for CD 11 c before use. Breifly, BMDC are 
harvested by gently scraping the cells with the plunger from a sterile 1ml 
syringe. Cells are labelled with CD1 lc MACS beads (30jal beads per 107 cells 
Miltenyi Biotec) and enriched using MACS LS columns according to the 
manufacturer’s instructions.
2.2.6  : Production of Flt3L BMDC
Mice femurs and tibias were removed under sterile conditions and bone marrow 
was flushed out with RIO and a 23G needle syringe. The resulting cell 
suspension was strained through a 70pm cell sieve and all cells except red blood 
cells were counted. Bone marrow cells are resuspended at 1.5 x 106 cells per ml 
in RIO supplemented with 50ng/ml FLT3L (R&D systems, Abingdon, UK) and 
seeded at 5ml per well of a 6 well plate (Falcon).
5 days later 4.5ml of supernatant is removed without disturbing the cell layer 
and 5ml of fresh RIO containing 50ng/ml FLT3L was replaced. On day 8 the 
partial medium exchange is repeated as on day 5. Day  10 FLT3L BMDC can be 
harvested and used, or a partial medium exchange can be performed as on day 
5, and cells used on day  11 (with lower yields of B220+ PDC-like cells)
2.2.7  : Cell lines
NIFI 3T3 fibroblasts were maintained in RIO, 37°C, 5% CO2 and split regularly. 
CD40L-fibroblasts were a kind gift from Drs R. Lapointe and P. Hwu (NCI, 
Bethesda, MD) They were derived by transducing NIH-3T3 with a retroviral 
vector expressing CD40L from the CMV promoter. SAMEN-3T3 were 
produced in parallel by transduction with the empty vector.
Two cell lines were used for retroviral production. GP293 cells (Clontech, 
Becton-Dickinson, Oxford, UK) are 293 cells stably transfected with a gag-pol 
expression vector and are maintained in D10. Phoenix-ecotropic cells were 
obtained from Dr. G Nolan and express the gag, pol and env genes from murine
55Maloney Leukaemia virus. Phoenix cells were grown in DIO or RIO as 
indicated.
LK35.2 cells [202] (LK cells, American Type Culture Collection HB-98) were 
maintained in DIO. Full-length, truncated, and point mutant Dectin-1 in pFB- 
Neo [55] or subcloned into pMSCV-EGFP ([203]; kind gift from Hideki 
Tsujimura, National Institutes of Health) were used for transfection of LK cells 
or for retroviral production in an ecotropic packaging cell line [204], followed 
by LK cell transduction. LK cells expressing Dectin-1   were selected on the 
basis of EGFP expression (pMSCV-EGFP vector) or neomycin resistance (pFB- 
Neo vector).
2.3  : Retrovirus production
2.3.1  : “Ping-pong” retrovirus production
GP2-293 cells (Clontech) are seeded at 2.6 x  106 per  10cm dish. The following 
day cells are transfected with retroviral vector and pVSV-G ( 23pl of Fugene is 
added to 557pl serum-free RPMI and incubated for 5mins. 7.5jng retroviral 
vector and 6pg of pVSV-G is added to a second tube and Fugene mixture is 
added drop-wise. After 15mins incubation at room temperature the transfection 
mix is gently added to the GP2-293 cells). The following day 2.5 x  105 Pheonix- 
ecotropic cells are plated in a well of a 6 well plate. 24 hrs later, supernatants 
are harvested and fresh RPMI is added back to the cells. The harvested 
supernatants are filtered through a 0.45micron Millex-HV PVDF filter 
(Millipore, Cork, Ireland) and polybrene (Sigma) is added to a final 
concentration of 5pg/ml. This virus-containing supernatant is used to replace 
the Phoenix cell medium. Phoenix cells are then centrifuged at 2600rpm at 26°C 
for 90 minutes. After centrifugation, supernatant is removed and cells are 
cultured overnight. Infection with GP2-293 virus-containing supernatant is 
repeated the following day. The resulting Phoenix-ecotropic cells stably 
produce retrovirus containing the introduced retroviral vector segment. If the 
viral vector contained a FACS-selectable marker such as GFP, stably transduced 
Phoenix cells can be FACS sorted to increase the frequency of viral producers.
562.3.2  : Transient transfection of GP2-293 cells
GP2-293 cells (Clontech) are seeded at 2.6 x 106 per 10cm dish (Falcon). The
following day cells are transfected with retroviral vector and pVSV-G 
(encoding the envelope protein of Vesicular Stomatosis Virus).
23jli1  of Fugene6 (Roche Diagnostics, Mannheim, Germany) is added to 557pl 
serum-free RPMI and incubated for 5mins. 7.5pg retroviral vector and 6pg of 
pVSV-G is added to a second tube and Fugene mixture is added drop-wise.
After 15mins incubation at room temperature the transfection mix is gently 
added to the GP2-293 cells. At 48hrs and 72hrs post-transfection supernatants 
containing VSV-G pseudotyped virus are harvested, sterile filtered using
0.45micron syringe-filters (Millipore) and snap-frozen on dry ice.
Retroviruses that include GFP-expression can be easily titred on NIH-3T3 
fibroblasts.  105  fibroblasts are plated per well of a 6 well plate and rested for 
24hrs at 37°C, 5% C02. Polybrene is added to the wells to a final concentration 
of 5pg/ml and 10 or lOOpl of virus-containing supernatant is added. After 24hrs 
the medium is exchanged and % transduction is determined by FACS for GFP 
expression.
2.4  : Retroviral transduction of bone marrow
2.4.1  : Retroviral transduction of GM-CSF BMDC
4 x  106 stably-transduced Phoenix cells are plated in a  15cm tissue culture dish
(Falcon) in 18ml RIO and incubated at 37°C, 5% CO2. A 50pg/ml solution of 
Retronectin (Takara Mirus Bio, Madison, WI) is made in endotoxin-free water 
(GIBCO-BRL) and  lOOpl is added per well of a 24 well plate, the plate is sealed 
using Parafilm (Peichiney Plastic Packaging, Menasha, WI) and incubated 
overnight at 4°C.
After 18-24hrs (day 1) supernatant is harvested from Phoenix cells and fresh 
medium is replaced. Bone marrow is harvested as for the normal BMDC
57protocol (see 2.2.5), then red blood cells are lysed in hypertonic buffer and cells 
are resuspended in virus supernatant (48ml per mouse) plus polybrene. 2ml of 
cell suspension is plated per well of the prepared retronectin-coated 24well 
plate. Plates of bone marrow are centrifuged (“spinfected”) at 2600rpm (1573g), 
26°C, 90mins (Allegra X-15R, Beckman-Coulter, Paulo Alto, CA). Following 
spinfection, supernatants are removed and spun to recover non-adherent cells. 
These are returned to the 24 well plate with fresh RIO supplemented with GM- 
CSF and bone marrow cells are incubated at 37°C, 5% CO2 overnight. On day 2 
Phoenix cell supernatant is harvested and fresh medium is added back to the 
phoenix cells as on day  1. Supernatants are removed from the BMDC to a 50ml 
Falcon tube and retained. 2ml of virus supernatant supplemented with 5pg/ml 
polybrene is added to each well and the plate is centrifuged at 2600rpm, 26°C, 
for 90mins. After centrifugation the viral supernatants are removed and non­
adherent cells are recovered as on day  I into the retained BMDC supernatant.
On day 3 BMDC supernatant is removed and discarded. Phoenix cell 
supernatant is harvested as on day  1   and phoenix cells can either be split for 
further passaging or discarded. 2ml of viral supernatant containing 5pg/ml 
polybrene is added per well and the centrifugation step is carried out as on day
1.  After 90 minutes virus supernatant is removed, non-adherent cells are 
recovered and fresh RIO supplemented with GM-CSF is replaced. On day 4 
non-adherent and loosely-adherent cells are removed by gentle washing with 
culture medium and fresh RIO supplemented with GM-CSF is replaced. BMDC 
are used on day 5 or day 6. Transduction efficiency with MSCV-EGFP is 
typically greater than 80%. (For a detailed discussion of this procedure see 
chapter 3)
2.4.2  : Retroviral transduction of FLT3L BMDC
The protocol for transduction of Flt3L BMDC is an adaptation of the protocol
for transduction of GM-CSF BMDC. The specific adaptations are that 50ng/ml
FLT3L (R&D systems, Oxford, UK) is used in place of GM-CSF and the
BMDC supernatants are retained and replaced after each spinfection, rather than
adding fresh supernatant on day 3. After day 3 the protocols diverge. FLT3L
DC are left undisturbed at 37°C 5% C02 on day 4 and day 5. On day 6, 4.5ml of
58supernatant is removed without disturbing the cell layer and 5ml of fresh RIO 
containing 50ng/ml FLT3L was replaced. On day 9 the partial medium 
exchanges is repeated as on day 6. Day 11  FLT3L BMDC can be harvested and 
used, or a partial medium exchange can be performed as on day 5, and cells 
used on day  12. (For a more detailed discussion of this procedure see chapter 3)
2.5  : In vitro assays for DC activation
2.5.1  : In vitro stimulation for DC cytokine production
4-20  x  104 CD1 lc-enriched BM-DCs per well (numbers indicated in figure
legends) are cultured overnight in 100-200 pi culture medium with or without 
GM-CSF in 96-well flat-bottomed plates in the presence of stimuli. In some 
experiments CD40L-expressing fibroblasts (plated on the eve of the experiment 
at 104 cells per well) are included in order to amplify IL-10 levels via CD40 
triggering [96]. Supernatants are removed, and cytokine levels measured by 
sandwich ELISA. For inhibition studies, cells are preincubated for 30 min with 
glucan phosphate (a gift from Dr D. Williams), latrunculin B (Sigma), U0126 
(Calbiochem, Merck Biosceinces, Nottingham, UK), PD98059 (Calbiochem) or 
SB203580 (Calbiochem) before addition of zymosan (InvivoGen, San Diego, 
CA). Cells are subsequently are cultured in the continued presence of the 
inhibitors. An identical protocol is used to identify cytokine production from 
LK cells stimulated with zymosan.
For intracellular staining of cytokines, DC are stimulated as for measurements 
of  secreted cytokine. After an indicated time-period in the presence of 
microbial stimuli Brefeldin A is added to a final concentration of 5pg/ml and 
cells are incubated for a further time period. For analysis DC are isolated and 
stained for surface markers (APC-CD1 lc) followed by fixation using “Fix and 
Perm” reagent A (Caltag). See section 2.8.2 for details of the staining 
procedure.
592.5.2  : In vitro stimulation for mRNA analysis of cytokines and 
Notch ligands
5 x  105  CD1 lc-enriched BMDC are plated per well of a 24 well plate (Falcon). 
Microbial stimuli are added and cells incubated at 37°C, 5% C02 for the 
indicated times. At the end of the incubation period cells are harvested into a 
1.5ml tube (Eppendorf, Fisher Scientific, Loughborough, UK). Cells are 
pelletted by centrifugation and the pellet is resuspended in 1ml TRIzol 
(Invitrogen) for RNA isolation.
2.5.3  : In vitro stimulation for analysis of MAP kinase activation
5 x  105  CD1 lc-enriched BMDC are plated per well of a 24 well plate. Microbial
stimuli are added and cells incubated at 37°C, 5% CO2 for the indicated times.
At the end of the incubation period paraformaldehyde (Sigma) is added to the 
cultures to a final concentration of 2%. Cells are harvested, pelletted and 
resuspended in 2% FCS. These cells are then stained for FACS (For a detailed 
discussion of this procedure see chapter 3)
2.6  : In vitro T cell differentiation assays
CD4+ T cells are isolated as described in 2.2.4.  104 BMDC and 2-5 x  10A 4 T 
cells are added per well of a 96 well U-bottom plate. Where OT-II T cells are 
used, OVA323-339 peptide (ISQAVHAAFIAEINEAGR synthesised and HPLC- 
purified by the Cancer Research UK peptide synthesis service) or OVA protein 
(Calbiochem) is added at the indicated concentrations along with microbial 
stimuli. In experiments with C57BL/6 T cells anti-CD3 (2C11, purified from 
hybridoma supernatant by the Cancer Research UK monoclonal antibody 
service) is added at the indicated dose along with microbial stimuli. On day 3 
each well of T cell-DC co-cultures is split into a fresh well and 1  OOjul of fresh 
RIO is added. On day 5 T cells are counted and total wells are restimulated for 
analysis of cytokine production either by plating on immobilised anti-CD3 for 
48 hours or by stimulating with PMA and Ionomycin in the presence of 
monensin for intracellular FACS staining.
602.7  : Molecular Biology and Cloning
2.7.1  : Transformation of Competent E. Coli Strain XL-1 cells
lOpl of ice-cold plasmid DNA solution was added to lOOpl of DH5a competent
cells (Invitrogen) in a 1.5ml tube (Eppendorf) and incubated on ice for 30mins. 
The tube was then transferred to a 42°C water bath for 30s before immediately 
returning it to the ice for lOminutes. the suspension was then transferred into a 
14ml snap cap (Falcon) and diluted in 2ml of SOC-medium (Invitrogen) and 
incubated for 90mins on a shaker.  1.5 ml of the innoculum was transferred to a 
fresh 1.5 tube and centrifuged to pellet the cells. The pellet was resuspended in
0.2ml LB (Cancer Research UK media services) and plated on selective agar 
plates. All plasmids used in this thesis contained Ampicillin resistance genes 
therefore L-agar (Cancer Research UK media services) plates containing 
50pg/ml ampicillin were used. Plates were incubated overnight at 37°C.
2.7.2  : Plasmid isolation
Single resistant clones were picked using sterile pipette-tips and expanded in 
5ml LB containing 50pg/ml ampicillin overnight at 37°C on a shaker. The cells 
were spun down and the pellet processed using the QIAGEN plasmid mini-kit 
(QIAGEN, Crawley, UK). For large-scale plasmid isolation 2ml of the 
overnight culture was added to  150ml of LB containing 50jug/ml ampicillin and 
incubated overnight at 37°C in a shaker. Overnight culture was centrifuged at 
3500rpm 30mins (Allegra 6R centriguge, Beckman-Coulter), supernatants were 
discarded and pellets were processed using the QIAGEN plasmid maxi-kit.
2.7.3  : DNA purification using Phenol/Chloroform
The DNA sample was transferred into at least  lOOpl of ddfUO in a clean 1.5ml
tube (Eppendorf). An equal volume of phenol was added and the tube was 
vortexed for 1  minute. Then an equal volume of chloroform:isoamylalcohol 
49:1 was added and the tube was vortexed for 1  minute. The rube was then spun 
at 13000rpm (15000g) and the upper, aqueous phase was transferred into a new 
Eppendorf tube.  1.5 volumes of chloroform was added and the tube was 
vortexed for 1   minute and centrifuged again. The aqueous phase was transferred
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ethanol (purum, Fulka) were added. The tube was incubated at -80°C for lhr or - 
20°C overnight before centrifugation for 5 minutes at 15000g. The pellet was 
washed once in cold 70% ethanol. The pellet was then air-dried and dissolved in 
ddH20.
2.7.4  : Gel Electrophoresis
DNA samples were prepared in TAE buffer and Sigma DNA loading buffer was 
added 1:10.  1  or 2% Agarose was suspended in TAE buffer and melted in a 
microwave oven.  1  pg/ml Ethidium Bromide (Sigma) was added and the 
solution was poured into a gel tray with an appropriate comb. The tray was then 
placed in a gel chamber filled with TAE buffer and a voltage of 30-120V 
applied for 0.5 to 2hrs.
2.7.5  : Restriction Enzyme digests
Restriction Enzyme digests were carried out to re-clone GFPCre downstream of 
the pgk promoter in pMSCV and to check the identity of plasmids obtained 
during the cloning and of plasmids obtained from outside sources. Restriction 
Enzymes, Buffers and BSA were purchased from New England Biolabs 
(Ipswich, UK) and used according to the manufacturer’s instructions. Briefly 
5 pi of plasmid solution (containing up to 2pg plasmid) was added to 2pl  lOx 
buffer, 0.2pl BSA, appropriate amounts of enzyme to ensure complete digestion 
in  l-3hrs and ddH20  to make the volume up to 20pl.
2.7.6  : Gel purification of Restriction Enzyme digest fragments
After separating the fragments by gel electrophoresis the desired band was
excised using a sterile scalpel, minimising UV exposure of the DNA by working 
quickly. DNA was purifed from the excised gel fragment using the QIAGEN 
gel purification kit according to the manufacturer’s instruction. 0.1ml NaAc pH 
5.2 was routinely added to the dissolved gel fragment as this was found to 
improve yields.
622.7.7  : Purification of DNA fragment from solution
Between Restriction Enzyme digests and other situations in which DNA needed
to be purified away from enzymes or resuspended in fresh buffer DNA was 
purified using the QIAquick PCR purification mini kit (QIAGEN) according to 
the manufacturer’s instructions. DNA was eluted in 30jnl ddfbO.
2.7.8  : Cloning of pMSCV-GFPCre8
pMSCV-GFP (a kind gift or Dr Hideki Tsujimura, National Institutes of Health) 
was cut with Hindlll (New England Biolabs) (just downstream of the pgk 
promoter) and Clal (New England Biolabs) (downstream of GFP) to remove the 
GFP sequence, leading a 5kb backbone fragment including both LTRs, the pgk 
promoter, the multiple cloning site and an Ampicillin resistance gene. This 5kb 
fragment was gel purified and then treated with mung bean nuclease (New 
England Biolabs) according to the manufacturer’s instructions to remove sticky- 
ends, followed by treatment with Shrimp Alkaline Phosphatase (Roche 
Diagnostics) used according to the manufacturer’s instructions to remove 5’ 
phosphates and therefore prevent vector self-ligation.
pMSCV-GFPCre-neo was cut with EcoRI (New England Biolabs) and Bglll 
(New England Biolabs)to excise a 2kb fragment containing the GFPCre 
sequence. The 2kb fragment was gel purified as described and treated with 
mung bean nuclease to remove sticky ends.
Between each set of the cloning protocol when different buffers were required 
DNA was purified using the QIAquick PCR purification mini kit (QIAGEN) as 
described.
Ligations were set up using an 8:1 molar ratio of insert to vector and the T4 
ligase () and incubated overnight at 25°C. After overnight ligation, the resulting 
DNA was transformed into DH5a competent cells (Invitrogen) and plated out 
on ampicillin-selective plates.
6326 colonies were obtained and expanded for mini-preps as described. Xhol 
(NEB) digestions which cuts at the 3’ end of the GFPCre sequence and in the 
multiple cloning site 5’ of the pgk promoter to produce 2 bands of 3kb and 4kb 
from the correctly assembled plasmids. One clone was obtained with the correct 
orientation and was used for large scale plasmid production, “ping-pong” 
production of stable Pheonix cell lines and retroviral transduction of ROS A26- 
YFP bone marrow to demonstrate activity of the Cre protein.
2.7.9  : Sequencing of pMSCV-GFPCre8
DNA sequencing was carried out by the Cancer Research UK sequencing 
facility. Breifly, a reaction mix was made using 8pi of BigDye Terminator mix 
v3.1   (Cancer Research UK in-house), 2pl of sequencing primer (equivalent of 
3.2pmol) and lOpl of ddFI20 containing  150-200ng of plasmid (parameters for 
sequencing up to  lOkb plasmids). The PCR reaction was carried out if a () 
thermal cycler using the following program:
Step  1 Denature 96°C 30s
Step 2 Anneal 50°C 15s
Step 3 Extension 60°C 4mins
Step 4 Return to step  1 x 25
Step 5 Chill 4°C Forever
The primers Cre 5’ and Cre 3’ were used to amplify the GFPCre sequence in the 
final vector:
Cre 5’: AT  CCG  A  A  A  AG  A  A  A  ACGTT G  A 
Cre 3’: AT CC  AGGTT  ACGG  AT  AT  AGT
2.8  : Flow cytometry
2.8.1  : Surface staining of DC, T cells and LK cells
For flow cytometry, cell suspensions were washed once in PBS/EDTA and
stained in ice cold FACS buffer for 30mins. This procedure was repeated when 
secondary reagents were used. Data were collected on a FACS Calibur
64cytometer (Becton Dickinson, Mountain View, CA) and analysed using FlowJo 
software (Treestar, San Carlos, CA) to gate on appropriate populations. All 
antibodies used were from Pharmingen unless otherwise indicated.
Antigen Clone/Isotype
CDllc HL3 / Armenian Hamster IgGl
CDllb Ml/70 / Rat IgG2b
CD 16/32 2.4G2 / Rat IgG2b
Jagged-1 72017 Mouse IgGl  (R&D systems)
CD4 RM4-5 / Rat IgG2a
CD25 3C7 / Rat IgG2b
2.8.2  : Intracellular staining for DC cytokines
DC were stimulated as described in section 2.5.1. DC harvested at the end of the 
culture period were stained for CD I lc for 20 minutes on ice (as described 
above). After washing in ice-cold FACS buffer, cells were resuspended in “Fix 
and Perm” Reagent A (Caltag) for fixation and incubated at room temperature 
for 20mins. Cells were washed once in FACS buffer and then resuspended in 
“Fix and Perm” Reagent B (Caltag) containing anti-cytokine antibodies and 
incubated for 20 minutes at room tempterature. If secondary reagents are used 
then after washing in FACS buffer, cells are suspended in “Fix and Perm” 
Reagent B containing the secondary reagent. Cells were washed once in FACS 
buffer and resuspended for acquisiton. All anti-cytokine antibodies are from 
Pharmingen unless otherwise stated.
Cytokine Clone/Isotype Concentration
IL-12 p40 C15.6 / Rat IgGl 1  pg/ml
TNFa MP6-XT3 / Rat IgGl 5|ig/ml
IL-6 MP5-20F3 / Rat IgGl 5pg/ml
IL-2 JES6-5H4 / Rat IgG2b 5pg/ml
IL-10 SXC-1 / Rat IgM 5pg/ml
IFNy XMG1.2 / Rat IgGl 1  pg/ml
65IL-17 TC11-18H10.1 / Rat IgGl 1  pg/ml
IL-4 11B11 / Rat IgGl 5 pg/ml
An identical protocol was used for the intracellular staining of T cell cytokines 
after restimulation with PMA/Ionomycin in the presence of monensin 
(described in section 2.6)
2.8.3  : Intracellular staining for FoxP3
T cells were surface stained for CD4 and CD25 as in 2.8.1. Cells are washed in 
ice cold FACS buffer and resuspended in eBiosceince (Boston, MA) 
Fixation/Permeabilisation solution (made up to lx from 4x concentrate with 
diluent). Cells are incubated at 4°C for 3Omins to overnight. After this period 
cells were washed once in FACS buffer and once in eBioscience 
Permabilisation buffer (made up from  lOx concentrate with ddFhO). Cells are 
resuspended in Permeabilisation buffer containing PE-anti-FoxP3 (eBiosceince) 
and 2.4G2 (Cancer Research UK monoclonal antibody service) and incubated at 
4°C for 30mins. Cells were then washed and resuspended for acquisition.
2.8.4  : Intracellular staining for Phospho-MAP kinases
BMDC are enriched for CD1 lc and plated at 5 x  105  per well of a 24 well plate
in RIO supplemented with GM-CSF. Cells are rested for 3hrs to overnight at 
37°C, 5% C02. Stimuli are added for the indicated lengths of time (where 
chemical inhibitors are used, these are added 30minutes before the stimuli and 
maintained throughout the experiment). To halt signalling cells are fixed by 
adding parafolmaldehyde to 2% then harvesting the cells and resuspending them 
in PBS containing 2% paraformaldehyde. Cells are fixed for 20mins at room 
temperature. After washing twice in FACS-buffer cells are resuspended in “Fix 
and Perm” Reagent B (Caltag) containing the appropriate anti-phospho-MAP 
Kinase or isotype control and incubated at room temperature for 20mins. Cells 
are then washed in FACS-buffer and resuspended in “Fix and Perm” Reagent B 
(Caltag) containing the appropriate secondary antibody. If a tertiary reagent is
66required (such as fluorescently labelled streptavadin) the intracellular staining
step is repeated after which cells are resuspended for acquisition.  Relevant 
isotype control stainings were always carried out in parallel to demonstrate that
background staining does not change with DC stimulation (data not shown).
2.9  : Sandwich ELISAs for cytokines
All ELISAs are carried out in MAXISORP immunoplates (Nunc 4-39454). 
Capture antibodies are diluted into ELISA coating buffer and 50pl pipetted per 
well of the 96-well flat-bottom immunoplate. Plates sealed with parafilm are 
incubated for 6 hrs to overnight at 4°C in a humidified chamber. Plates are then 
washed 3 times with ELISA wash and blocked for 2hrs with 200pl per well of 
ELISA block. ELISA block is disgarded and 50pl of experimental supernatants 
or serial dilutions of the test cytokine are added per well. Plates are sealed again 
with parafilm and incubated overnight at 4°C. Plates are washed 6  times in 
ELISA wash. The detection antibody is diluted in ELISA block and lOOpl 
added per well. Plates are incubated for lhr at room temperature and then 
washed 6  times with ELISA wash. Extravadin-Alkaline phosphatase  (Sigma) is 
diluted 1:5000 in ELISA block and 1  OOjul is added per well. Plates are incubated 
for lhr at room temperature and washed 6  times with ELISA block. ELISA 
substrate is made up using the Sigma-fast pNitrophenyl Phosphate tablet sets 
and lOOpl is added per well. A405 is measured at  15mins,  lhr and 2hrs (using a 
SpectraMax  190, Molecular Devices, Wokingham, UK) and Softmax Pro 
software (Molecular Devices Corp). Readings where measurements of 
experimental cytokine concentrations within the linear range of readings for the 
standard curve were exported to Excel (Microsoft) for further analysis. Error 
bars represent  1  standard deviation.
Cytokine Capture Antibody Detection Antibody Top concentration of 
standard
IL-2 JES6-1A12 JES6-5H4 Biotin 5ng/ml
4pg/ml 1 pg/ml
IL-4 11B11 MM-450D Biotin 5ng/ml
2 pg/ml (Endogen) 0.25 pg/ml
IL-5 TRFK5 TRFK4 Biotin 2 ng/ml
2 pg/ml 2 pg/ml
67IL-6 MP5-20F3
4pg/ml
MP5-32C11   Biotin 
1  pg/ml
5ng/ml
IL-10 JES5-2A5 SXC-1  Biotin 25ng/ml
4pg/ml 1  pg/ml
IL-12 p40 C15.6 C l7.8 Biotin lOng/ml
2pg/ml 1  pg/ml
IL-12 p70 9A5 C l7.8 Biotin lOng/ml
5 pg/ml 1  pg/ml
IL-17 555068 666067 Biotin lOng/ml
2|iig/ml 1  pg/ml
IL-23 G2308 (eBiosceince) C l7.8 Biotin 8ng/ml
2pg/ml 1  pg/ml
IFNy R4-6A2 XMG1.2 Biotin 300U/ml
5 pg/ml 0.5pg/ml
TNFa G281-2626 MP6-XT3 Biotin 2ng/ml
5 pg/ml 1  pg/ml
2.10  : Western Blotting
BMDC were lysed in SDS lysis buffer (2xSDS buffer:  125mM Tris-HCL pH 
6.8, 4% w/v SDS, 2% glycerol, 0.02% w/v Bromophenol blue, 2% 
(3mercaptoethanol). Samples were sonicated, boiled for 5mins then centrifuged 
at 13000rmp for 5mins. Proteins were separated on 10% Tris-glycine pre-cast 
mini-gels (Novex). A Transblot semi-dry transfer cell was used with methanol- 
transfer buffer (48mM Tris-base, 39mM Glycine,  1.3mM SDS, 20% MeOH) 
was used to transfer proteins onto Optitran BA-S83 Reinforced Nitrocellulose 
(Schleicher & Schuell, Whatman, Brentford, UK).
Ponceau red staining to check transfer and loading, was carried out at this stage, 
briefly, the membrane was incubated with 5ml Panceau Red staining solution 
(Sigma) for 3 minutes at room temperature with shaking. The blot was then 
washed for 3 minutes, or until a clear result was obtained, in  15ml of TBST.
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powder,  1% Tween-20, 20mM Tris,  136mM NaCl, pH 7.6). Anti-phospho-ERK 
(Cell Signalling technology) and anti-phopsho-p38 MAPK (Cell Signalling 
technology) were diluted 1:1000 in TBST/10% milk and membranes were 
incubated overnight at 4°C with shaking. The nest day membranes were washed 
3 x for 5minutes in 15ml TBST (1% Tween-20, 20mM Tris,  136mM NaCl, pH 
7.6). HRP-goat-anti-rabbit Ig was diluted 1:5000 in TBST/10% milk and 
membranes were incubated for lhr at room temperature with shaking. 
Membranes were washed 3x in TBST then incubated for 5 minutes with 
Supersignal WestPico Chemiluminsecent Substrate (Pierce, Perbio, Rockford, 
IL). The membrane was wrapped in saran wrap and exposed to X-ray film 
(Pierce) for 30s to 2hrs before developing.
2.11  : PCR
2.11.1  : Isolation of DNA from cells and tissues
Harvested cells were pelleted by centrifugation and resuspended in 500jnl
digestion buffer (lOOmM Tris-HCl„ pH 8.5, 200mM NaCl, 5mM EDTA, 0.2% 
SDS and Proteinase K 100pg/ml (QIAGEN)). Samples were digested at 55°C 
for 5hrs with shaking and pipetted to mix. 500pl of Isopropanol was added and 
the mixture was incubated overnight at -20°C. DNA was pelletted by 
centrifugation of 15mins at high speed and washed once in 70% EtOH. The 
pellet was then air-dried and resuspended in 20pl ddH2 0 .
Tissue samples (for example tail or ear snips from mice) were resuspended in an 
identical digestion buffer and incubated at 55°C for 5hrs. After this time the 
tubes were centrifuged at 13000 rpm for 15minutes to pellet out 
insoluble/indigestible components. Supernatant was transferred to a fresh 1.5ml 
tube and 500pl of isopropanol added. DNA was precipitated as for extraction 
from cells.
2.11.2 : Typing of Jagged-l-Flox mice and cells
Jagged 1-Flox/Flox mice were bred from heterozygous parent mice (a kind gift 
of Dr F Watt and Dr S. Etracht, Originally made by Dr K. Hozumi). Offspring
69were typed by tail-snip, and DNA was extracted as explained above. In order to 
type for homozygous mice primers were used that generated a 389bp product 
with the wild-type allele and a 545pb product from the floxed-allele (Primers 
listed as 5JagA and 3Jagl below).
To detect deletion of the floxed allele, cells expressing, or not expressing Cre 
recombinase were purified by cell sorting and DNA extracted as above. A 
duplex PCR was carried out using one 5’ primer and two 3’ primers, one of 
which binds between the two LoxP sites (giving a band of 229bp from 
undeleted cells) and the other of which binds downstream of both LoxP sites 
(giving a band of 333bp only when the intervening DNA has been excised by 
Cre). These primers are listed below as 5JagA, 3JagB and 3JagC.
All PCR reactions were performed using Cancer Research UK in-house Taq 
polymerase and lOx PCR buffer. Nucleotides were purchased from Invitrogen 
and peptides were synthesised by Sigma.
PCR reactions were carried out using a Dyad DNA engine running the 
following program:
Step  1: Denature 94°C 45s
Step 2: Anneal 58°C 60s
Step 3: Elongation 72°C 60s
Step 4: Repeat To Step 1 34 x
PCR products were mixed 1:10 with DNA loading buffer (Sigma) and run on 
2% Agarose gels containing Ethidium Bromide. DNA was visualised using an 
IMAGO Compact Imaging System (B &L Systems, Maarssen, the Netherlands)
Primers:
Name Sequence
5JagA T G  A  ACT C  AGG  AC  AGT  GCT CT
703Jagl GTTT C  AGT  GT  CT GCC  ATT  GC
3JagB CT  AG  ACT  CG  AGG  A  ATT  CCG  A
3JagC AT  AGG  AGGCC  AT  GG  AT  G  ACT
2.11.3 : Isolation of RNA from cells
Cells for analysis were pelleted by centrifugation at lOOOg for 5min (Beckman 
Coulter Allegra X-15R Centrifuge,  1500rpm). The supernatant was discarded 
and pellet resuspended in 1ml TRIzol (Invitrogen)(<10A7 cells per sample). 
Samples were incubated at room temperature for 5min then 200pl Choloform 
was added. Tubes were shaken vigorously by hand for 20seconds then 
incubated for a further 3min at room temperature. The samples were centrifuged 
at 12000g, 4°C for 15min. The upper phase was transferred to a new tube 
(approx 600pl) and 500pl Isopropanol was added. Samples were briefly mixed 
by inversion then incubated at room temperature for lOmin. Precipitated RNA 
was pelleted by centrifugation at 12000g, 4°C for 15mins. The supernatant was 
discarded and the pellet was washed with 500pl 70% Ethanol followed by 
centrifugation at 7500g, 4°C for 5min. Supernatant was aspirated and the pellet 
was dried and then resuspended in  lOmM Tris pH8.0 at 37°C.
2.11.4 : Production of cDNA
cDNA is produced using Superscript II according to the manufacturer’s 
instructions. Briefly, 20jli1  Extracted RNA is incubated with 2pl (50pg/ml) 
Random hexamers at 65°C for 5 minutes. The mixture is chilled on ice then 
18pl of a “master-mix” containing 2pl lOmM dNTP (Invitrogen), 8pl 5 x first 
strand buffer (part of Superscript II kit, Invitrogen), 4pl of 0.1M DTT (part of 
Superscript II kit, Invitrogen), 3.5pl of ddH20 and 0.5pl Superscript II is 
added to each tube and mixed by pipetting. The mixture is then incubated at 
42°C for lhr followed by 70°C for 15minutes to destroy the enzyme.
712.11.5  : Real-time PCR
40|il of cDNA produced as above was diluted to lOOpl and 5pi added to each 
well of a Thermo-Fast 96 Detection Plate (ABgene, Epsom, UK). RT-PCR was 
carried out either using SYBR-green primers or using Taqman primers and 
probes (VIC-MGB/FAM-MGB or VIC-TAMRA/FAM-TAMRA).
SYBR-green analyses were carried out using the Platinum SYBR Green qPCR 
Supermix-UDG with ROX (Invitrogen). Primers were added to the 2x mix to a 
final concentration of lOOnM and this 15 pi of this mix was added per well of 
the 96 Detection Plate.
Taqman analyses were carried out using 2 x Taqman Universal PCR mastermix 
(Applied Biosystems). Primer/probe sets uses to generate the data present in this 
thesis were ordered as “pre-developed assay reagents” from Applied Biosystems 
and used according to the manufactures instructions.
In all cases, mRNA levels are normalised to 18S ribosomal RNA levels using 
Applied Biosystems PDAR for 18S containing either a VIC-MGB or VIC- 
TAMRA probe as appropriate to the other reactions being carried out.
After pipetting 15pl of PCR mix into the plate, the plate was sealed using an 
Optical Adhesive Cover (Applied Biosystems, Foster City, CA) and analysed 
using an ABI PRISM 7700 Sequence Detection System (Applied Biosystems) 
and analysed using SDS  1.9.1  (Applied Biosystems) and Microsoft Excel.
Primers used:
Gene name Primer name Primer sequence
IL-2 MN-IL2-1F
MN-IL2-1R
CCT  AG  AGC  AGG  AT GG  AG  A ATT AC  A 
T CCAGAACATGCCGCAGAG
IL-6 muIL-6f GTT CT CT GGG  A  A  AT CGT GG  A
72muIL-6r T GT  ACT  CC  AGGT  AGCT  AT  GG
IL-23 pl9 MN-IL12pl9-lF
MN-IL12pl9-lR
T  GCT  GG  ATT  GC  AG  AGC  AGT  A  A 
GC  AT GC  AG  AG  ATT  CCG  AG  AG  A
IL-10 MN-IL10-2F
MN-IL10-2R
AT  GCT GCCT  GCT  CTT  ACT  G  ACT G 
CCC  A  AGT  A  ACCCTT  A  A  AT  CCT  GC
TNFa MN-TNFa-lF
MN-TNFa-lR
CATCTTCTCAAAATTCGAGTGACCA 
T GGGAGTAGACAAGGTACAACCC
Jagged1 SL208
SL209
AACGACCGTAATCGCATCGT
T AT C  AGGTT G  A  AT  AGT GT  C ATT  ACT G 
GAA
Jagged2 SL210
SL211
A  AGCCGT GT GT A  A  AC A  AGG  AT GT 
CCCTGCCAGCCGT AGCT
DLL1 SL202
SL203
GCAACCCCATCCGATTCC 
GAG  AGT  CT GT  AT  GG  AGGGCTT  C A
DLL4 SL204
SL205
AAGA  A  AGT  AG  AC  AGGT GT  ACC  AGC  A  A 
CGGCTTGGACCTCTGTTCAG
IL-12 p40, IL-12 p35, IL-2, IL-10, and  18S were assessed using Taqman 
PDARs (Applied Biosystems).
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Cell Signalling in Dendritic Cells
3.1  : Introduction
3.1.1  : Use of Flow cytometry in cell signalling research
Flow cytometry can be carried out on small numbers of cells and using mixed 
cell populations. In addition, it gives an accurate quantitative reading of 
antibody staining on a per-cell basis. This makes flow cytometry an ideal 
technique for the study of cell signalling in primary dendritic cells where only 
106-107 cells can routinely be obtained per mouse, and where  100% pure 
populations are rarely obtained (as purified in [205] [90]).
Two papers published in 2001  use phospho-specific antibodies to asses c-Jun 
and ERK phosphorylation [206], [207]. The paper from Chow et al examines 
ERK activity in human peripheral blood T lymphocytes with the aim of 
examining signalling in the blood T cells of patients undergoing chemotherapy,
i.e. where very few cells can be obtained for analysis. Zell et al used the 
technique to examine signalling in TCR-transgenic T cells in vivo after 
immunisation with peptide.
Whilst Chow et al used methanol permeabilisation [206], Zell et al used 0.5% 
Saponin [207] in order to stain intracellular proteins. Both groups used the same 
anti-phospho-ERK rabbit polyclonal, available through New England 
Bioscience or Cell Signaling Technology, which works well on both mouse and 
human samples. The technique is therefore broadly applicable in mouse and 
human cells and two different fixation and permeabilisation methods can be 
used successfully (method from Zell et al available in [208]).
The panel of available phospho-specific antibodies available and validated now 
includes many of the MAP kinase cascade components, PI3 kinase targets,
ST  AT proteins, antigen-receptor signalling components and more. Use of these 
antibodies directly conjugated to fluorophores rather than with secondary
74reagents decreases the strength of the specific signal generated but allows large 
numbers of different phospho-specific antibodies to be combined in the analysis 
of signalling networks [209].
Previous studies of MAP kinase signalling in Dendritic cells using classical 
biochemical techniques tend to use heroic quantities of primary cells [124, 210]. 
The use of FACS requires roughly 10-fold fewer cells per sample increasing the 
feasibility of these studies and providing further information such as per-cell 
measurements within mixed or asynchronous populations, and correlation of 
different signalling pathways on a per-cell basis. The first part of this chapter 
describes the optimisation of conditions for analysis of phospho-MAP kinases 
in murine dendritic cells.
3.1.2  : Genetic manipulation of signalling pathways in dendritic cells
In order to study signalling in dendritic cells and its outcomes we would like to 
be able to manipulate particular pathways, or dendritic cell proteins induced as a 
results of signalling through known pathways. Ideally we would like to do this 
acutely to avoid effects on DC development and additionally, to get around the 
problems associated with embryonic lethality of some germ-line modifications 
(e.g. MKK4[211], Net [199]). Retroviruses provide an efficient technique for 
the stable transduction of actively cycling primary cells (reviewed in [212]).
Dendritic cells themselves are non-dividing therefore retroviral transduction 
must target dividing precursors of dendritic cells. This has proved very 
successful in the GM-CSF BMDC system, where cycling bone marrow 
precursors are amenable to transduction [213] [214]. Although the exact 
reagents and vectors used vary between labs, the general principle uses a 
recombinant vector in which a gene of interest is cloned between two retroviral 
LTRs. Non-replicating, but infective retrovirus is produced by transfecting the 
vector into a packaging cell line stably expressed retroviral gag, pol and env 
genes [204, 215].
75PhoenixECO cells (provided by G.P. Nolan, Standford, CA) are a widely used 
retrovirus packaging cell-line. These are 293 T cells stably transfected with gag- 
pol and env sequences based on Moloney Murine Leukaemia Virus (MMuLV). 
Retroviral genes are under the control of constitutive non-viral promoters to 
achieve high-levels of expression, and are separated in different constructs to 
minimise the likelihood of recombination that could generate replicative virus. 
Recombinant retroviral vectors transfected into Phoenix cells transcribe the 
engineered insert and two Long Terminal Repeat sequences (LTRs) that allow 
packaging of the retroviral RNA by the gag-pol and env gene products already 
present in the cells. The packaged retroviruses contain RNA of your gene or 
interest flanked by LTRs, but no nucleic acid for gag, pol or env. This is 
sufficient to introduce the gene into the target cells, for reverse transcription to 
take place and for the resulting DNA to be integrated into the host genome but 
is insufficient for further viral production (detailed in [204, 215] [212] and at 
http://www.stanford.edu/group/nolan/retroviral_systems/retsys.html).
Retroviral transduction has now been used successfully in a range of in vitro 
studies such as complementation of knock-out phenotypes (for example re­
expressing mutated versions of CD40 in CD40-/- DC [216]). In addition, 
transduction of bone marrow has been successfully employed clinically to 
replace the defective common-y-chain gene in individuals with X-linked SCID
[217].
In the second section of this chapter I describe the optimisation of BMDC 
transduction with the aim of expressing Cre-recombinase in dendritic cells. Cre 
recombinase is a bacterial enzyme that releases concatentated bacterial 
chromosomes by site-specific recombination between LoxP sites (reviewed in
[218]). Cre will also catalyse recombination between LoxP-sites inserted into 
mammalian genomes, resulting in excision of the intervening DNA if the LoxP 
sites are in the same orientation, or reversal of the intervening DNA is the LoxP 
sites are in opposite orientations (reviewed in [218]). A large number of knock- 
in mice have been produced in which same-orientation LoxP sites flank genes 
of interest. An efficient retroviral Cre could be used to rapidly produce knock­
76out dendritic cells in vitro using bone marrow from any of these mice, making 
this an extremely useful tool.
773.2  : Optimisation of  protocols to study signalling in dendritic 
cells
3.2.1  Flow cytometry can be used to assess MAP kinase 
phosphorylation
As discussed in the introduction to this chapter, dendritic cells are rare and 
cumbersome to isolate ex vivo. To get around this problem I developed an 
intracellular staining protocol to assess MAP kinase signalling by FACS. From 
the scientific literature [206], [207], and in discussion with Cell signalling 
technology and Pharmingen I obtained antibodies that gave good staining of 
phosphorylated p38 MAP Kinase, phosphorylated ERK1/2, and phospho-c-Jun.
The basic protocol developed (and summarised in Chapter 2, materials and 
methods) is as follows. BMDC are enriched for CD 11  c expression using 
MACS. Enriched cells are plated at a relatively high density in the presence of 
GM-CSF and allowed to rest overnight at 37°C. Inhibitors, when used, are 
added 30mins before the stimulus to allow for passive diffusion into cells. 
Stimuli are added for indicated times, when the reactions are terminated by the 
addition of paraformaldehyde to 2% final concentration. Cells are then 
harvested and resuspended in fresh fixative (“Fix and Perm reagent A”Caltag) 
for 20 minutes. Staining for surface markers is carried out in 
PBS/1%FCS/0.05M EDTA, followed by staining for phospho-MAP kinases 
using “Fix and Perm” reagent B as the staining solution.
The validation of these stainings is shown in Figure 3-1. In part A, intracellular 
staining (using the final protocol detailed in chapter 2.8.4) for Phospho-ERK or 
Phospho-p38 is assessed in the presence of 2 different MEK inhibitors, U0126 
and PD98059 [219] [220]; or the p38 inhibitor SB203580. When BMDC from 
C57BL/6 mice are stimulated with zymosan for 30mins there is a significant 
increase in both phospho-ERK and phospho-p38 staining. In the presence of 
zymosan plus U0126 or PD98059, levels of phospho-ERK staining do not
78increase above those in unstimulated cells, whereas phospho-p38 staining looks 
identical to that in cells stimulated with zymosan alone. The staining therefore 
shows specificity for phospho-ERK. BMDC stimulated with zymosan in the 
presence of SB203580 show diminished (although not abolished) phospho-p38 
staining. Reassuringly there is no effect of SB203580 on phospho-ERK 
staining.
The specificity of phospho-c-jun staining was tested in separate experiments. 
BMDC were stimulated with CpG in the presence or absence of SP600125, an 
inhibitor of JNK [221] (3-IB). SP600125 effectively reduces the level of 
phospho-c-jun to that observed in unstimulated cells. However, variable effects 
of SP600125 were seen on the p38 and ERK pathway both by FACS and by 
western blotting so whilst this is suggestive of a specific staining, further 
evidence is required to determine true specificity.
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Figure 3-1: Assessment of MAP Kinase activation by FACS.  C57BL/6 BMDC were pre- treated 
for 30mins with lOpM U0126,  lOpM PD98059 or 1 pMSB203580. After 30minutes stimulation 
with 10pg/ml CpG cells were fixed in 2% PFA and assessed  for ERK and  p3 8 MAPK 
phosphorylation, as described in chapter 2.
803.2.2  : Optimisation of intracellular staining protocols
Several protocols for staining of intracellular MAP kinases are published. The 
paper of [208] successfully employs formaldehyde fixation of splenocytes 
followed by permeabilisation in 0.5% Saponin. The Nolan group has published 
an alternative protocol in which paraformaldehyde is used as a fixative followed 
by methanol permeabilisation at -20°C. The 3rd method investigated uses a kit 
made by Caltag (“Fix and Perm”).
Intracellular staining for the phosphorylated MAP kinase epitopes was 
essentially similar using methanol or saponin (Figure 3-2A). However, when 
starting with mixed populations of cells it is also important to maintain surface 
staining for the appropriate markers. Surface marker staining had to be carried 
out after fixation as paraformaldehyde to was used to stop the reactions at 
selected time points. This constraint largely ruled-out the use of methanol for 
our procedures as CD1 lc and CD1 lb staining of DC appears to be eliminated 
by this treatment (Figure 3-2B) if cells are stained either before or after 
methanol permeabiliztion.
Caltag “Fix and Perm” gave similar results to those obtained with Saponin 
Figure 3-2 A and B but with higher reproducibility. This kit was therefore 
employed in all intracellular staining experiments.
Many of the antibodies raised against phosphorylated signalling molecules are 
polyclonal rabbit sera. This requires a good anti-Rabbit Ig secondary reagent. I 
tested two such antibodies, a goat-anti-rabbit Ig from Caltag which was not 
cross-absorbed, and a donkey-anti-rabbit Ig from Jackson that was 
comprehensively cross-absorbed. BMDC unstimulated, or stimulated for 
30mins with CpG were used to determine which combination of antibodies gave 
the best staining. Despite not being cross-absorbed against rat IgG, the Caltag 
goat-anti-rabbit antibody only gave reliable staining in the presence of rat-anti- 
mouse Fc receptor blocking antibody (2.4G2). The donkey-anti-rabbit antibody
81from Jackson gave good staining with or without Fc receptor blocking 
suggesting this is a more reliable staining reagent and this was used in 
subsequent experiments for detecting rabbit polyclonal primary antibodies 
(Figure 3-2 C).
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Figure 3-2: Optimisation of  Intracellular staining protocol. A) C57BL/6 BMDC were stimulated 
for 5mins with 5pg/ml Anisomycin before fixation in 2% PFA.  Cells were the permeabilised in 
90% Methanol  for 5 minutes at -20°C or by washing in 0.5% Saponin FACS buffer. Staining for 
phospho-p38 MAPK was assessedflow cytometry. B) C57BL/6 BMDC were fixed in 2% PFA
82then stained directly for APC-anti-CDllc and FITC-anti-CD I lb and then left untreated or 
subsequently treated with ice-cold 90% Methanol  for 5 minutes at -20°C. A third group were 
fixed in PFA, then permeabilised in Methanol and then stained with APC-anti-CDllc and 
FITC-anti-CD I lb.  C) B6 BMDC were stimulated with Ig/ml CpG DNA for 30minutes before 
fixation and permeabilisation.  These cells were then stained with Rabbit-anti-phospho-ERK, 
followed by Caltag or Jackson biotin-anti-Rabbit-lg and PE-streptavadin.
3.2.3  : Optimisation of BMDC stimulation protocol
A potential pitfall of working with MAP kinases is that they are activated by a 
very broad range of stimuli, for example changes in adhesion triggered by re­
plating cells, responses to serum [222] and responses to GM-CSF [223]. 
Dendritic cells do not survive well in the absence of serum or GM-CSF, both of 
which have also been linked to ERK activation [222] [223]. As DC are purified 
and re-plated before experiments it was important to check the effect of these 
factors on the induction of MAP kinase activation in case the measurable 
window could be improved.
Figure 3-3 A demonstrates that withdrawal of GM-CSF  12 hrs before 
stimulation of BMDC with zymosan decreased the shift in phospho-ERK 
staining, possibly due to loss of viability. Withdrawal of serum had identical 
effects (data not shown). BMDC are therefore best maintained in GM-CSF at all 
times to obtain maximal responses.
I next tested whether moving and re-plating the cells had a positive or negative 
effect on MAP kinase activation. If BMDC were stimulated with zymosan 
simultaneously to plating out, the increase in ERK phosphorylation was 
negligible. However, after 3hrs, ERK phosphorylation at 30mins was easily 
observed (Figure 3-3B).
In order to obtain the best possible window for studying MAP kinase activation 
in BMDC enriched dendritic cells were always allowed to rest for at least 3hrs 
or overnight in the presence of GM-CSF before stimulation.
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Figure 3-3: Optimisation of  BMDC stimulation protocol. A) BMDC were isolated and MA CS 
enriched  for CD llc before plating for I2hrs in RIO, or RIO containing GM-CSF. ERK 
phosphorylation induced by 30mins stimulation with zymosan lOOpg/ml (blue line) is compared 
to resting levels (red line) by flow cytometry. Geometric mean fluorescence in FL2 is plotted  for 
cells rested in the absence (None) or presence (GM-CSF) or GM-CSF. B.  C57BL/6 BMDC were 
MACS enriched  for CD llc then plated out in R10 containing GM-CSF  for the indicated times. 
After these times zymosan was added to lOOpg/ml  for 30minutes, then signalling was stopped by 
addition of PFA to 2%. Phospho-ERK staining was assessed by  flow cytometry and Geometric 
mean fluorescence calculated and plotted
843.2.4  : Assessing MAP kinase activation in mixed cell populations 
and in vivo
The ability to measure MAP kinase activation on a per cell basis is very 
powerful because it allows measurements to be made in mixed populations 
[208] and it allows precise correlation of the states of different MAP kinases in 
any one particular cell [224]. Some examples that I have tested are shown in 
Figure 3-4.
Part A shows double staining for phopsho-p38 and phospho-ERK. 30minutes 
after zymosan addition to the cultures, the cells lie on an almost precise 
diagonal, with the highest phospho-ERK levels seen in cells that also have the 
highest phospho-p38 staining. By 60 minutes phospho-p38 staining is 
maintained, whilst phospho-ERK is starting to decrease. By  150 minutes, levels 
of phospho-ERK have returned to near baseline whilst phospho-p38 levels 
remain high. This demonstrates that in response to a saturating dose of zymosan 
all of the BMDC in the population activate both ERK and p38 MAP kinase 
pathway and that in all cells the p38 MAP kinase signal is more prolonged that 
the ERK signal.
Another use has been to establish whether MAP kinase activation is a direct or 
indirect effect of pattern recognition signalling. TLR9-/- BMDC are mixed with 
wild type congenic (B6.SJL CD45.1) BMDC which can be distinguished by 
staining with an anti-CD45.1  antibody. When the mixed BMDC population is 
stimulated with the TLR9-ligand CpG for 30 minutes, c-Jun phosphorylation, as 
assessed by intracellular flow cytometry, is only observed in the TLR9- 
sufficient CD45.1  positive cells (Figure 3-4 B). This indicates that at least at 
early time points, c-Jun phosphorylation is a direct effect of TLR signalling.
A slightly trickier situation in which the ability to gate on individual cell 
populations and assess the state of MAP kinases within the gated cells could 
become very useful (elegantly demonstrated in [208]) is elucidation of
85signalling in vivo. In Figure 3-4C BALB/C female mice were injected with CpG 
or PBS alone, or were just pricked with a syringe needle. The mice were 
euthanised after 30minutes and spleens were immediately mashed into 
paraformaldehyde. Fixed splenocytes were then stained for phospho-c-Jun. The 
interpretation of these data is highly complex with staining levels going both up 
and down after CpG stimulating in different spleen DC. Of note, there is a small 
percentage of phospho-c-Jun positive cells in the splenic DC of mice which 
have been pricked with a needle. Whether this represents simple mouse to 
mouse variation or a genuine neuroendocrine effect on spleen DC would require 
considerable further experimentation and will not be discussed further.
It is therefore clear that flow cytometry can be used to assess MAP kinase 
phosphorylation status in a quantitative manner and on a per-cell basis. In 
addition, the ability to correlate surface marker expression with phospho- 
epitope staining allows the study of signalling within mixed cell populations.
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Figure 3-4: Applications of  Intracellular staining ofphospho-epitopes. A) C57BL/6 BMDC 
were stimulated with lOOpg/ml of  zymosan for the indicated times before fixation and staining 
using the standard protocol. After first staining with purified anti-phospho-ERK, and PE-anti- 
mouse IgGl, cells were blocked in purified mouse IgGl. Alexa647-conjugated anti-phospho- 
p38 (Pharmingen) was then used to stain for p38-phosphorylation. B) C57BL/6.SJL CD45.1 
congenic BMDC were mixed 1:1 with TLR9-/- BMDC on a C57BL/6 background.  The DC were 
then stimulated with lOpg/ml CpG DNA and c-Jun phosphorylation assessed by flow cytometry. 
C) 200pi of25pg/ml CpG, or PBS alone was injected intravenously into age and sex-matched 
Balb/c mice, or a mouse was pricked with the syringe needle but nothing injected (sham). 
Spleens were removed after 30minutes, disrupted and cells fixed in 2% PFA. c-Jun 
phosphorylation was assessed by flow cytometry.
873.2.5  : Retroviruses can be used to efficiently transduce BMDC
Dendritic cells are not easily transfected. To circumvent this issue I have 
optimised a protocol for retroviral transduction of bone marrow to produce 
BMDC.
Using the pMSCV-EGFP vector ecotropic Phoenix cell lines were constructed 
that stably produce MSCV-EGFP retrovirus with the MLV envelope protein 
(protocol described in 2.3.1). Using these cells to transduce GM-CSF BMDC 
(Figure 3-5A) or Flt3L BMDC (Figure 3-5B) gave an average of 50% (GM- 
CSF) or 20% (Flt3L) transduction as assessed by GFP expression, making this a 
feasible experimental system.250
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Figure 3-5: Retroviral transduction of GM-CSF (A) and FLT3L (B) BMDC. Bone marrow was
transduced with MSCV-EGFP produced  from stably transduced phoenicECO cells as described 
in chapter 2. GFP expression is assessed by FACS on day 5 of GM-CSF BMDC culture or day 
10 of  Flt3L BMDC culture.
893.2.6  : Amount of virus added correlates well with transduction 
efficiency
The amount of virus added to each transduction correlates well with the 
percentage transduction obtained. This parameter was the major determinant of 
transduction efficiency compared to all other parameters tested. Figure 3-6A 
shows that when 10, 20 or 50% of the BMDC supernatant was replaced with 
neat viral supernatant before spinfection the percentage transduction increases 
accordingly. In order to maximise percentage transduction,  100% of supernatant 
is routinely replaced before spinfection. Paradoxically, spinfecting twice per day 
does not increase transduction efficiency despite exposing cells to twice as 
much virus (figure 3-6B).
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Figure 3-6: Increasing amounts of virus correlate with increased percentage transduction. A) 
Spinfections of GM-CSF BMDC were carried out as detailed in chapter 2 with 10, 20 or 50% of 
the supernatant replaced with virus before spinfection, rather than the standard 100%. 
Percentage of GFP+ cells was assessed on day 5. B) Spinfections of GM-CSF BMDC were
90carried out as detailed in chapter 2, or repeating each spinfection 3hrs later on the same day. 
Percentage of GFP+ cells was assessed on day 5.
3.2.7  : Optimisation of retrovirus production protocol
As the amount of virus added before spinfecting bone marrow is a major 
determinant of efficiency, it is critical that high titre viruses are produced. Three 
different methods were tried for the production of retroviruses from two 
different retroviral vectors that I was interested in using. The two packaging cell 
lines employed were PhoenixECO cells (from Dr G Nolan, Stanford, CA) or 
GP2-293 cells (Invitrogen). Transient transfections of the retroviral vectors 
(either pMSCV-GFPCre or pBabe-DLLl-puro) into Phoenix or GP2-293 cells 
were compared to “ping-pong” production from a stable Phoenix cell line 
(described in 2.3.1). A VSV-G expression plasmid was included in transfections 
of GP2-293 cells to provide a functional envelope protein for viral packaging. 
The results of titring lOOpl of the 48 hour supernatants on NIH-3T3 cells are 
shown in figure 3-7A. Stably expressing Phoenix cell lines reliably gave the 
highest titre virus for either vector, with transient transfection of GP2-293 cells 
giving a slightly higher titre than transient transfection of Phoenix cells.
The MLVA envelope protein expressed by Phoenix cells makes virus that is 
insufficiently stable to survive concentration by ultracentrifugation (a 
commonly used method with VSV-G pseudotyped retroviruses). However, 
using a much gentler method, over 10-fold concentration of virus can be 
obtained (figure 3-7B).  1.5ml viral supernatant is spun for lhr at 4°C,  13000rpm 
in a microfuge, after which time the top  1.45ml of virus is removed. The 
remaining 50pl contains the same infectivity as the full  1.5ml starting 
preparation when used to infect NIH-3T3 cells in vitro indicating that where 
very high titres of viruses are required then this method can be used.
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Figure 3-7: Optimal virus production from stably-transduced Phoenix cells: A) pMSCV- 
GFPCre or pBabe-DLLl-GFP-Puro were used to produce stable phoenix cells via the  “ping- 
pong ” method described in chapter 2, or to carry out transient transfections of Phoenix or GP2- 
293 cells. Retroviral supernatants obtained were used to infect NIH-3T3 fibroblasts and GFP 
levels assessed 48hrs after infection. B) 3ml of  supernatant from phoenix cells stably producing 
MSCV-GFPCre was added directly to NIH-3T3 cells or was first centrifuged  for I hr at 4°C in 
two 1.5ml tubes, after which the top 1.45ml  from each tube was discarded and the remaining 
100pi was added to the NIH-3T3 cells. Percentage GFP+ cells was assessed at 48hrs post­
infection.
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o3.2.8  : Optimisation of “spinfection” protocol
BMDC are grown in RPMI medium supplemented as described in chapter 2.
Phoenix cells and GP2-293 cells were originally grown in supplemented
DMEM therefore I assessed the effect of either adapting stably-expressing
Phoenix cells into RPMI and growing BMDC as usual, versus growing BMDC
in DMEM and using Phoenix cells in DMEM. The results of spinfections
carried out exclusively with DMEM or RPMI culture media are shown in figure
3-8. The titre of viral supernatant was determined using 3T3 cells. This revealed
a slightly lower titre from RPMI-adapted Phoenix cells and correspondingly a
slightly lower % of GFP-positive, CD1 lc-positive cells in the RPMI cultures.
However, the difference is small and BMDC responses are well characterised in
RPMI-based media, therefore Phoenix cells are now routinely adapted into
RPMI before use in transductions.
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Figure 3-8:  Tissue culture medium does not affect GM-CSF BMDC transduction efficiency. 
Phoenix cells stably-producing MSCV-GFP were grown in D10 or adapted into R10 and used 
to produce transduced GM-CSF BMDC in the respective media. GFP% is assessed at day 5 of 
culture.
933.2.9  : Polybrene improves retroviral transduction
It has previously been reported that inclusion of polycations such as polybrene 
can dramatically improve retroviral transduction (reviewed in [212]). The exact 
mechanism by which this works is unclear but is generally assumed to favour 
the close association of virus particles and cells. Figure 3-9 demonstrates an 
increase in the percentage GFP+ cells achieved by adding 2pg/ml polybrene to 
the retroviral supernatants before spinfection without a loss in total CD1 lc+ 
cells. Polybrene therefore appears to improve retroviral transduction of BMDC.
No virus  Virus alone  Virus + Polybrene
GFP
Figure 3-9: Polybrene improves transduction efficiency. Spinfections of GM-CSF BMDC were 
carried out with MSCV-GFPCre-neo produced  from stably transduced Phoenix cells as detailed 
in chapter 2. Either viral supernatant alone or viral supernatant containing 4pg/ml Polybrene 
was used in each spinfection and %GFP-positive cells assessed on day 5 of culture.
943.2.10  : pMSCV PGK promoter-driven expression is much stronger 
than LTR-driven expression
The initial vector I obtained for expression of GFPCre (a kind gift from Dr K 
Deinhardt, Cancer Research UK, London UK) used the viral LTR promoter to 
drive expression. This gave very weak expression when compared to another 
vector expressing GFP from the downstream PGK promoter of pMSCV. I 
therefore re-cloned the GFPCre protein downstream of the PGK promoter, 
generating the pMSCV-GFPCre8 vector. When phoenix cells expressing the 
original pMSCV-GFPCre-neo vector were compared to those expressing 
pMSCV-GFPCre8 there is a 1  to 2 log shift in GFP levels (figure 3-10A). This 
vector was therefore suitable for the introduction of Cre into dendritic cells and 
tracking of transduced cells.
In order to determine if the GFPCre fusion protein worked as an active Cre- 
recombinase, ROSA26-YFP bone marrow was transduced with either the 
pMSCV-GFPCre8 vector or a control pMSCV-Cre with no GFP expression 
(figure 3-1 OB). Cre-mediated recombination in ROSA26-YFP bone marrow 
results in YFP expression. GFP and YFP fluorescence were measured in day 5 
transduced BMDC using flow cytometry. The emission spectra of GFP and YFP 
overlap significantly therefore it was not possible to fully compensate between 
the two channels using the equipment available. However, no GFP+ or YFP+ 
cells were detected from untransduced C57BL/7 BMDC or ROSA26-YFP 
BMDC. After transduction, GFP expression was obvious in the C57BL/6 
BMDC transduced with GFPCre but not Cre alone. YFP+ cells could be 
detected in the ROSA26-YFP BMDC transduced with either virus indicating 
that the GFP-Cre was functional (Figure 3-10B).
In further proof that pMSCV-GFPCre8 produces retrovirus capable of 
mediating recombination between LoxP-sites, figure 3-10C shows the results of 
a representative transduction of Jagged-1-Flox bone marrow. Jagged-1-floxed 
mice were generated by Dr Katsuto Hozumi and were a kind gift of Dr Soline
95Estrach (Keratinocyte Laboratory, Cancer Research UK, London Research 
Institute, UK). The mice are homozygous for a knock-in of the construct shown 
in part C, such that the exons encoding the DSL-domain of Jagged-1  are flanked 
by LoxP sites. Introduction of Cre into cells from the Jagged-1   flox mice 
mediates deletion between the LoxP sites that can be monitored using a duplex 
PCR (primers marker a, b and c on the construct). Bone marrow from Jagged-1- 
Flox mice can be successful used in transductions with virus from pMSCV- 
GFPCre8 to generate BMDC. GFP-positive and GFP-negative DC were FACS- 
sorted on day 5 of culture and genomic DNA produced. The duplex PCR 
described above was carried out and the results are shown in figure 3-10D. The 
PCR product at 333bp can only be obtained if Cre-mediated excision has taken 
place, whereas the 229bp band can only be obtained if the Floxed construct is 
still present. Figure 3-10D shows that only ‘deleted’ allele is detected in sorted 
GFPCre-positive cells, and only ‘floxed’ allele is detected in sorted GFP- 
negative cells indicating that the GFPCre protein produced from PSCV- 
GFPCre8 is functional and can be used to track transduced and recombined 
cells. It should be noted that deleted allele was sometimes detected at quite 
significant levels in the sorted GFP-negative population, probably due to the 
presence of cells that had ceased to express GFPCre or which expressed at very 
low levels sufficient for recombination but not sufficient to give measurable 
GFP fluorescence.
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Figure 3-10: Stronger GFPCre-expression from the pgk-promoter of MSCV. A) GFPCre was 
re-cloned downstream of the pgk promoter within pMSCV and used to make stably transduced 
Phoenix cell lines. GFP levels in the Phoenix cells are assessed by FACS.B) MSCV-GFPCre8 
or MSCV-Cre are used to transduce bone marrow from C57BL/6 or ROSA-YFP mice, and 
produced GM-CSF BMDC. GFP and YFP levels are assessed by FACS on day 5. C) Construct 
inserted into the endogenous Jagged-1 locus of  Jagged-l-flox mice. Primers a, b and c used in 
duplex PCR to monitor recombination are shown. D) Day 5 Jagged-l-flox BMDC were 
transduced with MSCV-GFPCre8 as described in chapter 2.4. GFP-positive and negative cells 
were FACS-sorted and genomic DNA was isolated. Duplex PCR to monitor was carried out and 
run on a 2% agarose gel (right-handpanel). Deleted allele yields a PCR product of333bp, 
Floxed yields a product at 229bp.
993.3  : Discussion
3.3.1  : The optimal protocol for analysis of MAP kinase 
phosphorylation in dendritic cells
The aim of the experiments described in sections 3.2.1 to 3.2.4 was to maximise 
the specific signal for phosphorylated signalling molecules as measured by flow 
cytometry. A group of antibodies that gave specific staining with reasonable 
shifts is shown below:
Phospho-eptiope Antibody Secondary reagent
Phospho-ERK Mouse IgGl, 
Pharmingen
Pharmingen rat-anti- 
mouse IgGl OR directly 
conjugated
Rabbit polyclonal, Cell 
Signaling Technology
Jackson, Donkey-anti- 
rabbit (cross-adsorbed)
Phospho-p38 MAPK Mouse IgGl, 
Pharmingen
Directly conjugated to 
Alexa 647
Rabbit polyclonal, Cell 
Signaling Technology
Jackson, Donkey-anti- 
rabbit (cross-adsorbed)
Phospho-JNK Rabbit polyclonal, Cell 
Signaling Technology
Jackson, Donkey-anti- 
rabbit (cross-adsorbed)
Phospho-c-Jun Mouse IgGl (KM-1), 
Santa Cruz
Pharmingen rat-anti- 
mouse IgGl
There are now a large number of phospho-specific antibodies being marketed as 
suitable for flow cytometry and many more will be relevant to DC research.
This list will be expanded as different reagents are required in the future.
“Fix and Perm” (Caltag) is the best method for intracellular staining of dendritic 
cells, both for preservation of surface marker staining and for ease of use and 
reliability. Interestingly Krutzik et al [225] report that although they find there is 
a loss of almost 1  log between positive and negative populations staining for
100CD1 lb or CD1 lc in methanol-fixed splenocytes the populations are still clearly 
discemable. This appears to relate to a wider separation of their populations of 
interest in unfixed cells as positive and negative populations become 
indistinguishable after methanol treatment in my hands.
It is very clear that physical manipulation of dendritic cells affects both their 
basal level of phosphorylated MAP kinases and their ability to activate MAP 
kinase cascades in response to stimuli (figure 3-3). In order to measure the 
response to stimuli it is therefore critical to rest cells after purification and re­
plating. DC maintained in serum and GM-CSF during the resting period 
respond optimally to PAMPs, most likely because removal of either of these 
factors compromises DC viability.
3.3.2  : Possible applications for flow cytometric analysis of signalling 
in dendritic cells
The ability to assess MAP kinase activation in individual DCs allows these 
techniques to be applied to numerous situations. The examples shown in figure 
3-4 demonstrate that this can be used to examine multiple MAP kinase 
pathways simultaneously, can be used to examine DC responses in mixed 
populations separable by a congenic markers, and can be used to examine MAP 
kinase status in DCs after in vivo stimulation. All of these areas could be 
investigated much more thoroughly -  it would be particularly interesting to 
work out what signalling events occur after in vivo stimulation and the 
differences in signalling when a PAMP is injected versus saline alone or sham 
injection as this would provide clues as to the necessary signals for dendritic 
cell maturation in vivo, and would discern whether the signalling response to 
sham injection was a real phenomenon. Eventually, this may allow 
comprehensive analysis of signalling networks activated in DC by particular 
stimuli. The differences in mice genetically deficient in signalling molecules or 
cell populations could provide multiple insights into the in vivo control of DC 
phenotype.
101In addition to this, flow cytometry can now routinely be used as a quick and 
simple assay for signalling in situations in which western blotting may 
previously have been used. Throughout chapter 5 of this thesis ERK 
phosphorylation in BMDC is monitored by flow cytometry and the simplicity 
with which quantitative data is obtained without the need to normalise for 
protein loading etc. provided a powerful research tool.
3.3.3  : Optimal protocol for retroviral transduction of GM-CSF and 
Flt3-L BMDC
BMDC can be efficiently transduced with MSCV-based retroviruses. The 
optimal protocol is described in section 2.4. The main limit of efficiency of 
retroviral transduction of DC is the titre of retrovirus produced. The most 
reliable virus production method appears to be the construction of stable 
PhoenixECO lines (described in section 2.3.1), which routinely allow 50 to 90% 
transduction of dendritic cells.
Improvement of percentage transduction can be achieved by including 
polybrene in the transduction reactions.
3.3.4  : Expression of Cre-recombinase in dendritic cells
The original aim of optimising retroviral transduction of DC was to produce 
dendritic cells expressing Cre-recombinase. A GFPCre fusion protein was used 
such that Cre-positive cells could be positively identified even in situations 
where there is strong selection against recombined DC. MSCV vectors in which 
the gene of interest are expressed from the LTR promoter and GFP is expressed 
from the pgk promoter were therefore not optimal as selective silencing of the 
LTR could lead to selection of transduced cells that were not expressing Cre. It 
is interesting that expression from the pgk promoter of pMSCV is much 
stronger than expression from the LTR, both in Phoenix cells (293T cells) and 
BMDC (figure 3-10A). The reasons for this are not clear but may involve 
selective LTR silencing or lack of positive transcriptional activators. Regardless
102of the reasons, it was obviously better to express GFPCre from the pgk 
promoter of this vector. This produced a virus that induced efficient 
recombination in Rosa26-YFP and Jagged-1-Flox bone marrow.
A disadvantage to this system is that GFP-negative cells cannot necessarily be 
used as negative controls in this system as the GFP signal from the GFPCre 
fusion protein is still dim and cells expressing low amounts of GFPCre overlap 
very significantly with the untransduced population. The correct controls are 
therefore transduced cells differentiated from control bone marrow.
The applications of a Cre retrovirus system are wide-ranging. There are a large 
number of mice available that have LoxP-sites knocked-in around a gene of 
interest or which are transgenic for a construct in which expression of a gene of 
interest is controlled by Cre-mediated excision of an upstream cassette. Bone 
marrow from any of these animals can be used to rapidly generate knock-out 
dendritic cells in vitro.  This is used in chapter 6 of this thesis to make dendritic 
cells lacking Jagged-1.
An extension of this work could be used to transduced the splenic precursors of 
conventional DC recently described by Naik et al [87]. These cells, once 
transduced, could be re-introduced into mice to quickly generate knock-out 
splenic DC, although these would then need to be differentiated from 
endogenous DC for analysis.
The ability to assess cell signalling in DC by FACS and to generate knock-out 
or transduced DC are useful tools for the study of DC signalling and effector 
function, as will be described in subsequent chapters.
1034  Chapter 4: Zymosan recognition activates signalling 
via Syk to induce high levels of IL-2, IL-10 and 
Jagged-1: Dectin-1 is a putative |3-glucan-binding 
PRR.
4.1  : Introduction
Zymosan is known to stimulate DC maturation, both in terms of surface marker 
upregulation and in the induction of IL-10, IL-12 p40 and very low levels of IL- 
12 p35/IL-23 p70 [96]. I extended these observations to other candidate markers 
of dendritic cell activation and analyse kinetics of cytokine production. The 
second part of this chapter addresses the role of different receptors for zymosan 
in signalling for dendritic cell activation.
4.1.1  Pattern recognition receptors and zymosan
In the context of dendritic cells “PRRs” can be defined very strictly as receptors 
that signal for dendritic cell maturation resulting in differentiation (not just 
proliferation) of naive T cells into effector T cells [77]. This is a particularly 
important distinction in the case of zymosan recognition as several receptors 
such as the Mannose Receptor [46], and Complement Receptors (with and 
without complement fixation) [45] [226] can bind zymosan. However, there is 
limited evidence that these receptors alone are sufficient to induce full DC 
maturation and cytokine production.
As discussed in chapter 1, zymosan is a particulate cell-wall extract of 
Saccharomyces cerevisiae and a good, if complex, source of yeast PAMPs such 
as P-glucans [39]. TLR2/6 heterodimers and Dectin-1  are both implicated in 
cytokine production in response to zymosan in macrophages [55, 56], and 
Dectin-1   is known to specifically recognise the (3-glucan component of zymosan 
[55, 56] [57]. At the point when this project was initiated it was known that
104dendritic cells produced IL-12 in response to zymosan in a TLR2 and MyD88- 
dependent manner, whilst IL-10 was produced independently of both TLR2 and 
MyD88 [205]. This was particularly intriguing as this TLR-independent 
production of IL-10 was one of the first indications of bona fide pattern 
recognition at the cell surface that was not dependent on Toll-like receptors. We 
set out to further investigate the TLR-dependence of cytokine production in 
response to zymosan.
4.1.2  : Production of cytokines in response to zymosan
The cocktail of cytokines produced by DCs is carefully regulated and depends 
on the stimulus (or stimuli) received and the type of DC stimulated (for a 
detailed discussion see Chapter 1.3.3 and 1.3.4 and references therein). In this 
study, only GM-CSF BMDC have been considered and the patterns of cytokine 
production reflect the signature of stimulation via particular PRRs in this cell- 
type. Necessarily this will differ slightly from the in vivo responses of other DC 
subsets to zymosan, with the possible exception of “inflammatory DC” 
suggested to be the in vivo counterpart of GM-CSF BMDC [87].
Zymosan induces the production of very high levels of IL-10 (up to 20ng/105  
cells after 18hrs of stimulation -  data presented within). IL-10 production is 
also observed with TLR2, TLR4 and TLR9 ligands [227] [228] [229]. The 
production of a cytokine typically associated with anti-inflammatory properties 
by a pathogen-associated stimulus is intriguing although the role of IL-10 
production specifically by dendritic cells is unknown.
Recently it was reported that zymosan induces very high levels of IL-2 
production from dendritic cells [145]. The striking difference between TLR and 
zymosan-induced IL-10 and IL-2 levels (demonstrated in this chapter) hints at 
profound differences between the recognition of zymosan and less complex 
TLR ligands and provides an assay in which dendritic cell recognition of 
zymosan can be tested.
1054.1.3  : Dectin-1: the MyD88-independent receptor for zymosan?
Dectinl  is a type II membrane protein with an extracellular C-type lectin 
domain and an intracellular IT AM-like motif [52]. This receptor is essential for 
the nonopsonic uptake of zymosan by macrophages [60]. In addition, several 
pieces of evidence suggest that Dectin-1  has functions beyond phagocytosis.
The ITAM-tyrosines of Dectin-1, are required to enhance TLR2-dependent 
TNFa secretion in RAW264.7 cells in response to zymosan [230, 231]. In 
addition, an oxidative burst in response to zymosan could be triggered in 
macrophages lacking TLR2 [230, 231]. This suggests that signalling capacity of 
Dectin-1  is required for it to enhance TLR2-mediated recognition of zymosan, 
and that Dectin-1  may be able to signal for innate immune cell activation 
independently of TLR2.
Dectin-1  is expressed on myeloid cells including splenic dendritic cells, 
macrophages and neutrophils [232].
4.1.4  : ITAM signalling in dendritic cells
Underhill et al demonstrate that the cytosolic tail of Dectin-1  is tyrosine 
phosphorylated on zymosan binding in macrophages [233] and sequence 
analysis has identified motif in the cytoplasmic tail of Dectin-1  which bears 
similarity to an ITAM. This led us to hypothesise that ITAM signalling, as 
occurs downstream the B cell receptor of Fc-Receptors, may be playing a role in 
dendritic cell responses to zymosan.
Syk mediates IT AM-dependent signalling in dendritic cells [234] and can signal 
downstream of the FcyReceptor for the induction of IL-12 p40, indicating that 
Syk can signal for DC maturation [234]. The same study found that Syk- 
deficient DC responded normally to TLR-ligands. The ITAM-like motif in 
Dectin-1 contains an extra amino acid residue in the N-terminal YXXL (see 
figure 1-5). This suggests that the interaction of Syk with Dectin-1 may differ 
from Syk-activation induced downstream of consensus ITAM-containing 
receptors. Atypical modes of Syk activation have been proposed, in particular
106tyrosine-independent Syk activation in response to Integrin signalling [235]. 
The unusual ITAM pattern in the cytoplasmic tail of Dectin-1 may be sufficient 
for Syk recruitment and activation. My results, together with those by others in 
the Immunobiology lab, led to the demonstration that this is indeed the case 
[146].
The aim of work described in the chapter was to describe more fully the 
activation of DC stimulated by zymosan and to examine the roles of different 
potential PRRs (namely Dectin-1  and TLR2) in signalling for this activation.
1074.2  : Results - Syk-dependent cytokine and Notch-ligand 
production
4.2.1  : Zymosan induces high levels of IL-2, IL-10, IL-12p40, IL-12 
p35, IL-6 and TNFa from DC
Previous work suggests that zymosan is particularly potent at inducing IL-10 
and relatively poor at inducing IL-12 p70 from splenic DC [205]. To extend this 
observation, BMDC were screened for cytokine mRNA upregulation in 
response to a panel of inflammatory mediators, conventional TLR ligands, and 
P-glucan-rich stimuli (zymosan and curdlan). TNFa, and IFNa were chosen as 
inflammatory stimuli as these have been reported to promote the upregulation of 
costimulatory molecules and MHC II on DC but are not thought to induce 
cytokine production, or to be sufficient for the instruction of T cell 
differentiation [105] [101]. ProstaglandinE2 has been implicated in induction of 
DC maturation leading to Th2 priming [236]. The TLR ligands used are 
Pam3Cys (TLR 1/2), MALP2 (TLR2/6), LPS (TLR4), Flagellin (FliC, TLR5) 
and CpG (TLR9) (reviewed in [22]) as these are known to induce differential 
patterns of cytokine production from DC. Of these, MALP2 signals through the 
same TLR combination as zymosan [59] [237]. All microbial stimuli are used at 
a previously established sub-saturating dose and one saturating dose.
Cytokine production was initially monitored by RT-PCR analysis due to the 
high sensitivity and broad dynamic range, as well as simplicity of screening 
several different cytokines. A 3hr time-point was chosen for analysis as being 
early in the response, this minimises the effects of major autocrine signals such 
as IL-10.
Results are shown in Figure 4-1A-G. The level of cytokine mRNA at 3hrs 
varies significantly between BMDC stimulated with different ligands, reflecting 
the flexibility of dendritic cell maturation. There is no induction of cytokines by 
stimulation with TNFa, PGE2 or IFNa, as would be expected from published
108work. Among the TLR ligands tested, CpG induces the highest levels of IL-6, 
IL-12 p35 and p40, IL-23 p i9, IL-2 and TNFa. However, LPS induces higher 
levels of IL-10 mRNA. Flagellin does not induce significant levels of any of the 
cytokines tested and TLR2 ligands are consistently less potent in cytokine 
production than either CpG or LPS. Zymosan is a ligand for TLR2/6. 
Interestingly, zymosan induces much higher levels of all of the cytokines tested 
than the purified TLR2/6 ligand (MALP2), inducing significantly higher levels 
of IL-10, IL-2 and TNFa mRNA than even CpG (figure 4-1  E-G) and 
comparable levels of IL-6, IL-12 p40, IL-12 p35 and IL-23 pl9 to those seen 
with CpG. This suggests that zymosan can act in a similar way to a strong TLR 
agonist in the induction of IL-6, IL-12 and IL-23. The extremely potent 
induction of IL-2, IL-10 and TNFa further implies that zymosan can bias 
cytokine induction in a manner rarely observed as a result of pure TLR 
stimulation. With respect to this observation, the highly purified p-glucan, 
Curdlan, which is recognised by DC in a Dectin-1-dependent manner (Salome 
LeibundGut-Landmann, Caetano Reis e Sousa, manuscript in preparation) does 
not induce high levels of IL-6, or IL-12 but is sufficient to induce moderate 
levels of IL-2 and IL-10 implying that p-glucan recognition is sufficient for 
cytokine induction and that it couples particularly well to cytokines that show 
strong induction with zymosan, as compared to the purified TLR agonists.
To confirm that mRNA levels for the cytokines tested correlate with levels of 
cytokine produced at the protein level, BMDC were stimulated with maximal 
doses of zymosan or CpG and production of cytokines was measured by ELISA 
after 18hrs (figure 4-1H). This reveals that, as for mRNA levels, zymosan 
induces markedly higher levels of IL-2 and IL-10 and slightly higher levels of 
TNFa from BMDC than CpG stimulation. CpG DNA is however a slightly 
stronger stimulus for IL-12 p40 protein production, suggesting that the mRNA 
data is largely in agreement with protein measurements.
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Figure 4-1: Cytokine upregulation in BMDC stimulated with inflammatory or microbial stimuli 
A-G: C57BL/6 BMDC (5 x 10s per well of  a 24 well plate) were stimulated with TNFa 50ng/ml, 
IFNa 5000U/ml, ProstaglandinEl (PGE2) InM, O.lnMPam3Cys 2,  lOpg/ml; MALP2 0.2, 
lpg/ml; LPS (highly purifiedfrom Salmonella) 1, 5pg/ml; Flagellin (FliC) 0.2,  lpg/ml; CpG 
1668 0.5, 2,5pg/ml; Zymosan (Zym) 20,  lOOpg/ml; Curdlan (Curd) 20,  lOOpg/ml. After 3hrs 
cells were lysed in Trizol (Invitrogen) and RNA was extractedfor RT-PCR and Q-PCR analysis 
using SYBR-green (IL-6, IL-2,  TNFa, IL-23pI9) or Taqman (IL-10, IL-12 p35, IL-12p40). 
Results are normalised to 18S rRNA. Data is representative of 3 separate experiments. H: 
BMDC were plated out in complete medium supplemented with GM-CSF and stimulated with 
lpg/ml CpG DNA or 25 pg/ml of  zymosan.  Cytokine production was determined by ELISA after 
I8hrs of culture. Data is representative of  over 8 independent experiments.
1124.2.2  : Zymosan-stimulation induces IL-10, IL-2, IL-12 p40 and 
TNFa from overlapping sets of dendritic cells but with different 
kinetics.
It is intriguing that dendritic cells make cytokines such as IL-10, IL-2, IL-12 
p40 and TNFa to high levels despite the proposed disparate functions of these 
cytokines. As RNA analysis averages mRNA levels over the entire population 
of cells present, it is possible that the cytokines are being made by subsets of 
dendritic cells or even that the cytokines are being produced in sequence by 
individual cells, but out of phase with each other in the population, leading to 
the observed results in figure 4-1.
The kinetics of mRNA upregulation for IL-2, IL-10 and IL-12 p40 was 
determined up to 9hrs post-stimulation. Data shown in figure 4-2A reveals that 
IL-2 and IL-12p40 mRNA is induced rapidly after zymosan stimulation with 
maximal mRNA levels found at the 3hr time-point. IL-2 levels have decreased 
dramatically by 6hrs whilst IL-12 p40 levels are sustained. Conversely, the 
highest IL-10 mRNA levels are found at 9hrs, indicating a much slower 
induction.
To really determine if dendritic cells were producing multiple cytokines or if 
there were sub-populations of cytokine-producing cells I employed intracellular 
staining for cytokines after BrefeldinA treatment to measure cytokine 
production at the protein level on a per-cell basis. BrefeldinA disrupts ER to 
Golgi transport leading to fragmentation of the Golgi apparatus [238, 239] and 
the accumulation of newly synthesised cytokines in the secretory pathway. 
Initially, dendritic cells were treated with BrefeldinA from 3 to 9hrs after 
zymosan stimulation followed by fixation and staining for IL-2, IL-10, IL-12 
p40 and TNFa. Figure 4-2B clearly shows IL-2 production uniquely by cells 
that also make the highest levels of IL-12p40 and TNFa. Some IL-10 producing 
cells are positive for IL-12 and IL-2 although the overlap here is partial. There 
is a stronger correlation between TNFa production and IL-10 production. At a
113low frequency, there are cells in this experiment that stain positively for all 4 
cytokines, i.e. are IL-2 positive and IL-10 positive. Since IL-2 production only 
occurs from cells expressing the highest levels of IL-12 p40 and TNFa this 
demonstrates that it is possible for a single dendritic cell to produce IL-2, IL-10, 
IL-12 p40 and TNFa in response to zymosan.
Given the 6hr period of BrefeldinA treatment employed in generating figure 4- 
2B it is possible that the cytokines are being produced in sequence, rather than 
simultaneously. As demonstrated in 4-2A, the kinetics of IL-10 and IL-2 mRNA 
induction show the greatest differences, making these good candidates for 
sequential production. I analysed IL-2 and IL-10 intracellular staining over a 
crude time-course of BrefeldinA treatment to look for evidence of dendritic 
cells making first IL-2, followed by IL-10. If BrefeldinA is included in the 
cultures from 3 to 6hrs and intracellular staining is performed at this time-point, 
IL-2 producers are found, with very few IL-10-positive cells. Flowever, if 
BrefeldinA is added from 6 to 9 or 9 to 12 hours, predominantly IL-10 
producing cells are detected. Double positive cells are only detected at a 
measurable level if BrefeldinA is present from 3 to 9hrs of culture, over the 
period at which IL-2 production ceases and IL-10 production commences. 
Whilst there are caveats to this experiment associated with toxicity of 
BrefeldinA and the disruption of autocrine and paracrine signalling during the 
period in which BrefeldinA is present in the cultures this is a hint that whilst the 
same DC that have recognised zymosan can in fact produce both IL-2 and IL-10 
they do so in a sequential manner. It is also probable that there are DC present 
that have made either IL-10 or IL-2 as the percentage of double positive cells is 
low. The regulation of cytokine production over time is an interesting 
phenomenon which may explain the ability of DC stimulated with factors that 
lead to IL-10 production to induce robust T cell responses despite production of 
a cytokine typically associated with tolerance.
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Figure 4-2: Single BMDC can produce IL-12 p40, IL-2,  TNF and IL-10. A. C57BL/6 BMDC (5 
x 105 per well of  a 24 well plate) were stimulated with 50pg/ml Zymosan for the given lengths of 
time before lysis in Trizol and RNA extraction. B. C57BL/6 BMDC (10A6 per well of  a 24 well 
plate) were left unstimulated or stimulated with 50pg/ml zymosan for 3hrs, before adding 
Brefeldin A to a final concentration of 5pg/ml. 6hrs later cells were recovered and stained  for 
intracellular cytokines C. As part B with alterations is the timing of  Brefeldin A addition and 
cell isolation as marked. Data is representative of 3 separate experiments
1164.2.3  : Modulation of Notch-ligands by microbial stimuli
Recently there has been a resurgence of interest in Notch-ligand expression by 
DC and modulation of T cell differentiation with the proposal that Jagged- 
ligands induce Th2 differentiation [160]. Detailed analysis of Notch-ligand 
regulation in response to different stimuli is currently lacking, therefore I tested 
whether the stimuli used in 4-1 could also modulate mRNA levels for the Notch 
ligands Jagged-1, Jagged-2, DLL1  and DLL4.
The conventional TLR2, TLR4 and TLR9 ligands give poor induction of both 
Jagged 1  (< 2-fold)  and Jagged2 (decrease from unstimulated) and strong 
induction of DLL4 (figure 4-3 A, B and D). This correlates well with the ability 
of these stimuli to induce robust Thl responses when used as adjuvants 
(reviewed in [240]). The TLR5 ligand, Flagellin, dose not lead to any noticeable 
change in Notch-ligand expression. It is possible that the 3hr snapshot provided 
by this screen misses later events in this case.
In contrast the j3-glucan-containing ligands induce up to 4-fold induction of 
Jagged 1  mRNA (figure 4.3A) and either no change or roughly 2-fold induction 
of Jagged2 mRNA (figure 4-3B) which may correspond to the more mixed 
responses seen when zymosan is used as an adjuvant [90] [175]. In addition, 
zymosan, but not curdlan, is a good stimulus for induction of DLL 1  and DLL4 
(figure 4C and D). This may reflect the presence of significant levels of TLR2 
ligands in zymosan that are absent from curdlan [Dr Salome LeibundGut- 
Landmann, manuscript in preparation].
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Figure 4-3: Upregulation of Notch-ligands by inflammatory and microbial stimuli.  C57BL/6 
BMDC (5 x 10s per well of a 24 well plate) were stimulated with TNFa 50ng/ml, IFNa 
5000U/ml, ProstaglandinE2 (PGE2)  InM,  O.lnM;, Pam3Cys 2, lOpg/ml; MALP2 0.2, lpg/ml; 
LPS (highly purified  from Salmonella) 1, 5pg/ml; Flagellin (FliC) 0.2,  lpg/ml; CpG 1668 0.5, 
2,5pg/ml; Zymosan (Zym) 20,  IOOpg/ml; Curdlan (Curd) 20,  lOOpg/ml. After 3hrs cells were 
lysed in Trizol (Invitrogen) and RNA was extracted  for RT-PCR and Q-PCR analysis using
118SYBR-green. Results are normalised to 18S rRNA measured by Taqman. Data is representative 
of 3 separate experiments
4.2.4  : Zymosan up-regulates Jaggedl at the cell surface
Little is known about the relationship between mRNA levels for Notch-ligands 
and protein levels found at the cell surface where they can interact with Notch. 
To establish what my mRNA data represented on a per cell basis I developed a 
flow-cytometry protocol to stain for Jaggedl. Using this method the induction 
of Jaggedl by zymosan is even more striking (figure 4-4A) with 12% positive 
cells at 24hrs after stimulation compared to  1-2% after TLR stimulation.
It was necessary to validate the specificity of staining for Jaggedl. Jagged-1- 
floxed mice were generated by Dr Katsuto Hozumi (See figure 3-IOC). Bone 
marrow from these mice was transduced with a retrovirus expressing a Cre- 
recombinase-GFP fusion protein (MSCV-GFPCre8) and GM-CSF BMDC were 
grown out. The resulting DC population appeared to be around 60% GFPCre- 
positive (figure 4-4B) and bulk populations were used for these assays. 
Remaining cells were sorted on the basis of GFP-expression (for a separate 
experiment detailed in chapter 6) and a fraction was treated to extract genomic 
DNA. A duplex PCR for recombination was carried out on cells and is shown in 
figure 4-4B. All GFP-positive cells have fully deleted Jagged-1. However, 
around half of the sorted GFP-negative cells are also positive for the 
recombined allele suggesting that overall transduction was roughly 70-80%. 
When the unsorted, bulk populations were stimulated with zymosan for 6hrs or 
were left unstimulated it is clear that Jagged-1   staining is decreased in 
“Jagged 1-/-“ BMDC in both the unstimulated and stimulated samples. In 
addition, there is no significant increase in Jagged-1   staining after zymosan 
stimulation in the Jaggedl-/- cells, with the exception of a small shift in the side 
population, likely corresponding to the c 20% non-recombined cells remaining 
(figure 4-4B).
119An interesting aspect of Jaggedl  staining is that at saturating doses of zymosan 
only a fraction of the cells are ever found to be positive (up to around 50%) with 
the negative population precisely overlaying isotype control staining. Jagged 1- 
positive cells are present by 4hrs with the highest percentages found after 6hrs 
of stimulation (figure 4-4C) that then persist or drop slightly by 24hrs. There are 
many possible reasons for this non-uniform staining, ranging from inefficency 
of the staining, through stochasticity of signalling induced by zymosan, to a role 
of Notch signalling in trans between DC leading to shedding or internalisation 
of the notch ligands.
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120Figure 4-4: Upregulation of  Jagged-1 production by Zymosan stimulation of  BMDC.  C57BL/6 
BMDC (5 x 105 per well of a 24 well plate) were stimulated with TNFa 50ng/ml, IFNa 
5000U/ml,  CD40L-trimers lpg/ml; MALP2 0.2,  lpg/ml; LPS (highly purified  from Salmonella) 
1, 5pg/ml; Flagellin (FliC) 0.2, lpg/ml; R848 0.2,  1 nM; CpG 1668 0.5, 2,5pg/ml; Zymosan 
(Zym) 20, lOOpg/ml, at 37°C overnight in the presence of GM-CSF. BMDC were recovered and 
stainedfor surface Jaggedl.  The percentage of CD1 lc+ cells that are Jaggedl-positive (as 
determined by isotype control staining) is shown in part A. Data is representative of  2 separate 
experiments. Part B: Bone marrow from Jaggedl-flox or littermate controls was transduced 
with MSCV-GFPCre8 (as described in section 2.4) to generate Jaggedl-/- cells. Resulting 
control or “Jagged-/- “ BMDC  (5 x 105 per well of a 24 well plate) were cultured  for 6hrs in the 
presence (zymosan) or absence (no stimulus) of lOOpg/ml zymosan. Recovered cells were 
stained  for Jaggedl. Data is represented as histograms of  Jaggedl staining. BMDC were 60% 
GFP-positive as shown in bottom right-hand plot.  GFP positive and negative fractions of these 
cells were separated by FACS sorting and genomic DNA was extracted.  This was analysed  for 
the presence of recombined alleles using a duplexed PCR (described in chapter 2.11). Products 
obtained were run on a 2% agarose gel and imaged. Part C: C57BL/6 BMDC were stimulated 
with lOOpg/ml zymosan for 0, 4 or 6hrs before surface staining for Jaggedl. Data is 
representative of 4 separate experiments.
4.2.5  : MyD88-independent responses to zymosan
Zymosan is known to stimulate dendritic cells through both a TLR-dependent 
and TLR-independent pathway [205]. Previous experiments suggested that IL- 
10 induction in spleen DC was stimulated through the TLR-independent 
pathway [205]. I therefore checked whether other factors induced by zymosan 
stimulation were more dependent on one pathway or the other in BM-DC. The 
TLR component of zymosan is recognised through TLR2/6 heterodimers [59]. 
MyD88 is absolutely required for TLR2/6 to signal (reviewed in [28]), therefore 
TLR2/6 signalling can be effectively eliminated using dendritic cells genetically 
deficient in MyD88 [241],
MyD88-/- DC stimulated with zymosan and CD40L produce as much IL-10 as
C57BL/6 DC (figure 4-5A). In the absence of CD40L there is some MyD88-
dependence but MyD88-/- cells still produce IL-10 above background. IL-2
production shows a partial decrease in MyD88-/- DC cultures, again, not to zero
121and is unaffected by CD40L costimulation (figure 4-5A). IL-12 p40 
demonstrates a similar partial decrease in MyD88-/- cultures stimulated with 
zymosan in the absence of CD40L-fibroblasts. However, in the presence of 
CD40L fibroblasts, IL-12 p40 production cannot be increased by zymosan 
stimulation (figure 4-5A). It should be noted that CpG stimulation, as an 
example of a strong IL-12-inducing stimulus, further increases IL-12 p40 levels 
above the background achieved with CD40 ligation [242].
During the course of these experiments it was observed that GM-CSF and 
CD40L had differing abilities to amplify the production of IL-2, IL-10 and IL- 
12 p40. GM-CSF efficiently amplifies IL-2 induction in response to zymosan, 
leaving IL-10 and IL-12p40 unaffected. Conversely CD40L strongly amplifies 
IL-10 and IL-12 production but has only a limited effect on IL-2 (figure 4-5B). 
The regulation of cytokine production clearly involves multiple pathways that 
can synergise or not depending on their nature (figure 4-5A and B, [32, 33]). It 
is possible that this goes some way to explaining the variation in MyD88 
dependence of IL-10 and IL-12 p40 induction between experiments (production 
of these cytokines is much less affected by MyD88-deficiency in 4-5B than in 
4-5 A!) although the actual source of this variation has been elusive.
Despite some variability, the important observation remains that in the absence 
of TLR signalling, recognition of zymosan can lead to the production of 
significant levels of IL-10 and IL-12 p40 and low levels of IL-2 implying the 
existence of a non-TLR receptor that is capable of coupling microbial 
recognition to cytokine production by dendritic cells.
MyD88-/- BMDC also up-regulated Jaggedl  at the mRNA and protein level in 
response to zymosan demonstrating that this component of DC maturation can 
also be induced by TLR-independent pattem-recognition (figure 4-5C and D).
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Figure 4-5: IL-10 and Jagged-1 upregulation in response to zymosan can occur independently 
of TLR signalling.  C57BL/6 or MyD88-/~ BMDC were enriched to >95% purity using MACS.
10A 5 BMDC were plated per well of  a flat-bottomed 96 well plate in the presence or absence of 
CD40L-expressing fibroblasts. After 24hrs cells were freeze-thawed and cytokine 
concentrations determined by sandwich ELISA. B: Cells handled as in part A were cultured with 
25pg/ml zymosan in the presence of CD40L fibroblasts or GM-CSF.  Cytokine production at 
24hrs was determined by sandwich ELISA.  C: BMDC as in A and B were stimulated for 6hrs 
with lOOpg/ml of  zymosan. BMDC were stained  for Jaggedl and analysed by fo w  cytometry.
All data shown is representative of  more than 3 experiments.
1234.2.6  : P-glucan recognition in cytokine induction
As discussed in section 4.1.4 the p-glucan receptor Dectin-1  is known to play an 
important role in zymosan recognition by macrophages [230, 231]. To 
determine whether a P-glucan receptor such as Dectin-1  might be responsible 
for the TLR-independent response to zymosan we performed inhibition 
experiments using a known inhibitor of Dectin-1, glucan phosphate [230].
When glucan phosphate was added to cultures of BMDC and zymosan it could 
partially inhibit production of IL-10, IL-2 and IL-12 p40 (figure 4-6A). The 
interpretation of these data is complicated by the possibility that P-glucan 
receptors could be required for the uptake of zymosan before recognition in the 
endosomal compartment by receptors with other specificities, such as TLR2. 
However, inhibition of phagocytosis using the actin-polymerisation inhibitor 
Latrunculin B [243] (figure 4-6B) had no effect on either IL-10 or IL-12 p40 
production suggesting that the effect of glucan phosphate was not simply to 
block internalisation. IL-2 production, in contrast, is strongly inhibited by 
Latrunculin B treatment but it is unclear whether this reflects a requirement for 
internalisation or a possible role for G-actin in regulating signalling [244] to IL- 
2 gene expression. These results hint that a beta-glucan receptor may be 
involved in the TLR-independent response to zymosan.
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Figure 4-6: IL-10 production induced by zymosan is inhibitable with soluble Glucan phosphate, 
but not Latrunculin B. A) C57BL/6 BMDC (105 per well of a flat-bottomed 96 well plate) were 
pre-treatedfor 30mins with 50 or lOOpg/ml of  glucan phosphate. Indicated concentrations of 
zymosan were added and cells were cultured at 37°C overnight. Freeze-thawed supernatants 
were assayed  for cytokines by sandwich ELISA. B) Bulk C57BL/6 BMDC (Unenriched by 
MACS; 2 x I05 per well) were cultured with the indicated concentration of  zymosan in the 
presence or absence of 10pMLatrunculin B or vehicle (DMSO) alone.  Cytokine concentration 
in the supernatants after overnight culture was determined by sandwich ELISA. Data is 
representative of 3 independent experiments
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4.2.7  : Dectin-1: A (3-glucan receptor with a HemlTAM.
p-glucan recognition appears to play a role in zymosan recognition by BMDC
making Dectin-1 a good candidate receptor for zymosan on DC. As discussed,
the 30aa intracellular tail contains what initially looked like a putative IT  AM
motif (figure 4-7  A) [52]. The presence of a possible IT  AM was an exciting clue
125that the signalling initiated by Dectin-1 may be similar to conventional IT  AM 
signalling leading to the activation of Syk or Zap70 [245] [246]. Dectin-1 is 
widely expressed in myeloid cells [232], as is Syk, whilst Zap-70 is largely 
restricted to the T cell lineage [247].
As we wanted to define whether Dectin-1  signals for cytokine production rather 
than presents zymosan to other receptors for recognition we carried out gain-of- 
function experiments. Neil Rogers (Immunobiology Lab, Cancer Research UK, 
London [146]) first established that the LK B cell hybridoma line was 
unresponsive to zymosan but could produce IL-2 and IL-10 on BCR cross- 
linking. LK cells expressing full-length Dectin-1  but not Dectin-1  lacking the 
intracellular tail could respond to zymosan by making IL-2 and IL-10 indicating 
that the cytoplasmic domain of Dectin-1 was critical for its function [146]. This 
requirement was not at the level of Dectin-1 binding as cells expressing 
truncated Dectin-1 bound zymosan as efficiently as cells expressing wild-type 
Dectin-1  [146]. Given that IL-10 production is independent of phagocytosis, as 
determined by Latrunculin B inhibition, these data suggest that Dectin-1   plays a 
direct signalling role in the induction of cytokines.
In macrophages the intracellular tail of Dectin-1  becomes tyrosine- 
phosphorylated on zymosan binding [233]. The two tyrosines that could be 
phosphorylated are tyrosine 3 (in the first YXXXL motif  of the IT  AM (figure 
4-7A) and tyrosine 15 in the second YXXL motif. LK cell lines expressing 
Dectin-1   in which the two tyrosines were mutated separately or simultaneously 
to pheylalanine were tested for responsiveness to zymosan. Surprisingly, 
mutation of tyrosine-3 to phenylalanine (Y3F) had no effect on induction of IL- 
2 or IL-10 by zymosan (figure 4-7B) or in recruitment of phospho-Syk to the 
site of zymosan-binding (figure 4-7C, produced by Martijn Nolte and 
reproduced with kind permission here). Despite requiring only a single YXXL- 
motif Dectin-1 was still able to recruit phospho-Syk to the phagocytic cup as 
determined by confocal microscopy. In addition Neil Rogers demonstrated that 
peptides corresponding to the Dectin-1   intracellular tail mutants required only 
the membrane-proximal tyrosine-15 to immunoprecipitate purified Syk [146].
126Together, this data implies that Dectin-1  can signal through Syk using a novel 
half-ITAM or “hemlTAM” motif and can induce cytokine production in a B cell 
hybridoma.
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Figure 4-7: Dectin-1 only requires one of its ITAM tyrosines to signal for IL-10 and IL-2
127production. A) Sequence of  the intracellular tail of  Dectin-1 compared to a standard ITAM or 
ITIMsequence. B) LK cells expressing either wild-type Dectin-1 or the indicated Dectin-1 
mutants (10s per well) were stimulated with the indicated concentrations of  zymosan. Levels of 
IL-10 in the supernatants after overnight culture were determined by sandwich ELISA.  C)
WORK OF DR MNOLTE.  The same LK cells as in (B) were stimulated with Cy5 zymosan 
(blue) for 5 min then fixed and stained  for phospho-Syk (red) and CD 16/32 (green). Images are 
optical sections through representative cells.
4.2.8  : Syk is necessary for IL-2, IL-10 and Jaggedl induction in 
response to zymosan
We wanted to test whether Dectin-1 might be signalling for cytokine production 
and Notch-ligand upregulation in DC. As we did not have access to Dectin-1- 
deficient DC at this time we formulated a hypothesis that since Dectin-1   could 
associate with Syk, loss of Syk in dendritic cells should abrogate Dectin-1  
signalling. Chimeric mice were made using Syk-/- foetal liver or womb-mate 
controls. Syk-/- BMDC grew normally from the bone marrow of these mice and 
responded normally to TLR ligation [146]. However, when Syk-/- BMDC were 
stimulated with zymosan they showed a drastic reduction in levels of both IL-10 
and IL-2 (figure 4-8A). The production of IL-12 p40 did not differ from 
controls in these cells implying that the TLR2/MyD88 dependent recognition 
was occurring normally (figure 4-8A). In addition, Jaggedl upregulation was 
also markedly reduced in Syk-/- BMDC at both the level of mRNA induction 
and surface staining (figure 4-8B). Syk-dependent pattem-recognition clearly 
plays an important role in the response of dendritic cells to (3-glucan-containing 
stimuli and appears to bias DC towards the production of high levels of IL-2, 
IL-10 and Jaggedl. Dectin-1 is expressed in DC and may be acting upstream of 
Syk to induce signalling. It should however be noted that the effects of Syk- 
deficiency (figure 4-8) are much more profound than the effects seen by 
antagonising |3-glucan recognition using glucan phosphate (figure 4-6) leaving 
open the possibility that receptors for components other than [Lglucans may 
also signal through Syk in the BMDC response to zymosan. We have now 
observed that Dectin-1   deficient DC, whilst completely refractory to stimulation
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by the purified p-glucan, Curdlan, are only partially impaired in their response 
to zymosan (IL-2, IL-10 and IL-12 p40 induction at the protein level. Salome 
Leibundgut, manuscript in preparation) adding weight to the hypothesis that 
further Syk-dependent receptors may be involved.
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Figure 4-8: IL-2, IL-10 and Jagged-1 induction in response to zymosan is dependent on 
signalling through Syk. A: syk-/- or control BMDC (10s per well) were cultured with the 
indicated doses ofzymosan for 24hrs.  Cytokine concentrations in freeze-thawed supernatants 
were determined by sandwich ELISA. B: syk-/- or control BMDC (106 per well of  a 24 well 
plate) were stimulated with I OOpg/ml zymosan for 6hrs.  Cells were recovered and stained  for 
Jaggedl. All data is representative of  3 independent experiments.
1294.3  : Discussion
4.3.1  Dectin-1 is a Pattern Recognition Receptor capable of inducing 
cytokine production and Notch-ligand upregulation in DC
I have demonstrated that small soluble |3-glucans inhibit the BMDC cytokine 
response to zymosan, hinting that the P-glucan receptor, Dectin-1  may play a 
role in this induction (figure 4-6). Blocking experiments cannot differentiate 
between requirements to tether and phagocytose zymosan, aiding its 
presentation to TLR2/6 heterodimers, or actual signalling. Latrunculin B 
treatment of dendritic cells effectively blocks zymosan phagocytosis without 
affecting IL-10 or IL-12 production demonstrating that the effect of p-glucan 
was independent of any inhibition of phagocytosis (figure 4-6). Further 
demonstration that Dectin-1  can indeed signal for cytokine production was 
provided by reconstruction of the Dectin-1 pathway in LK cells. This 
demonstrated a requirement for an intact membrane-proximal YXXL motif in 
the cytoplasmic domain of Dectin-1  for induction of IL-2 and IL-10 in response 
to zymosan (figure 4-7). This is strong evidence that Dectin-1  is involved in 
signalling for cytokine production, rather than simply presenting zymosan for 
TLR2-mediated recognition.
Further evidence that a zymosan-binding receptor was capable of signalling for 
cytokine production is revealed in the upregulation of IL-10 and Jagged-1   in 
response to zymosan in MyD88-deficient DC (figure 4-5). We hypothesised that 
Dectin-1   may be a TLR-independent PRR involved in zymosan (and therefore 
yeast) recognition by DC.
The IT  AM-like sequence in the short intracellular tail led us to investigate 
signalling through Syk. Tyrosine-phosphorylation of Dectin-1 has been 
demonstrated previously [233] suggesting that the ITAM may be functional. 
Martijn Nolte elegantly demonstrated that Dectin-1  can recruit phospho-Syk to 
zymosan-containing phagocytic cups (figure 4-7). In the LK cell system this
130requires the presence of tyrosine-15 in the intracellular tail but not tyrosine-3, 
i.e. only the membrane-proximal half of the ITAM is required for Syk 
recruitment [146]. Interaction between purified recombinant Syk and synthetic 
peptides of the entire Dectin-1  intracellular domain, with mutations in the 
ITAM tyrosines confirmed the requirement for tyrosine-15 but not tyrosine-3. 
Half-IT AMs or “HemlTAMs” appears to be a novel signalling motifs capable of 
binding and activating signalling through Syk (figure 4-7, [146]).
There is prcedent for non-IT  AM signalling through Syk. In a reconstruction of 
proximal B cell Receptor signalling in Drosophila S2 Schneider cells, a BCR in 
which the only one ITAM tyrosine remained could induce low level 
phosphorylation of SLP-65 via Syk that was absent if both tyrosines were 
mutated [248]. However, compared to the activity of Syk in the presence of 2 
full IT  AMs, this induction is marginal suggesting there may be other facets of 
the Dectin-1   tyrosine motif that favour Syk recruitment. Intriguingly it has 
previously been noted that the N-terminal SH2 domain of Syk does not bind 
efficiently to phospho-ITAMs in isolation whilst the C-terminal SH2 domain 
binds with moderate affinity [249]. The N-terminal SH2 domain and adjacent 
linker can bind to the intracellular tails of p 1, P2 and |33 integrins 
independently of tyrosine phosphorylation [235]. This demonstrates that non- 
IT  AM motifs can  bind and activate Syk and hints that similar interactions could 
play a role in Dectin-1-Syk interactions.
Dendritic cells deficient for Syk are markedly impaired in their responses to 
zymosan, in particular in the induction of IL-10, IL-2 and Jaggedl, whilst IL-12 
p70 production is unaffected (figure 4-8, [146]). This is evidence in favour of 
the involvement of Dectin-1  signalling in zymosan recognition by DC, although 
other Syk-activating receptors may also be involved.
A critical observation in this series of experiments is that neither removal of 
MyD88 nor removal of Syk leads to a complete loss of production in any 
cytokine tested, although there are quantitative decreases (sometimes 
pronounced, figure 4-5, 4-8). This has led us to conclude previously that IL-10
131induction is Syk-dependent whilst IL-12 induction is TLR-dependent [146]. On 
closer inspection this turns out to be a simplification and the majority of 
cytokines induced by zymosan can be induced, at least to low levels, by either 
signalling pathway. This data correlates with recent data generated using a 
purified Dectin-1 agonist that signals exclusively through Dectin-1  and Syk and 
can lead to the induction of IL-2, IL-10, IL-23, IL-12 p40, and IL-6 (Salome 
LeibundGut Landmann, manuscript in preparation). A Syk-dependent pathway 
for pattern recognition in DC exists, pi,3 and pl,6-glucans are essential 
structural components of yeast cells walls. Dectin-1  can recognise these 
conserved pathogen-associated molecules and signal into dendritic cells for 
maturation and cytokine production, fulfilling both of the original criteria for 
the identification of bona fide “Pattern Recognition Receptors”.
4.3.2  Zymosan induces high levels of IL-2, IL-10 and Jagged-1
What is the significance of the very high IL-2, IL-10, Jaggedl  and TNFa 
production by zymosan and curdlan-stimulated DCs (demonstrated in figure 4- 
1)? So far the role of these cytokines in instructing T cell differentiation has not 
been conclusively demonstrated. Several possibilities exist. Firstly, T cells and 
dendritic cells are not the only cells in the body and some DC cytokines may be 
required to act on cells other than T cells. It is interesting to note that 
intracellular staining of DC demonstrates that IL-2 production only occurs from 
cells also making high levels of IL-12 p40 and TNFa (figure 4-2) suggesting 
that at least at some point these cytokines are produced together. IL-10, on the 
other hand appears to be produced after IL-2 production has ceased (figure 4-2) 
suggesting that the targets of these two cytokines are different, or that the timing 
of cytokine signals is an important factor in programming T cell differentiation. 
Pulse-chase experiments on antigen-processing and presentation suggest that 
antigen-presentation can be detected (using the C4H3 antibody to detect MHC- 
class II-HEL complexes) by around 3-4hrs after protein uptake in vitro [250], 
roughly coincident with the start of IL-2 and IL-12 p40 production (figure 4-2).
132The ability of GM-CSF to amplify IL-2 but not IL-10 or IL-12 production is 
additionally intriguing (figure 4-5). It is unclear whether this simply represents 
differences in the signalling requirements of the different cytokines or whether 
feedback amplification by different cell types promotes the delivery of DC 
cytokines in cis.
This work helped us to understand how signalling via a Syk-dependent, TLR- 
independent PRR activated by zymosan produces a specific cytokine and 
Notch-ligand signature in DCs. In addition, I have demonstrated that Dectin-1  is 
capable of signalling, via Syk and a novel HemlTAM motif for the induction of 
IL-2 and IL-10. This raises two sets of interesting questions, firstly in the cell 
signalling activated in response to zymosan and secondly in the physiological 
role of Dectin-1   ligation in DC maturation and T cell priming. In the next 
chapter I will discuss the some advances on dissecting the signalling 
downstream of zymosan recognition.
1335  Chapter 5: Signals linking Syk activation to the 
production of high levels of IL-2 and IL-10
5.1  introduction
Zymosan induces signalling through Syk, at least in part by binding to Dectin-1. 
Syk is essential for the induction of IL-2 and IL-10 in response to zymosan. 
What is going on downstream of Syk to lead to the strong induction of these 
cytokines?
5.1.1  Signalling in response to zymosan: What do we know?
As discussed in chapter 4, zymosan can induce signalling through Dectin-1/Syk 
and through TLR2/MyD88. Whilst the TLR/MyD88 signalling pathway is now 
quite well-defined (reviewed in [23]), the half-ITAM motif used by Dectin-1  is 
novel and therefore research into the signalling induced is only just beginning.
Classical ITAM signalling through Syk/ZAP-70 can activate all of the MAP 
kinase pathways as well as NF-kB and calcium signalling [251]. Recruitment of 
Syk/ZAP-70 to ITAMs results in tyrosine-phosphorylation of Syk and 
subsequent recruitment of downstream signalling components [252] including 
two adaptor proteins, LAT and SLP-76. These act as scaffolds for the activation 
of PLCy, Sos/Grb2, Vav, etc. Ras can be activated by Grb2/Sos associated with 
LAT; by activation of RasGRP (Ras guanyl nucleotide-releasing protein) 
downstream of PLCy; or via PKC (Reviewed in [251]). In addition, Vav appears 
to be necessary to couple ZAP-70 activation to ERK activation and calcium 
mobilisation in murine T cells [253].
134Signalling to the MAP kinases triggered by cross-linking of the high affinity 
IgE receptor on Mast cells proceeds via an almost identical pathway using Syk, 
rather than ZAP-70 as the non-receptor tyrosine kinase (reviewed in [254]). B 
cell receptor signalling through Syk is very similar to T cell receptor signalling, 
with a few notable differences. There is a B cell homologue of LAT, called 
NTAL/LAB which is phosphorylated by Syk and recruits Grb2 to enhance 
BCR-induced ERK activation (reviewed in [255]). However, unlike LAT, 
NTAL does not associate with PCLy suggesting there may be a further adaptor 
in B cells that links to PLCy and calcium mobilisation.
ITAM signalling to NF-kB has recently been elucidated. Mice deficient in 
Bel 10, CARMA1 or MALT1 all have severe defects in TCR-induced NF-kB 
activation (reviewed in [256, 257]). On TCR ligation PKC0, Bel 10, MALT1 
and CARMA1 are recruited into lipid rafts. Oligomerised Bel 10 and MALT1 
form an E3 ubiquitin ligase which together with the E2-ubiquitin-conjugating 
complex UBC13 and MMS2 catalyse the K63 poly-ubiquitination and 
activation of NEMO and therefore NF-kB [256, 257]. Intriguingly, MALT1- 
deficient mice also show a defect in p38 MAP kinase and JNK signalling on 
PMA/ionomycin treatment of T cells, although the link between MALT1  and 
MAP kinase signalling is currently unclear[256]. Contradictory results have 
been reported for B cell signalling in the MALT-1 knock-out although B cell 
development is impaired suggesting a similar signalling machanism is likely to 
play a role (reviewed in [258] [259]). PKC0 is not expressed in B cells therefore 
a PKCp is instead required for CARMA1  recruitment (reviewed in [258]).
5.1.2  Activation of NF-kB downstream of Dectin-1
A recent publication by Gross et al [147] elegantly demonstrates that NF-kB 
activation downstream of Dectin-1   is achieved by a homologous pathway to that 
downstream of the TCR. In place of CARMA1, Dectin-1  signalling uses 
CARD9, which lacks the membrane guanylate kinase domain found in 
CARMA1 but is sufficient to form an active E3 ubiquitin ligase complex with 
MALT1 and Bel 10 leading to NF-kB activation. Dendritic cells deficient in
135CARD9 show a severe defect in IL-10 production in response to zymosan 
stimulation [147].
5.1.3  Signals associated with IL-2 and IL-10 induction in DC
IL-2 induction in DC, like IL-2 induction in T cells, can be inhibited by 
cyclosporin A [260]. This inhibitor targets calcineurin, preventing the calcium- 
induced dephosphorylation, and activation of NFAT [261]. However, 
cyclosporine has also been reported to affect calcium-dependent signals leading 
to AP-1 transcriptional activation [262].
Cyclosporin A is an extract from Tolypocladium inflatum Gams a member of 
the Cordyceps family of parasitic fungi (predominantly entemoparasites) 
isolated from Norwegian soil under certain conditions [261]. The function of the 
peptide in intact Tolypocladium inflatum Gams is unknown but although NFAT 
is restricted to vertebrates, calcineurin is present in both C. elegans and 
Drosophila [263] and it is an intriguing possibility that Cyclosporin A may 
inhibit evolutionarily conserved anti-fungal innate responses in its host 
organism.
IL-2 production is best characterised in T cells. ERK, JNK and calcium 
signalling are required for T cell IL-2 production [262, 264, 265]. The IL-2 
promoter contains AP-1, NFAT and NF-kB binding sites, all of which are 
necessary for the efficient induction of IL-2 [266]. IL-2 is also known to be 
regulated post-transcriptionally at the level of mRNA stability [132]. As 
discussed in chapter 1, this appears to require p38 MAP kinase signalling to re- 
localise mRNA bound to TTP away from stress-granules where it is otherwise 
rapidly degraded [126,  132].
In dendritic cells IL-2 is known to be induced by microbial stimuli and to 
require autocrine IL-15 [133].
A number of reports now associate high levels of IL-10 production by DC with 
robust ERK activation [267] [175] [94].  c-Fos is implicated as a downstream
136target of ERK required for IL-10 induction [94]. It has recently been suggested 
that in macrophages ERK activation is essential for Histone H3 phosphorylation 
and chromatin modification in the IL-10 promoter allowing transcription factor 
binding although whether this is also the case in DC is unknown [268].
Further factors required for the inducible transcription of IL-10 are IRF1 
downstream of type IIFN signalling [269]; Sp-1 downstream of p38 MAP 
Kinase signalling [270] and STAT3, which is required for IL-10 induction by 
LPS [229] [269] although the mechanism of STAT3 activation in this case is 
unclear.
5.1.4  The ERK pathway is a strong candidate for modulating 
zymosan-induction of IL-2 and IL-10
A large number of signalling components are likely to be activated downstream 
of Dectin-1 and will play a role in modulating the transcription and translation 
of IL-2 and IL-10. I have therefore started to investigate the possible signalling 
by examining a good candidate pathway. Published data supports a role of ERK 
signalling in the induction of these cytokines in a variety of cell types [262, 264, 
265] [267] [175] [94].
Zymosan has been used as a strong stimulus for ERK activation in macrophages 
for some time [271, 272] and both TLR signalling and classical ITAM 
signalling can couple to ERK activation (reviewed in [251] [23]). Interestingly, 
TLR2 induced ERK activation is implicated in the ability of TLR2-ligands to 
induce IL-10 [136], despite the observation that TLR signalling is dispensable 
for IL-10 production in response to zymosan (Chapter 4, [96] [146]). In 
macrophages, ERK activation downstream of TLR2 requires the proteasomal 
degradation of NF-kB 1  pi 05, which releases active TPL2 to phopshorylate and 
activate MEK1/2 [135]. Targeting of NF-kB 1  pi 05 for proteasomal degradation 
is achieved through activation of the IKK complex [135].
137Experiments discussed in this chapter aim to examine the role of ERK 
signalling in dendritic cell responses to zymosan. The data presented here 
demonstrate that zymosan is a strong stimulus for ERK activation and that ERK 
inhibitors decreased IL-10 and IL-2 induction in response to zymosan.
5.1.5  What are the candidate downstream targets of ERK 
signalling?
Many diverse ERK targets have been identified, many of which are direct 
transcriptional activators, but also including proteins associated with control of 
mRNA processing, translation, cytoskeletal function, cell cycle progression and 
organelle-specific functions [273]. c-Fos has previously been implicated as a 
target of ERK required for IL-10 production [136]. However, c-Fos 
upregulation, rather than the direct phosphorylation of c-Fos was required 
indicating a possible role for an intermediate transcription factor. Growth-factor 
induced c-Fos transcription requires ERK signalling to phosphorylate and 
activate the Ternary Complex Factor Elk-1, leading to association with Serum 
Response Factor and transcriptional activation from the Serum Response 
Element in the c-fos promoter [274]. There are two other TCF family members 
Sap-1  and Net, both of which are direct targets of ERK (reviewed in [275]).
LPS signalling in macrophages induced TNFa expression via the ERK 
pathway. This requires the phosphorylation of Elk-1  by ERK and subsequent 
transcription of Egr-1   [276].
The ERK cascade can also activate a number of kinases, including p90 
Ribosomal S6 Kinase (RSK)l, RSK2, RSK3, RSK4, MNK1, MNK2, MSK1 
and MSK2. These can phosphorylate numerous transcriptional regulators such 
as Jun, c-Fos and Nur77. MSK1/2 can phosphorylate CREB at Seri33, as well 
as the NF-kB p65 isoform and STAT3 (Reviewed in [273]). MNK1/2 are 
implicated in control of translation through their ability to phosphorylate eIF4E. 
The physiological consequences of eIF4E phosphorylation remain to be 
definitively investigated, with both increased and decreased translation reported.
138There is a correlation between eIF4E phosphorylation and decreased 5’-cap- 
dependent translation (Reviewed in [273]).
The ERK pathway can also regulate protein expression downstream of 
transcriptional activation. RSK1  can phosphorylate glycogen synthase kinase 3(3 
within polyribosomes. This inhibits the kinase activity of RSK1  and results in 
increased protein translation through eIF2B (Reviewed in [273]). MNKs can 
bind and phosphorylate hnRNP Al, decreasing its specific interaction with the 
3’AU-rich element in TNFa mRNA and stabilising TNFa mRNA [277].
Experiments presented in the latter half of this chapter explore the involvement 
of possible signalling events downstream of ERK in controlling DC activation 
by zymosan.
1395.2  : Results - ERK activation is necessary for IL-2 and IL-10 
induction
5.2.1  : Zymosan recognition activates the ERK pathway in BMDC
The ERK pathway has previously been reported to play a role in the control of 
IL-10 production by TLR2 ligands and zymosan [94,  136] [175]. Figure 5-1A 
shows a western blot of phospho-p38 MAP Kinase and phospho-ERK over a 
short time-course of zymosan stimulation. Whilst there is some background 
ERK phosphorylation this is increased to a maximum level by 15 to 20 minutes. 
p38 MAP kinase activation in contast appears to be induced by  15minutes and 
then remains stable up to 40 minutes after stimulation. FACS for phospho-ERK 
demonstrates a robust shift in specific antibody staining 30minutes after 
zymosan stimulation (figure 5-IB). As demonstrated in chapter 3, increased 
FACS-staining for phospho-ERK after zymosan-stimulation is abolished by pre­
treatment with the ERK inhibitor U0126, supporting the specificity of staining 
(Figure 3-1B). To determine if Dectin-1 is capable of activating the ERK 
pathway LK cells transfected with wild-type or tyrosine-mutated Dectin-1 were 
used. Zymosan stimulation could induce ERK activation by FACS in the LK 
cells expressing wild-type Dectin-1  but not in cells expressing the mutant 
receptor that cannot signal (Figure 5-1C). Therefore zymosan recognition by 
DC results in robust ERK activation, and Dectin-1  can initiate a signalling 
cascade that results in ERK activation.
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Figure 5-1: Stimulation of  BMDC with zymosan results in ERK activation. A) C57BL/6 BMDC 
were plated at 106 per well of  a 24 well plate and stimulated with 100  pg zymosan for the 
indicated time-periods. Signalling was halted by addition of  SDS-sample buffer. Samples were 
run on a 10% Tris-glycine gel, blotted onto nitrocellulose and probedfor phospho-ERK and 
phospho-p38. B) BMDC as in (A) were stimulated  for 30minutes with 100pg zymosan then fixed 
and stained  for phospho-ERK before analysis by flow cytometry. C) LK cells stably expressing 
Dectin-1 ofDectin-1 -FF were stimulated with lOOpg/ml zymosan for 30 minutes before fixation 
and analysis of levels ofphospho-ERK by flow cytometry.
1415.2.2  : IL-10 and IL-2 production is decreased in the presence of 
MEK inhibitors
MEK inhibitors PD98059 and U0126 are unrelated chemical compounds that 
attenuate ERK activation upstream of phosphorylation and activation of ERK 
[220] [219]. These inhibitors were therefore used to assess the contribution of 
ERK activation to cytokine production induced by zymosan. BMDC were pre­
treated for 30mintues with the ERK inhibitors before addition of zymosan and 
over-night culture. Measurements of cytokines in the supernatants showed that 
both U0126 (figure 5-2A) and PD98059 (figure 5-2B) significantly decreased 
the production of IL-2 and IL-10 across the full dose-response of zymosan- 
treatment. Correspondingly neither inhibitor affected IL-12 p40 production in 
response to zymosan suggesting that the effect of the compounds was specific 
and not due to a non-specific effect on receptor expression or cell survival.
In order to determine whether U0126 affected IL-2 and IL-10 production at the 
mRNA level saturating doses of zymosan or the TLR2-ligand Pam3Cys were 
used to stimulate dendritic cells pre-treated with the ERK inhibitor U0126. At 
3, 6 or 18hrs mRNA was harvested and analysed by quantitative real-time PCR 
for IL-2 and IL-10 upregulation. Corresponding protein levels from parallel 
cultures were determined after 18hrs of culture. Data shown in figure 5-2D 
demonstrate a strong reduction in IL-2 and IL-10 protein levels, correlating well 
with decreased in mRNA levels, particularly at later time-points suggesting that 
at least part of the effect of ERK is on mRNA production or stability. The ERK 
pathway therefore makes an important contribution to induction of both IL-2 
and IL-10. These data also reveal that whilst the levels of mRNA induced by 
Pam3Cys and zymosan are very different, corresponding to the induction of 
protein, the peak of cytokine mRNA production occurs at similar time-points 
(i.e. at 3hrs of IL-2 and at 6hrs for IL-10). Pam3Cys induced IL-2 and IL-10 
mRNA appears to be more strongly inhibited by U0126 than zymosan induced 
mRNA levels, suggesting that TLR2/Pam3Cys-induced IL-2 and IL-10 may be 
more heavily dependent on ERK signalling than that induced by zymosan.
142In order to determine the contribution of ERK signalling to Dectin-1  dependent 
responses LK cells expressing wild-type Dectin-1 were pretreated with the ERK 
inhibitor, followed by 18hrs stimulation with zymosan. Measurements of 
cytokines in the supernatant revealed that U0126 will also inhibit IL-2 and IL- 
10 production by Dectin-1-expressing LK cells stimulated with zymosan (figure 
5-2C) suggesting that ERK may be a crucial link between Dectin-1  and the 
production of these cytokines.
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Figure 5-2: Zymosan-induced IL-2 and IL-10 is diminished by MEK inhibitors.  C57BL/6 BMDC 
were enriched  for CD llc and plated at 10A 5 per well of  a 96 well plate.  Cells were pre-treated 
for 30 minutes with lOpM UOI26 (A) or lOpMPD98059 (B) before stimulation with the 
indicated doses of  zymosan.  Cytokine secretion was determined after I8hrs using sandwich 
ELISA.  C) LK cells expressing full-length Dectin-1 were pre-treated with 10pM U0126 before 
stimulation with lOOpg/ml zymosan. Cytokine production was measured after I8hrs of 
stimulation by sandwich ELISA. D) and E) C57BL/6 BMDC were pre-treated  for 30minutes 
with UOI26 then stimulated with lOOpg/ml zymosan or lOpg/ml Pam3Cys. For part D) 
supernatants were collected after I8hrs and used to determine cytokine production by sandwich 
ELISA. For part E), cells were harvested at the indicated time points and mRNA extracted and 
subjected to real-time PCR to determine mRNA levels of  IL-2 and IL-10.
1445.2.3  : Zymosan-induced ERK-activation is Syk-dependent
Experiments described in 5.2.1 and 5.2.2 using Dectin-1  LK cell lines suggest 
that Dectin-1  can induce ERK activation on zymosan binding. Data presented in 
chapter 4 (and published [146]) demonstrate that this receptor couples to 
downstream events by signalling through Syk. I set out to determine whether 
ERK activation in BMDC in response to zymosan was triggered by the 
TLR2/MyD88 pathway or the Dectin-1/Syk pathway.
C57BL/6 or MyD88-/- Dendritic cells were stimulated with a saturating dose of 
zymosan (lOOpg/ml) for the indicated times before harvesting for analysis. As 
can be seen in figure 5-3A, dendritic cells deficient in MyD88 shown essentially 
normal ERK activation in response to zymosan. Geometric mean-fluorescences 
were calculated for phospho-ERK staining by FACS over a 2hr time-course of 
zymosan stimulation. Figure 5-3A shows this data plotted against time, 
demonstrating near identical kinetics and amplitudes of ERK activation induced 
by zymosan in MyD88-sufficient and deficient cells. This implies that the TLR2 
pathway is not necessary for ERK activation in response to zymosan. In order to 
confirm this data using classical biochemistry wild-type or MyD88-deficient 
BMDC were stimulated with zymosan for 30 minutes then lysed into SDS- 
containing sample buffer and proteins resolved on a  10% Tris-glycine gel. 
Western blotting for phospho-ERK in BMDC lysates reveals that ERK- 
phosphorylation in response to zymosan is normal in MyD88-deificent cells. A 
low molecular weight f3-glucan, Glucan Phosphate, here fails to induce 
measurable ERK activation in B6 or MyD88-/- BMDC.
When Syk-/- BMDC were assessed in the same system (Figure 5-3B) Syk-/- 
cells failed to induce any ERK activation above background on zymosan 
stimulation. Again, BMDC were stimulated with zymosan over a 2hr time- 
course and ERK phosphorylation was analysed by FACS. Syk deficient cells 
show no positive phospho-ERK staining at any time-point after zymosan 
stimulation indicating that ERK activation is completely blocked rather than just
145delayed in these cells. However, Syk-deficient cells stimulated with the TLR2- 
ligands Pam3Cys (figure 5-3C) or MALP2 (data not shown) stained for 
phospho-ERK similarly to or better than wild-type cells demonstrating that 
there was no intrinsic defect in ERK activation in Syk-/- BMDC.
These results demonstrate that ERK activation downstream of zymosan 
recognition is dependent on Syk; and IL-2 and IL-10 induction are dependent on 
both Syk and ERK. Syk-signalling to ERK may therefore be crucial for the 
induction of IL-2 and IL-10 in the BMDC response to zymosan.
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Figure 5-3: ERK activation downstream of  zymosan recognition requires Syk and is MyD88- 
independent. A) B6 or MyD88-/~ BMDC were stimulated with lOOpg/ml zymosan for 30minutes 
(LH panel) or  for the indicated time points (RH panel) before  fixation and assessment of  ERK 
phosphorylation by flow cytometry or western blotting (loading control determined by Ponceau-
147red staining of blotted membrane -  data not shown). Geometric mean fluorescence was 
calculated  for >10000 events per time-point. B) B6 or Syk-/- BMDC were stimulated with 
100pg/ml zymosan for 30minutes (LH panel) or  for the indicated time points (RH panel) before 
fixation and assessment of  ERK phosphorylation by flow cytometry.  Geometric mean 
fluorescence was calculated  for >10000 events per time-point.  C) B6 or Syk-/- BMDC were 
stimulated with lOpg/ml Pam3Cys for 30 minutes before fixation and assessment of  ERK 
phosphorylation.
5.2.4  : c-fos is dispensable for zymosan-induced IL-10 production
c-fos has been demonstrated to play a role in the induction of IL-10 in response 
to TLR2 ligands [136] [94], and is suggested to be the downstream target of 
ERK that controls this cytokine [136] [94]. To investigate whether c-fos might 
play a role in ERK dependent IL-10 production induced by zymosan, I obtained 
bone marrow from c-fos and control foetal-liver-reconstituted bone marrow 
chimeras, c-fos-/- BMDC developed normally and yielded expected numbers. 
When c-fos-deficient BMDC were stimulated with zymosan and cytokine 
secretion was measured by ELISA, I found that c-fos was completely 
dispensable for the induction of either IL-10 or IL-2 in response to zymosan 
(figure 5-4A) in agreement with recently published data [175]. When 
peptidoglycan was used as a stimulus containing TLR2-ligands to stimulate c- 
fos or control BMDC, I found a significant decrease in IL-10 production in c- 
fos-deficient cells (Figure 5.4B) also in agreement with published data [136]. 
Peptidoglycan was used as opposed to Pam3Cys employed in the cited 
publications [94,  136] as the levels of IL-10 induced by peptidoglycan (which 
also contains ligands for NOD proteins and may be contaminated with different 
TLR ligands) are easily measurable compared to those induced by Pam3Cys 
which are at or below the detection limit of our IL-10 ELISA.
The kinetics of ERK activation can have profound effects on downstream events 
induced by ERK signalling (Reviewed in [144]). I therefore carried out a time- 
course experiment in which wild-type BMDC were stimulated with a satutating 
dose of Pam3Cys or Zymosan. ERK phosphorylation was measured by FACS at 
each time point and geometric means of the fluorescence were determined. 
Plotting these values against time demonstrates almost identical kinetics of ERK
148activation induced by the two ligands (figure 5-4C), despite the differences in 
upstream activators. Zymosan reproducibly induces a slightly higher peak 
amplitude of ERK activation although it is unclear whether this would be 
sufficient to explain the differences between IL-2 and IL-10 levels observed.
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Figure 5-4: c-fos-deficient BMDC show no defect in IL-2 or IL-10 production in response to 
zymosan. A) BMDC were grown from the bone marrow of chimeras which had been 
reconstituted with c-fos-/- or littermate control foetal liver, c-fos-/- and WT BMDC were 
stimulated with the indicated doses of  zymosan and cytokine production assessed by ELISA 
18hrs later. B) c-fos-/- and WT BMDC, as in (A) were stimulated with 0.5pg/ml Zymosan or 
50  pg/ml peptidoglycan.  Cytokine production was analysed by ELISA 24 hrs later. C) C57BL/6 
BMDC were stimulated with 100pg/ml zymosan or 10pg/ml Pam3Cys for the indicated times 
before fixation and analysis ofphospho-ERK levels by flow cytometry.  Geometric means were 
calculated  from >10000 events.
1505.2.5  : TCF family members are not required for IL-10 or IL-2 
production in response to zymosan or Pam3Cys
The Ternary Complex Factor (TCF) family comprises of 3 transcription factors, 
Sap-1, Elk-1 and Net,, that form transcriptional activators or repressors in 
complex with Serum Response Factor (SRF) [278]. TCFs are direct targets of 
ERK phosphorylation and both Sap-1 and Elkl have been implicated in the 
upregulation of c-fos after ERK pathway activation [278] [274]. I used BMDC 
deficient either in Sap-1, Elk-1, or all three TCFs to determine whether 
differences in TCF usage could account for the differential requirement of c-fos 
downstream of Pam3Cys or zymosan recognition. To confirm that any effects 
observed were downstream of ERK, the effects of the MEK-1 inhibitor U0126 
on cytokine production by each genetype of cells was assessed. Neither the Sap- 
1-/-, the Elk-1-/- nor the triple -/- cells showed any defect in IL-10 or IL-2 
production in response to zymosan (Figure 5-5A-C). In addition all 3 genotypes 
of cells were stimulated with Pam3Cys and cytokine mRNA levels determined 
by quantitative RT-PCR. This demonstrated that the TCFs are also not required 
for IL-2 or IL-10 upregulation by Pam3Cys (Figure 5-5D). Although the TCF- 
family members are expressed in BMDC they do not appear to play a non- 
redundant role in signalling downstream of the pattem-recognition receptors 
tested in these experiments.
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Figure 5-5: TCF-deficient BMDC show no defect in IL-2 or IL-10 production in response to 
zymosan. BMDC were grown from Sap-1-/- (A), Elk-1-/- (B) mice or from bonemarrow 
chimeras reconstituted with control or Sapl/Elkl/Net triple -/- foetal liver (C and D) or Sapl-/- 
foetal liver (D). Cells were stimulated with the indicated doses of  zymosan and cytokine 
production assessed after 18hrs of  stimulation using sandwich ELISA. D) Control, Sapl-/- and 
Sapl/Elkl/Net triple-/- BMDC were stimulated with lOpg/ml of  Pam3Cys and IL-10 mRNA 
levels determined by real-time PCR after 3hrs of  stimulation. Data is representative of 3 
experiments.
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-5.2.6  : IL-2 induction is independent of de novo transcription
It is now well documented that induction of IL-2 from T cells after stimulation 
involves mRNA stabilisation [132]. To determine whether this was also the case 
in dendritic cells BMDC were treated with the transcriptional poison 
Actinomycin D [279] and stimulated with zymosan for 3hrs before 
measurement of mRNA levels by quantitative RT-PCR. ActinomycinD 
dramatically decreased IL-10 production in response to zymosan but had almost 
no effect on IL-2 production (Figure 5-6) indicating that de novo transcription is 
not required for the upregulation of IL-2 mRNA and any effects of signalling on 
this phenomenon are likely to be at the level of mRNA stabilisation, including 
the effects of ERK signalling. In contrast, IL-10 and IL-12 p40 appear to be 
regulated at least partially at the transcriptional level.
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Figure 5-6: IL-2 mRNA upregulation induced by zymosan is independent of de novo 
transcription.  C57BL/6 BMDC werepre-treatedfor lOminutes with lOOnMActinomycin D 
before stimulate for 6hrs with lOOpg/ml zymosan. mRNA was extracted and subjected to RT- 
PCR to determine mRNA levels of  IL-2, IL-10 and IL-12 p40.
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+5.3  : Discussion
5.3.1  ERK is required for IL-10 and IL-2 induction
Data described in this chapter demonstrate robust inhibition of zymosan- 
induced IL-2 and IL-10 production by the ERK inhibitors PD98059 and U0126, 
both in BMDC and in LK cells (figure 5-2). This correlates well with published 
data demonstrating a role of the ERK pathway in the production of these 
cytokines by dendritic cells [267] [175] [94] and T cells [264]. As discussed in 
the introduction to this chapter, ERK targets can affect transcription, mRNA 
stability and translation [280]. Measurements of mRNA levels for IL-2 and IL- 
10 in the presence of the ERK inhibitor indicates that zymosan-induced ERK 
activation can decrease message-levels for IL-10 and IL-2 (figure 5-2E) 
suggesting that effects on transcription and mRNA stability may play a role. In 
the case of IL-2, Actinomycin D inhibition of transcription has almost no effect 
of mRNA levels at 3 hours (figure 5-6). When combined with the observation 
that ERK inhibition decreases IL-2 mRNA levels this is highly suggestive ERK 
mediates IL-2 induction by stabilising IL-2 mRNA. IL-10 mRNA upregulation 
is significantly inhibited by Actinomycin D suggesting that de novo 
transcription is playing an important role, therefore ERK could affect both 
transcription and message stabilisation of IL-10.
5.3.2  ERK activation in response to zymosan requires Syk, but not 
MyD88
MyD88-deficient BMDC activate ERK signalling identically to wild-type DC in 
response to zymosan, whereas Syk-deficient BMDC completely fail to activate 
ERK in response to zymosan stimulation (figure 5-3). ERK signalling in 
response to zymosan is therefore mediated entirely downstream of novel Syk- 
dependent PRRs such as Dectin-1, providing further evidence that this mode of 
pattern recognition is genuinely independent of TLRs.
155There is one intriguing facet to this data. Zymosan can signal through TLR2/6 
heterodimers and we, and others, have reported that this event is critical for the 
induction of IL-12 p70 in response to zymosan [59]  [96]. However, TLR2 
ligation by zymosan is not sufficient to induce ERK activation in the Syk- 
deficient cells stimulated with zymosan (figure 5-2). In contrast, Syk deficient 
BMDC stimulated in parallel with the TLR2/1  ligand Pam3Cys or the TLR2/6 
ligands MALP2 exhibit ERK activation similar or greater than that seen in wild- 
type cells (Figure 5-3C). At this time, the reasons for TLR2 coupling to ERK in 
response to lipopeptides, but not zymosan, is unclear but the observation that 
TLR2 can signal differently in response to two different ligands is clearly 
interesting. Possible explanations are either that conformation of the receptor 
induced by lipopeptides is different to that induced by zymosan or that the 
microenvironment around TLR2 during lipopeptides and zymosan recognition 
allows or denies access to particular signalling components.
5.3.3  Differences in transcription-factor usage by TLR and Dectin- 
1/Syk for IL-10 induction
It appears that c-fos contributes to IL-10 production induced by the TLR ligand 
Pam3Cys [94,  136] and the complex ligand Peptidoglycan (from S. aureus, 
figure 5-4). However, c-fos is not required for IL-10 production in response to 
zymosan (figure 5-4). This is an interesting observation as it suggests that the 
induction of IL-10 by either TLR2 or a Syk-dependent pattern recognition 
receptor (such as Dectin-1) requires different factors downstream of ERK 
activation. Additionally, my data clearly demonstrate that TCF transcription 
factors (known targets of ERK) are not responsible for ERK-dependent 
induction of IL-10 by zymosan or Pam3Cys. Assuming the published data 
demonstrating a requirement for c-fos in TLR2-mediated IL-10 production are 
correct [94,  136], this suggests that TCFs are not required for c-fos upregulation 
in response to TLR2 ligands. It is therefore clear that signalling downstream of 
Syk renders c-fos redundant in the induction of IL-10 implying that the precise 
mechanism of IL-10 induction downstream of Syk-coupled PRRs and MyD88- 
coupled PRRs is divergent.
156In the papers of Agrawal et al and Dillon et al [94, 136] ERK dependency of c- 
fos upregulation in TLR2-stimulated DC is only implied from the literature, 
rather than directly demonstrated. An alternative explanation for the observed 
results is therefore that ERK signalling plays an identical role in TLR2 and 
Dectin-1 induced IL-10 production but that TLR2 also requires the induction of 
c-fos via an alternative pathway. It should also be noted that peptidoglycan- 
induced IL-10 production (figure 5-4) is known to occur at least partially by 
signalling via NOD2 (reviewed in [34]) therefore the effects of c-fos-deficiency 
shown in figure 5-4 could be attributable to either TLR2 or NOD2 signalling.
The kinetics of ERK activation are similar in response to saturating doses of 
Pam3Cys and saturating doses of zymosan, although the initial peak of ERK 
activation with zymosan is slightly higher (figure 5-4). Differences in the 
kinetics of ERK activation therefore cannot explain the differential requirement 
for c-fos or the large differences in the amount of IL-10 and IL-2 produced in 
response to saturating doses of the two stimuli. ERK signalling is therefore 
necessary, but not sufficient, for induction of high levels of IL-10 and IL-2 in 
response to zymosan. Transcription factors activated downstream of zymosan 
recognition make c-fos redundant in the induction of IL-10.
My data clearly demonstrate that the ERK pathway is a necessary link between 
Syk and the production of high levels of IL-2 and IL-10 by dendritic cells 
stimulated with zymosan. Additionally there must be signalling events triggered 
via Syk and zymosan recognition, but not by TLR2  and lipopeptide 
recognition, that lead to the widely different levels of cytokine production 
observed with the two stimuli.  This interesting area of research remains open.
A further interesting conclusion from my data is that TLR2 signalling induced 
by binding to lipopeptides or zymosan is somehow qualitatively different, such 
that TLR2-ligation by zymosan in the absence of Syk-dependent pattern 
recognition fails to activate ERK, whilst ERK activation downstream of TLR2- 
recognition of lipopeptides in Syk-independent.
1576  Chapter 6: T cell differentiation induced by 
zymosan-stimulated BMDC
6.1  : Introduction
Dectin-1   signalling induces a mature BMDC phenotype that is significantly 
different from that induced by signalling through any TLR (high IL-10, IL-2, 
Jagged-1  and DLL1 for example). How does this affect T cell differentiation 
induced by zymosan-stimulated DC? In order to start addressing this question I 
investigated the effect of zymosan on in vitro T cell differentiation assays.
6.1.1  T cell polarisation by zymosan: What do we know?
Dendritic cells that have encountered microbial stimuli display an activated 
phenotype that primes T cells to best deal with the class of microbe encountered 
(for a detailed discussion of this see chapter 1). Most well characterised TLR 
ligands are predominantly viral or bacterial in origin and induce a mature DC 
phenotype that biases strongly towards Thl induction (reviewed in [240]). DC 
stimulated with an extract of shistosome eggs adopt an alternative phenotype 
that biases towards Th2 induction (reviewed in [281]). Furthermore it has 
recently been discovered that DC can instruct Thl7 differentiation in the 
presence of TLR ligands and a high density of Tregs [102]. The mature DC 
phenotype induced by zymosan differs from that of TLR-stimulated DC in the 
production of IL-10, IL-2 and Jagged-1, all of which have controversial effects 
on T cell differentiation (as described in chapter 4). We were therefore 
interested in the ability of zymosan to act as an adjuvant for T cell 
differentiation in vitro.
Previous attempts to assess the adjuvant function of zymosan in vitro suggest 
that zymosan is a relatively weak inducer of Thl polarisation and that some Th2 
differentiation can be induced in the presence of zymosan [90]. A more recent 
publication observes a decreased proliferation of antigen-specific CD4 T cells
158when zymosan is used as an adjuvant in vitro although cytokine production is 
not assessed in these experiments [175]. In vivo immunisations with zymosan 
and antigen again suggest that zymosan is a poor inducer of Thl responses 
[175]. However, the majority of zymosan injected I.V is rapidly taken up by 
neutrophils (Dr M.N Nolte, unpublished observations) such that the authors are 
primarily considering indirect DC activation [175]. These experiments hint that 
when compared to highly purified TLR ligands such as CpG DNA or LPS, 
zymosan induces T helper responses that are less Thl-skewed.
In vitro T cell differentiation assays are to some extent a useful simplification of 
T cell priming in vivo since the cell-types present, antigen-dose and cell contacts 
can be tightly controlled. However their interpretation is still complex. The 
requirements for T cell priming in vitro are less stringent than corresponding in 
vivo situations. In addition, in the absence of innate stimuli the T cell 
differentiation induced depends heavily on the antigen-dose [78], APC:T cell 
ratio [90], starting cell densities, foetal-calf serum batch, T cell purification 
protocol [90] and the genetic background of the cells used (to name just a few). 
Care has therefore been taken to assess the adjuvant effects of zymosan over a 
range of antigen-doses and always to compare to relevant control assays.
6.1.2  Jaggedl and T cell differentiation
A striking observation made in chapter 4 is the upregulation of Jagged-1  by 
Dectin-1  ligands. As discussed in chapter 1, the role of Notch-ligands in T cell 
differentiation has been suggested by a plethora of different experiments 
yielding contradictory results ([160], reviewed in [161]). Jagged-1  presentation 
by APCs has been suggested to induce the differentiation of nai've T cells into 
Th2 cells [160] or regulatory T cells [169] [170] in experiments over-expressing 
Jagged-1   on fibroblasts, splenic DC or B cells respectively. The second part of 
this chapter presents a preliminary investigation of the role of Jagged-1   on 
BMDC by selective deletion rather than over-expression.
159The data presented aims to address how zymosan can bias T helper 
differentiation and the part played by Jagged-1, induced on DC by zymosan 
stimulation, in instructing these T cell responses.
1606.2  : Results - Zymosan can act as an adjuvant in vitro
6.2.1  : Zymosan can amplify Thl or Thl7 differentiation in vitro
In vitro T cell differentiation assays can be carried out in a variety of different 
ways, with variable results [78, 90]. In order to avoid issues associated with 
antigen processing and variation in polyclonal T cell populations, zymosan was 
first tested in the differentiation of OTII transgenic T cells induced by BMDC 
presenting cognate peptide. CD4+ T cells were purified from spleen and lymph 
nodes by lineage depletion, followed by CD4-enrichement using MACS. 
Purified T cells were labelled with CFSE and cocultured with BM-DC, cognate 
peptide and innate stimulus. With reference to the experiments of Boonstra et al, 
I examined the effect of adding zymosan to the cultures over a 41og dose- 
titration of peptide. As shown in Figure 6-1 A, although OTII CD4+ T cells 
contain very few FoxP3 positive cells compared to the T cells from a C57BL/6 
mouse, these T cells expand during coculture with DC, as demonstrated by 
CFSE dilution, and can be identified by FoxP3 intracellular staining on d5. The 
FACS profile shown represents data acquired on day 5 of stimulation with InM 
peptide, where expansion of Tregs is almost maximal but expansion ofFoxP3- 
negative cells is still minimal and was hence chosen for clarity of staining. A 
known number of beads (easily gated on by low forward-scatter and high side- 
scatter) were included in the FACS samples during acquisition to allow 
calculations of the number of FoxP3-negative and FoxP3-positive cells after 5 
days of coculture. Zymosan does not appear to increase the peptide-dose- 
dependent expansion of FoxP3-negative cells and high doses of zymosan 
(50pg/ml) mildly suppress proliferation. The effect of peptide dose on 
proliferation of FoxP3-positive cells is less clear, with almost maximal numbers 
of Tregs obtained with very low peptide doses, particularly in the presence of 
zymosan. However, the maximal number is very low (less than 1200 per well, 
compared to >200,000 FoxP3 negative cells) and does not appear to have a 
major impact on T cell effector function as demonstrated by the minimal Thl7 
differentiation shown in figure 6-IB.
161The production of cytokines from the T cells counted in 6-1A was determined 
after 48hrs of restimulation on plate-bound anti-CD3. Cytokines secreted into 
the supernatants were measured by ELISA. As suggested by Boonstra et al  [78] 
there is a significant effect of peptide-dose on the induction of different 
cytokines. IFNy production is maximal at 10 to 30nM peptide whilst IL-4 
production peaks at 3 to lOnM. Zymosan induces a slight increase in IFNy 
production that is not dependent on the peptide dose. However, IL-4 production 
appears to be unaffected by zymosan. Production of IL-17 in this system is 
extremely low, although variable between experiments, due to the low numbers 
of Tregs found in OTII TCR-transgenic mice (figure 6-1 A). Experiments by 
Salome Leibundgut demonstrate that supplementing the OTII populations with 
OTII-Tregs results in robust Thl7 induction when Dectin-1  agonists are used as 
adjuvants (manuscript in preparation).
A second in vitro T cell differentiation assay is employed in Figure 6-1C & D.
In these experiments total CD4+ T cells were purified from C57BL/6 spleen and 
lymph nodes. As demonstrated in figure 6-1C, these CD4+ T cells contain a 
much higher percentage of FoxP3-positive cells, observable both before and 
after stimulation. CD4+ T cells were cocultured with C57BL/6 or MyD88-/- 
(back-crossed onto a C57BL/6 background) BMDC and 0.1 pg/ml anti-CD3. 
Addition of zymosan to these cultures increases the recovery of T cells at day 5 
through effects of survival and proliferation. B6 BMDC are slightly better 
stimulators of T cell proliferation than MyD88-/- BMDC in the absence of 
zymosan although the percentage increase appears similar for both.
IFNy production appears to be maximal in the absence of innate stimulus when 
C57BL/6 BMDC are used as APC. However, MyD88-/- BMDC show an 
increased induction of IFNy (Thl) and IL-17 (Thl7) responses when zymosan is 
added (figure 6-ID) implying that the TLR-independent, Syk-dependent pattern 
recognition pathway is capable of promoting both Thl and Thl7 differentiation.
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Figure 6-1: Zymosan acts as an adjuvant for in vitro T cell differentiation. A and B) 104 BMDC 
were used to present indicated doses of O VA peptide to  5 x 104 purified, CFSE labelled OTII T 
cells in the presence of indicated doses of  zymosan. After 5 days of  stimulation CD4+, FoxP3 
positive and negative cells were counted by FACS (A) and total T cells from each well were 
restimulated on plate-bound anti-CD3. 48hrs later cytokine production was determined by 
ELISA (B).  C and D) C57BL/6 or MyD88-/- BMDC were used to stimulate CD4+ T cells from 
MyD88-/- spleen and lymph nodes in the present of 0.1 pg/ml anti-CD3 and 50pg/ml zymosan.
163As in part A, T cell number is determined by FACS (C) and cytokine production after 48hr 
restimulation on anti-CD3-coatedplastic is determined by ELISA (D).
6.2.2  : Jaggedl is not essential for T cell expansion or Thl 
polarisation of OTII T cells.
I would like to test whether particular factors, or combinations of factors, 
strongly induced by zymosan stimulation of BMDC influenced the outcome of 
in vitro T cell differentiation assays. This work is on-going but the first factor 
tested was Jagged-1. Bone marrow from Jagged-1-Flox/Flox mice was 
transduced with a GFPCre retrovirus (figure 6-2A) as described in chapter 2.4 
and chapter 3.2.5-10. The CD1 lc-enriched BMDC populations obtained on day 
5 are shown in figure 6-2B. GFPCre-positive, CD1 lc-positive cells were sorted 
and a sample was taken to determine deletion of Jagged-1   in genomic DNA. A 
duplex PCR was carried out using primers marked in 6-2D. Within the GFP+ 
Jagged 1-flox sorted population only deleted allele is detected, indicating that all 
GFP+ cells are Jaggedl-/-. A considerable proportion of GFP-negative cells 
also contain the deletion either because transient expression of GFPCre is 
sufficient for deletion and GFPCre-expression has been lost by the time of 
sorting, or because low-expressers fall into the GFP-negative gate during the 
sort. For this reason, GFPCre-transduced wild-type littermate-control BMDC 
were used as the controls in this experiment.
An in vitro T cell differentiation assay was carried out as in 6-1A&B. The 
sorted GFPCre+ wild-type or Jagged-/- BMDC were plated with purified OTII 
T cells and a dose-titration of OVA. As observed in figure 6-1 A, inclusion of 
50pg/ml zymosan as an adjuvant had an inhibitory effect on the proliferation of 
OTII cells. This effect is nearly identical with wild-type and Jaggedl-/- BMDC 
indicating that upregulation of Jagged-1   is not necessary for this effect under 
these conditions. After 5 days of culture the OTII T cells were restimulated for 
6hrs with PMA/ionomycin in the presence of monensin. The production of IFNy 
was assessed by intracellular staining, rather than by ELISA. This reveals fewer 
T cells producing IFNy in the cultures where zymosan was used as an adjuvant, 
in contrast to the IFNy production measured by ELISA after 48hrs of
164restimulation in figure 6-IB. Regardless of discrepancies with previous data, the 
number of IFNy producing cells on day 5 of culture is almost identical between 
wild-type and Jaggedl-/- DC, again suggesting that in this particular type of 
assay Jagged-1  upregulation was not required for the zymosan-mediated effects 
on Thl induction. In this experiment, as in that shown in Figure 6-1, there was 
minimal IL-17 induction, probably due to the very low numbers of Tregs present 
in the starting OTII population that went into the cocultures.
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Figure 6-2: Deletion of  Jagged-1 does not affect Thl induction in response to zymosan- 
stimulated BMDC. Bone marrow from Jaggedl -Flox homozygous mice or wild-type litter-mate 
controls was transduced with retrovirus made from pMSCV-GFPCre. GFP-positive cells were 
FACS sorted and used as stimulators for purified OTII T cells in the presence of the indicated 
concentration of OVA protein and 50  pg/ml zymosan. A) Diagram of Cre-mediated deletion of 
Jaggedl. B) CD I lc+ GFP+ and GFP- cells obtained on day 5 before FACS sorting.  The 
results of  a duplex PCR carried out on FACS-sorted Jaggedl F,  GFPCre-positive and negative 
cells is shown in the right hand panel.  C) OTII T cells were restimulated with PMA and 
ionomycin in the presence of  monensin for 6hrs before fixation and analysis of T cell number 
(LHpanel) and intracellular IFNy levels (RH panel). D) Schematic diagram illustrating primer 
binding sites used  for Duplex PCR.
1666.3  : Discussion
6.3.1  Zymosan is a weak inducer of Thl responses
T cell expansion of highly purified antigen-specific T cells induced by BMDC 
is minimally affected by the presence of zymosan (figure 6-1A and B). At high 
doses of zymosan a slight suppression of T cell expansion is observed, possibly 
due to physical inhibition of the formation of T:DC conjugates early in the 
response. However, when polyclonal T cells are stimulated with BMDC and 
anti-CD3, a high dose of zymosan improves T cell expansion induced by both 
MyD88-/- and C57BL/6 BMDC (figure 6-1C and D). There are many potential 
differences between the antigen-specific and polyclonal systems. A notable 
example is the higher frequency of regulatory T cells that are being optimally 
stimulated by anti-CD3 treatment in the polyclonal system. DC that have been 
activated by a microbial stimulus can induce Treg-independent T cell 
proliferation and Thl differentiation [173]. It is therefore possible that zymosan 
increases BMDC/anti-CD3-induced proliferation of polyclonal T cells as innate 
signals are required to overcome Treg-mediated suppression in this system. 
However, the nature of T:DC interaction may also be different in anti-CD3- 
stimulation versus MHC-peptide:TCR interaction.
It is intriguing that MyD88-deficient DC, in the absence of added microbial 
stimuli, are less potent inducers of Thl differentiation than C57BL/6 BMDC 
(figure 6-1C and D). In fact, despite the marked cytokine production by B6 
BMDC stimulated with zymosan, there is only a very marginal effect on IFNy 
accumulated in the supernatant after 48hrs of T cell restimulation with plate- 
bound anti-CD3. However, MyD88-/- DC stimulated with zymosan are 
markedly better inducers of Thl differentiation than their unstimulated 
counterparts (figure 6-1C and D). Given the inherent instability of in vitro T cell 
differentiation assays the validity of this observation needs to be confirmed by 
assessing a full dose-response of anti-CD3 stimulation and including known 
strong Thl and Th2 inducing stimuli with which the amount of T cell effector 
function achieved with zymosan-stimulated BMDC can be compared.
1676.3.2  Thl7 induction in response to zymosan requires the presence 
of Tregs in vitro
Thl7 effector differentiation is only robustly observed for the polyclonal T cell 
differentiation assays shown in figure 6-1C and D. TGFp production, promoted 
by the presence of Tregs in the cocultures is known to drive Thl 7 
differentiation in the presence of inflammatory cytokines [102, 282]. However, 
IFNy inhibits Thl7 differentiation induced in this manner [102]. MyD88-/- 
BMDC stimulated with zymosan promote strong T hl7 differentiation of 
polyclonal T cells as measured by IL-17 production on restimulation (figure 6- 
1D). It is an attractive hypothesis that MyD88-deficient BMDC stimulated with 
zymosan produce a cytokine cocktail that, possibly along with TGF|3 induced 
by Tregs, biases towards Thl7 induction whilst additional factors produced by 
BMDC in the presence of TLR (or IL-1  Receptor) signalling dampen Thl 7 
differentiation and rather promote Thl differentiation. Since MyD88-deficient 
BMDC stimulated with zymosan are predominantly activated via the Syk- 
dependent pathway (chapter 4, [146]) this could be an indicator that BMDC 
activated via Syk-dependent PRRs such as Dectin-1   bias naive T cells towards 
the Thl7 lineage. This hypothesis requires further validation in a variety of 
models but would link intriguingly with the requirement for IL-17 to clearance 
of yeast infections such as Candida [191].
6.3.3  Jagged-l-loss does not appear to modify T cell responses to 
zymosan
BMDC lacking Jagged-1   can be generated in the expected numbers and Jagged- 
1  deletion can be confirmed by PCR of genomic DNA purified from GFPCre- 
positive sorted BMDC (figure 6-2A and B). When these cells are tested in their 
ability to induce T cell differentiation of highly purified naive OTII T cells they 
display no apparent defect in the induction of T cell expansion or Thl 
polarisation induced in the absence of innate stimuli or in the presence of 
zymosan (figure 6-2C). From this, we can conclude that in this particular 
system, Jagged-1  does not play a non-redundant role in T cell expansion or in
168Thl polarisation. However, as demonstrated in chapter 4, zymosan stimulation 
of BMDC results in upregulation of mRNA levels not only of Jagged-1, but also 
Jagged-2, DLL1 and DLL4 such that any functional redundancy between the 
ligands would compensate for loss of Jagged-1   in this system. It is possible that 
T cell polarisation induced by BMDC activated via Syk-dependent PRRs is only 
revealed in the absence of TLR signalling, for example the instruction of Thl7 
differentiation by MyD88-/- BMDC stimulated with zymosan (figure 6-1C and 
D). A better system in which to test the role of Jagged-1  might therefore be to 
use MyD88/Jagged-l doubly deficient BMDC to stimulate polyclonal T cells as 
in figure 6-2C and D. Alternatively, pure Dectin-1 agonists could be used to 
selectively ligate Dectin-1   and activate BMDC via Syk. Using either zymosan 
in MyD88-/- BMDC of purified Dectin-1  agonists may provide a more sensitive 
system in which to check the effect of Jagged-1  deletion. This remains an 
interesting question, in particular given the published links between Jagged-1  
overexpression and regulatory T cell development [ 169,  170] and between 
regulatory T cells and Thl7 differentiation [102]. Work being carried out 
currently, and in the near future will hopefully shed more light on this matter.
1697  Chapter 7: Final Discussion and Perspectives
The results presented in this thesis fully support the designation of Dectin-1, 
signalling via Syk, as a bona fide pattern recognition receptor as originally 
defined by Charlie Janeway Jr [1]. In addition, the same results help to define 
the activated DC phenotype induced by signalling through Dectin-1 /Syk or 
similar Syk-coupled receptors and demonstrated a requirement for ERK 
signalling downstream of Syk. Finally this thesis presents preliminary evidence 
that zymosan-stimulation of BMDC can increase their ability to induce Thl and 
Thl7 T cell differentiation in vitro.
7.1  Dectin-1 and Pattern Recognition
7.1.1  Is Dectin-1 a PRR?
In his 1989 opinion [1], Janeway proposed the existence of pattern recognition 
receptors with the following properties:
“non-clonally distributed... receptors that allow recognition of certain 
pathogen-associated molecular patterns that are not found in the host... the 
pattern recognized should be the product of a complex and critical enzymology 
in the microorganism”.
What evidence do we have that Dectin-1   fulfils these criteria?
Dectin-1  is clearly non-clonally distributed, as demonstrated by Taylor et al 
[283], i.e. it is expressed on neutrophils, monocyte/macrophage lineage cells, 
dendritic cells and a subset of Gr-1-positive T cells.
Dectin-1  is a C-type lectin-like receptor recognising pi,3 and pi,6-glucans [57, 
60, 230, 231, 284]. P-glucans are an essential structural component of yeast cell 
walls [61, 62], i.e. are critical for yeast viability and are not synthesised by
170mammals, fulfilling the criteria to be defined as a PAMP. It is therefore 
reasonable to state that Dectin-1  is a PAMP receptor.
In a later review, Medzhitov and Janeway further added:
“The signals that control the induction of any particular effector  function 
should therefore convey information about the features of the pathogen so that 
it can stimulate an adaptive immune response that chooses the relevant effector 
mechanism.^ [285]
The work presented in this thesis contributes to the evidence that Dectin-1  
fulfils this last postulate. At the commencement of this project, work in 
macrophages had implicated Dectin-1   signalling in oxidative burst and TNFa 
production induced by zymosan [230, 231]. However, production of TNFa and 
reactive oxygen species by macrophages is not known to be instructive for 
adaptive immunity.
Dendritic cells are innate immune cells that, when appropriately activated, can 
potently stimulate the differentiation of naive T cells into appropriate effectors 
(recently reviewed in [77]). As discussed in chapter 1, the production of 
cytokines by DC correlates well with direct pattern recognition and with the 
instruction of adaptive immunity [101]. We have previously published that 
MyD88-independent recognition of zymosan resulted in robust IL-10 
production by dendritic cells [96] implying the existence of a non-TLR pattern 
recognition receptor for zymosan. A more thorough examination of cytokine 
production by MyD88-/- BMDC stimulated with zymosan revealed production 
not only of high levels of IL-10 but also significant Jagged-1  upregulation 
(detailed in chapter 4). In addition, moderate levels of IL-2 and IL-12 p40 
production were detected. This suggests that signalling through a non-TLR PRR 
is particularly effective in the induction of IL-10 and Jagged-1, but it is also 
capable of inducing many of the cytokines previously ascribed to TLR-activated 
DC, albeit to lower levels. It would appear that MyD88-/- DC activated with 
zymosan are quantitatively, rather than qualitatively different to DC activated
171by TLR ligands. TLRs are well defined as PRRs that convey information about 
the features of the pathogen for translation into adaptive immunity [286]. This is 
strong evidence that zymosan is recognised by a true TLR-independent PRR 
sufficient to induce adaptive immunity.
What is the evidence that this PRR is Dectin-1  ? Overexpression of Dectin-1   in a 
B cell hybridoma (LK cells) confers the ability to bind zymosan and to produce 
IL-2 and IL-10 in response to zymosan (as detailed in chapter 4, [146]). This 
requires the presence of tyrosine-15 in the intracellular tail of Dectin-1 which, 
when phosphorylated, can mediate binding of Dectin-1  to the non-receptor 
tyrosine kinase, Syk (chapter 4, [146]). In BMDC, the observed MyD88- 
independent IL-10 production, as well as production of high levels of IL-2, 
requires signalling through Syk (chapter 4, figure 4-8), and is inhibitable with 
the Dectin-1 antagonist Glucan phosphate (figure 4-6). This strongly suggests 
that Dectin-1   or a related receptor is acting as a novel P-glucan-sensing PRR 
sufficient to induce cytokine production from DC.
Conclusive evidence that Dectin-1   can “convey information about the 
pathogen” and couple innate to adaptive immunity requires demonstration that 
activation of DC via Dectin-1  alone is sufficient to induce effector T cell 
differentiation. Very preliminary data presented in chapter 6 suggests that 
zymosan stimulation of MyD88-/- DC improves the ability of these cells to 
instruct Thl and Thl7 differentiation. However, further experiments are 
required to establish exactly how this is occurring.
There is one aspect in which Dectin-1  deviates from the established model of 
PRRs, in the observation that PRRs are phylogenetically ancient. Dectin-1  and 
Toll-like receptors appear to have strikingly different evolutionary histories. 
Dectin-1   is encoded within a large cluster of C-type lectins including the NK 
cell receptor NKG2D [53]. The C-type lectins within this cluster show 
remarkably conserved gene structures, indicative of recent gene duplication and 
diversification (for example TLR1,2 and 6 [21]). The Toll-like receptors, in 
contrast, are scattered throughout the genome and have more diverse genomic
172structures suggesting that they are evolutionary much more ancient. This 
correlates with the distribution of Dectin-1 and TLRs throughout the animal 
kingdom. Proteins showing highly significant homology to TLRs are found in 
organisms as diverse as man and fruit flies. Dectin-1  homologues, are found 
only as far back as vertebrates. Although there is no Dectin-1  homologue in 
flies, p-glucan recognition does occur. GNBP is a soluble protein with 
homology to the pl,3 glucanase of Bacillus circulans [66] which on p-glucan 
binding induces cleavage of Spaetzle and activation of Toll signalling. At some 
point in evolutionary history it appears that vertebrates lost the gene for a 
soluble p-glucan receptor which signals via an indirect PRR, and gained the 
ability to directly signal for the presence of P-glucans. Therefore the ability to 
recognise p-glucans has been selected for over aeons of evolutionary history, 
despite a more recent diversification of the recognition machinery.
7.1.2  Dendritic cell responses to zymosan are the results of signalling 
through multiple PRRs
My work and that of others has now confirmed that the recognition of zymosan 
by dendritic cells occurs via both TLR2/6 signalling through MyD88, and 
Dectin-1 signalling through Syk (chapter 4, [146] [59]. Of note, inhibition of 
zymosan responses by soluble p-glucan is at best 30-40% in BMDC (figure 4- 
6). In contrast, production of IL-10 and IL-2 in response to zymosan is almost 
completely abrogated in Syk-/- BMDC (figure 4-8). Whilst this could simply 
represent inefficiency of Glucan phosphate as an inhibitor, it is also possible 
that alternative Syk-dependent PRRs for zymosan are expressed by BMDC. 
Good candidates include Complement Receptor 3 which has previously been 
implicated in zymosan binding [45] [226] and contains an integrin p chain that 
can mediate Syk activation [235]. Whether further receptors are involved or not, 
it is clear that at least 2 PRRs present on BMDC are engaged by zymosan 
(chapter 4, [146]). The production of cytokines in response to zymosan is 
therefore the result of combinatorial PRR signalling, rather than a single 
pathway. As suggested [32]  [33], synergy between different receptors can
173dramatically alter the cytokine profile induced compared to ligation of single 
receptors.
On one hand, this can be seen as an advantage as zymosan provides something 
approaching the complexity of a model of the interactions between DCs and live 
pathogenic yeasts. On the potentially synergistic interactions between receptors 
can amplify small differences between experiments and between different labs 
and can significantly complicate the interpretation of experiments. Future 
elucidation of the effects of particular PRRs on DC activation and in DC 
signalling would benefit from the use of much cleaner ligands such as pure 
preparations of p-glucans.
We started this project from the observation that DC produce high levels of IL- 
10 when stimulated with zymosan. Despite the complexity of our chosen system 
we have successfully identified a receptor that is capable of mediating this 
effect and have determined that signalling via Syk into BMDC can lead to DC 
activation and cytokine production that loosely resembles that induced by 
known PRR signalling occurring via MyD88. As discussed in chapter 1, 
zymosan is a good source of yeast PAMPs. The robustness of phenotype 
induced by Syk-deficiency suggests that despite the many possible receptor- 
ligand interactions that may, or may not be occurring between zymosan and 
DCs a Syk-dependent PRR such as Dectin-1  is likely to play an important 
physiological role in recognition of yeasts by dendritic cells.
7.2  Dectin-1 signals for DC activation via Syk and ERK
7.2.1  Dectin-1 couples to Syk via a novel HemlTAM motif
The signalling occurring downstream of Dectin-1  was initially suggested by the 
presence of an IT  AM-like motif in the intracellular tail of Dectin-1  [52]. IT  AMs 
couple to the non-receptor tyrosine kinases Syk and ZAP-70 via binding of the 
two tandem SH2 domains to two phosphotyrosines of the IT  AM [246]. As 
ZAP-70 expression is largely restricted to cells of the T cell lineage, we
174examined the role of Syk in DC responses to zymosan and found that Syk- 
deficient DC showed a severe defect in the induction of IL-2, IL-10 and Jagged- 
1   in response to zymosan but were unaffected in their production of IL-12 
(figure 4-8).  Syk has not previously been implicated in PRR signalling 
although it is required for activation of DC by immune complexes [234] and has 
been suggested to negatively regulate TLR signalling via TREM1  [287].
The same LK cell model which was successfully employed to demonstrate 
Dectin-1   signalling for IL-2 and IL-10 production was employed again to 
investigate Dectin-1  coupling to Syk. LK cell lines were produced in which the 
intracellular tyrosines of Dectin-1   are individually or doubly mutated to 
phenylalanine [146]. When I tested these LK cell lines for cytokine production 
in response to zymosan we were very surprised to observe that only the 
membrane proximal tyrosine (Y15) was required for IL-2 and IL-10 production. 
Further work from Neil Rogers, and work by Dr M. N. Nolte (Immunobiology 
Lab, London Research Institute, London, UK) confirmed that only this single 
tyrosine was necessary for association of Dectin-1  with Syk [146]. Dectin-1  
therefore appears to signal via Syk using an unusual half-IT  AM, or HemlTAM 
motif not previously documented (chapter 4, [146]). The ability of Syk to signal 
through non-classical motifs is not unheard of, but is also slightly controversial. 
There are reports that intergrin p chains can signal via Syk [235] in a tyrosine- 
independent manner. However, there is little or no homology between intergrin 
P chains and the intracellular domain of Dectin-1  (by sequence alignment -  data 
not shown). There is also a single report that suggests a low level of Syk 
activation can be achieved with a single IT AM tyrosine [248] but this is orders 
of magnitude less efficient that full IT  AM signalling. It is possible that Syk 
could bind two phosphotyrosines by bridging two Dectin-1   molecules brought 
into close proximity by P-glucan binding but this remains to be fully 
investigated.
1757.2.2  Zymosan activation of ERK signalling is Syk dependent
It is clear that Syk-dependent DC activation results in the production of high 
levels of IL-2 and IL-10. Scientific literature indicated that ERK signalling was 
a strong candidate for mediating the robust induction of IL-2 and IL-10 in 
response to zymosan. This pathway is known to be activated by zymosan 
recognition [271, 272], and is implicated in IL-10 production in response to 
TLR2 ligands Pam3Cys and MALP2 [136]. Accordingly, I found that zymosan 
induced robust ERK activation in BMDC. ERK inhibitors PD98059 and U0126 
both significantly inhibited IL-10 production as well as IL-2 production induced 
by zymosan. Although TLR2 signalling is known to couple to ERK activation 
via the TPL2 pathway [135] IT  AM signalling via Syk is also a strong inducer of 
ERK signalling (reviewed in [245]). As zymosan can induce signalling via both 
MyD88 and Syk it was interesting to assess the contributions of each PRR 
pathway to ERK activation. Slightly surprisingly, I found that ERK activation 
induced by zymosan signalling occurs exclusively downstream of Syk, with 
ERK activation undetectable in Syk-deficient cells stimulated with zymosan 
(figure 5-3). However, purified TLR2 ligands show stronger ERK activation in 
Syk-deficient cells than in wild-type BMDC (figure 5-3), possibly due to loss of 
Syk-dependent inhibitory signalling via the TREM proteins [287].
Clearly zymosan can induce signalling via TLR2 as IL-12 production is 
MyD88-dependent (figure 4-5). IL-12 production in response to zymosan is 
unaffected by Syk-deficiency (figure 4-8) and is higher than IL-12 production 
induced by saturating concentrations of Pam3Cys or MALP2 (figure 4-1). It 
would therefore appear that TLR2 signalling induced by purified lipopeptides is 
qualitatively different from TLR2 signalling induced by zymosan. There are 
numerous possible explanations for this that fall broadly into two categories:  1) 
TLR2-interactions with its ligand in zymosan induces a different conformation 
change in the receptor which affects its ability to couple to the pathway for ERK 
activation and 2) the microenvironment induced by massive receptor clustering 
in response to zymosan may affect coupling of TLR2 to ERK.
176As the TLR2-ligand in zymosan is not defined it is hard to test explanation-1  
directly. However, direct coupling of Pam3Cys or MALP2 to zymosan would 
result in a particle that could activate ERK in a Syk-dependent manner if the 
nature of the ligand, rather than the membrane microenvironment, was 
important.
It is an intriguing possibility that receptor microenvironment may play a role in 
receptor coupling to ERK. Zymosan is a large particulate ligand, compared to 
the small soluble lipopeptides MALP2 and Pam3Cys, and in addition, (3-glucans 
of zymosan are bound by Dectin-1  with a very high affinity [57] meaning that 
TLR2 associated with zymosan must be recruited into the membrane patch 
containing high levels of Dectin-1. Indeed membrane microdomains have been 
implicated in both TLR and IT AM signalling [288]  [108]. The exclusion of 
factors required for MyD88-coupling to ERK activation from Dectin-1-enriched 
membrane patches could account for the observed results. A further possibility 
involving the microenvironment around TLR2 is that zymosan may ligate a 
Syk-independent inhibitory receptor which actively blocks TLR2 signalling to 
ERK. Experiments are currently being carried out to test these hypotheses.
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Figure 7-1: Signalling induced by IT  AMs, Dectin and TLR2. A) Signalling to NF-kB, NFAT and 
ERK downstream of classical ITAMs such as those found in antigen receptors. [256, 257]
[255]. B) Signalling to NF-kB and ERK downstream ofDectin-1. [147] figure 5-3 C) Signalling 
to ERK induced by TLR2 ligands Pam3Cys or MALP2. [94,  136]  D) Signalling to ERK induced 
by zymosan (figure 5-3).
1787.2.3  What are the ERK targets involved in production of IL-2 and 
IL-10?
There are a large number of proteins defined as direct targets of ERK kinase 
activity [273]. Published data suggested that c-fos is a critical downstream 
mediator of ERK signalling induced by Pam3Cys and TLR2 which is required 
for IL-10 production [94] [136]. I tested the ability of c-fos-/- DC to produce 
IL-10 in response to zymosan. In contrast to TLR2-mediated IL-10 production, 
IL-10 production in response to zymosan is c-fos independent (figure 5-4). This 
is slightly surprising as it suggests that activation of a single signalling pathway 
in a single cell-type can show differential requirements for downstream factors 
in the induction of a single cytokine. An explanation may be suggested by the 
magnitude of IL-10 production induced by zymosan recognition versus 
Pam3Cys or MALP2 recognition. It is possible that components of the 
signalling network activated by zymosan recognition result in very strong 
activation of the IL-10 promoter such that loss of c-fos dependent transcription 
has a negligible effect on IL-10 induction.
c-fos upregulation, as demonstrated to occur downstream of TLR2 signalling 
[94] [136], can be achieved either by ERK-mediated phosphorylation and 
stabilisation of c-fos [289] or by direct transcriptional upregulation via the TCF- 
family of transcription factors [274]. I was therefore interested to test whether 
ERK activation downstream of TLR2 and Dectin-1  required different TCF 
family members. My efforts to establish a role for TCF family members in 
controlling cytokine transcription downstream of ERK demonstrated that there 
was no non-redundant role for TCF proteins in IL-10 production downstream of 
either zymosan or Pam3Cys recognition (figure 5-5). The question of what ERK 
targets are required to support IL-2 and IL-10 production therefore remains 
open. An interesting suggestion comes from work of Lucas et al [268] 
proposing a role for ERK activation in modification of Histone H3 at the IL-10 
promoter allowing binding of STAT3 and Spl. However, there is an extensive
179collection of ERK targets that I have not considered here, many of which may 
be involved in this process [273].
My experiments suggest that the ERK pathway at least partially acts to control 
IL-10 and IL-2 production at the mRNA level (figure 5-2). It should be noted 
that IL-2 mRNA upregulation induced by zymosan stimulation appears to be 
largely independent of de novo transcription (figure 5-6), suggesting that ERK 
may be playing a role in stabilising IL-2 mRNA, rather than in direct 
transcriptional activation of the IL-2 gene. Indeed, there is evidence to suggest 
that ERK signalling could modify the production of secreted proteins at 
multiple stages in the production process (summarised in figure 7-2) including 
transcriptional, post-transcriptional and translational events [126, 127, 268, 295, 
296]. It is probable that ERK activation downstream of Syk affects IL-10 and 
IL-2 production at several different levels. Measurements of the effects of ERK 
inhibition on mRNA half-life will help to establish whether ERK targets 
mediate mRNA stabilisation in activated DC.
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181Experiments on Fee Receptor signalling in the Rat basophilic leukaemia 2H3 
cell line RBL-2H3 suggested that ERK inhibition decreased Syk 
phosphorylation induced by Fc-receptor cross-linking [291]. In addition, the 
authors observed direct serine phosphorylation of Syk by ERK in vitro [291]. It 
is possible that whilst ERK is activated downstream of Syk in response to 
zymosan, it plays an important role in promoting Syk phosphorylation in a 
positive feedback loop required for initiation of signalling. Examining Syk 
phosphorylation induced by zymosan recognition in the presence of the ERK 
inhibitor, and considering the behaviour of Syk-/- cells reconstituted with 
appropriate Syk mutants would allow assessment of this effect on cytokine 
production.
During the course of these experiments, it became clear that the differences in 
kinetics and magnitude of ERK signalling induced by Pam3Cys signalling via 
TLR2 and Zymosan signalling via Dectin 1/Syk were not dramatically different 
at least as far as per cell measurements can ascertain (figure 5-4). Although it 
remains possible that the slightly higher peak of ERK activation achieved with 
zymosan stimulation (figure 5-4) is responsible for the 10 to  100-fold higher 
induction of IL-10, or that differences in the subcellular distribution of active 
ERK can contribute to this (not yet assessed in this system), it appears 
that ERK signalling is necessary for production of high levels of IL-2 and IL- 
10, but other signalling components specifically activated downstream of Syk 
are also required. What pathways could contribute? An interesting candidate in 
this respect is calcium signalling via calcineurin. Calcium signalling is robustly 
activated by IT  AM signalling [292] but has not been reported downstream of 
TLR ligation. Evidence in support of this is provided by the observation of 
Granucci et al [145] that IL-2 production is inhibitable with the calcineurin 
inhibitor, cyclosporin A.
In conclusion, Dectin-1  -  a (3-glucan receptor that can be activated by zymosan 
-  signals via a novel hemlTAM motif to activate ERK (data presented in 
chapter 4 and 5). TLR2-mediated recognition of zymosan fails to result in ERK
182activation (figure 5-3) and the mechanistic explanation of this is currently under 
investigation. Signalling components required downstream of ERK are elusive 
but do not include the TCF family members Sapl, Elkl or Net, or the 
downstream AP-1 component c-fos (figure 5-4 and 5-5). The absence of c-fos 
requirement distinguishes between zymosan-induced and TLR2-ligand induced 
IL-10 production. This suggests that signalling downstream of ERK in zymosan 
responses requires an alternative range of effectors and can collaborate with 
alternative signalling pathways not strongly activated by TLR signalling.
7.3  How zymosan recognition by DC couples to adaptive 
immunity.
Data presented in chapter 6 represent the first tentative steps into study of the 
effects of zymosan as an adjuvant. This is an important study as it would finally 
confirm a role of Dectin-1  in translating innate into adaptive immunity and may 
shed light on how immunity to pathogenic yeasts is established. One of the main 
challenges in addressing this question is the potential complexity of zymosan 
itself as a stimulus for DC maturation [39]. In order to consider Syk-dependent 
DC activation, all experiments would need to be carried out in MyD88-deficient 
DC (chapter 4), which means that in order to genetically manipulate the system 
further, for example by knocking-out Jagged-1  we really need to use Jagged- 
l/MyD88 double knock-out animals produced as the result of time-consuming 
breeding. A far preferable system would allow selective ligation of Dectin-1  in 
DC in order to examine the phenotype of mature DC and T cell differentiation 
induced. On-going work is examining these possibilities.
Work to establish a role for Jagged-1   upregulation induced by Dectin-1/Syk 
signalling is also on-going. Although there did not appear to be a role for 
Jagged-1  on Thl differentiation of naive OTII-TCR-transgenic T cells (figure 6- 
2) this may not be the ideal system in which to test this hypothesis, as the 
window of zymosan-induced increase in Thl differentiation was very small. A 
more promising system is to use DC stimulated exclusively via Syk-dependent 
PRRs in a system where either Thl or Thl7 differentiation can be induced and 
where DC can interact with regulatory T cells. It is likely that observed effects
183will be relatively subtle therefore it is important to establish as robust a system 
as possible in which to test this hypothesis. The experiments presented so far 
demonstrate that the system for retroviral introduction of Cre into dendritic cells 
is feasible and can be used to produce Jagged-1-deleted dendritic cells (figure 6- 
2).
Further experiments with genetic manipulation or blocking antibodies could 
investigate the roles of DC-derived IL-2 and IL-10 in T helper differentiation. 
Extending these observations to in vivo T cell priming and yeast infection 
models would eventually allow us to determine the physiological role of Syk- 
dependent pattern recognition and would firmly establish Dectin-1   as a novel 
cell-surface pattern recognition receptor.
7.4  The future
It is intriguing to speculate that the evolution of adaptive immunity required the 
evolution of direct PRRs such that antigen presentation and “information about 
the pathogen” [285] could be restricted to single antigen-presenting cells. TLRs 
have diversified from the original Toll proteins such that they are now thought 
to bind directly to lipid, peptide and nucleic acid ligands [27] [26]. However, 
carbohydrate recognition does not appear to have evolved amongst the TLRs 
despite the requirement for Drosophila Toll signalling downstream of (3-glucan 
recognition by GNBP. Instead this function appears to have been taken over by 
Dectin-1. Once Dectin-1  has been fully established to be a PRR it would be 
interesting to determine whether it is one of a family of such PRRs.
The closest homologues of Dectin-1  are other C-type lectins (CLECTs) encoded 
alongside Dectin-1  within the NK-cell receptor cluster, many of which have 
been implicated in NK cell function [53]. However, a number of these receptors 
are orphan receptors and one such, CLEC-2, has recently been found to activate 
Syk via a HemlTAM motif on artificial cross-linking or binding of the snake 
venom rhodocytin [293]. It is currently unclear whether other genes in the 
cluster can act like Dectin-1. In addition, it is possible that gene conversion has 
resulted in use of the HemlTAM motif in non-CLECT receptors that are
184potential novel Syk-dependent PRRs. As well as identifying full homologues of 
Dectin-1, it would therefore be interesting to identify genes with regions 
homologous to the first exon of Dectin-1, which encodes its ability to interact 
with Syk via the HemlTAM motif
Another interesting questions which, despite our best efforts so far remains 
unanswered is to identify what Syk-dependent signalling events are responsible 
for the extremely high levels of IL-10 induced downstream of Dectin-1/Syk 
signalling. Although ERK plays a role, it is clearly not sufficient as TLR2 
signalling induces ERK activation similarly to Dectin-1, but induces 10 to 100- 
fold less IL-10. Two approaches to this problem are possible. One is to consider 
strong candidates likely to be activated downstream of Dectin-1   such as calcium 
signalling/ NFAT [292] or autocrine production of type I interferons [33]. An 
alternative approach is being carried out elsewhere, examining transcription 
factors bound to the IL-10 promoter under different conditions (started in 
[294]). The identity of these transcription factors may lead us to the nature of 
signalling events required for their induction.
A final area that requires further investigation is the putative link between Thl7 
differentiation and MyD88-/- DC primed with zymosan. It has been suggested 
that IL-17 is critical for productive immunity against systemic challenge with 
Candida albicans [191] and more historically, that TGFp is important in 
establishing resistance to Candida infection [192]. A link between yeast 
infection and Thl 7 induction could also open up new avenues of investigation 
in the large number of autoimmune conditions in which Th 17 effector T cells 
are responsible for pathology (Crohn’s disease [156,  182], EAE [280] etc).
7.5  Concluding Remarks
I have presented evidence to strongly support the designation of Dectin-1   as a 
bona fide PRR that can function to induce DC cytokine production completely 
independently of the TLR system. Dectin-1   signals via a novel HemlTAM motif 
which couples pattern recognition to activation of Syk. ERK signalling,
185activated downstream of Syk, is required for the production of high levels of IL- 
2 and IL-10 induced in response to zymosan. Several new techniques (retroviral 
transduction of bone marrow, assessment of cell signalling by flow cytometry) 
have allowed the first steps to be made in detailed analysis of signalling induced 
by the recognition of a complex yeast-derived stimulus (zymosan). Many 
interesting questions remain. The phenotype of BMDC activated via the Syk- 
dependent pathway qualitatively resembles that of TLR-stimulated DC, in that 
IL-12 p40, IL-2, IL-6, TNFa and IL-10 are induced. Intriguingly, there are large 
quantitative differences in levels of these cytokines produced when compared to 
cytokine induction induced by TLR-ligands. In particular high levels of IL-10, 
IL-2 and Jagged-1  suggest that DC activated in this way may bias T cell 
differentiation towards different T cell effector functions. In addition the 
observation that TLR2-mediated zymosan recognition is insufficient to induce 
ERK activation highlights the fact that TLR signalling induced by different 
ligands or induced from within different receptor complexes can vary 
qualitatively. Future work will help to provide further insight into the precise 
mechanisms of yeast recognition by DC and the induction of anti-fungal 
adaptive immunity.
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